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Abstract 
 
Multiple myeloma is an incurable B cell malignancy characterised by the expansion 
of malignant plasma cells in the bone marrow. It has been suggested that during 
initial colonisation of bone and possibly during therapy, some myeloma cells may 
occupy a bone marrow niche similar to that inhabited by haemopoietic stem cells. 
Haemopoietic stem cells residing in BM niches adhere to osteoblastic cells via a series 
of molecules that promote haemopoietic stem cell quiescence. Therefore, we 
hypothesise that myeloma cells express the same molecules as haemopoietic stem 
cells, chemokine C-X-C-motif-receptor 4, notch-1, tyrosine kinase-2 and n-cadherin, 
which interact with their complementary ligands expressed by osteoblastic cells, 
chemokine C-X-C-motif-ligand 12, jagged-1, angiopoietin-1 and n-cadherin. These 
interactions may result in myeloma cell adhesion to an osteoblastic niche, resulting 
in myeloma cell dormancy. The aims of these studies were to determine the 
expression of haemopoietic stem cell niche molecules and ligands by murine 
myeloma cell lines and osteoblastic cells and to determine the role of one of the key 
molecules in vitro and in vivo.  
5T33MMvt and 5TGM1 cells expressed the haemopoietic stem cell niche molecules; 
chemokine C-X-C-motif-receptor 4, notch-1, tyrosine kinase-2 and n-cadherin and 
the MC3T3-E1 cells and primary osteoblast lineage cells expressed the ligands 
chemokine C-X-C-ligand 12, jagged-1, angiopoietin-1 and n-cadherin. Knock-down of 
n-cadherin was achieved in the 5TGM1 cells, with 71% gene and 75% protein 
reduction. 5TGM1 n-cadherin knock-down cell attachment to primary osteoblast 
lineage cells was reduced in vitro, though this did not reach significance. Mice 
injected with 5TGM1 n-cadherin knock-down cells had significantly less tumour in 
vivo compared to controls.  
In conclusion, murine myeloma cells expressed the same repertoire of molecules as 
haemopoietic stem cells and osteoblastic cells expressed their complementary 
ligands. Knock-down of one of these key molecules, n-cadherin, did not significantly 
Abstract Page xxii 
 
inhibit myeloma cell attachment to primary osteoblasts in vitro but potentially 
impaired tumour growth in vivo. Further experiments are required to confirm this.
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GPCR Guanosine nucleotide-binding protein-coupled  
receptor 
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Kv    Kilo volt 
LEPR    Leptin receptor 
l    Litre 
LT-HSC    Long-term haemopoietic stem cell 
M    Molar 
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MHC    Major histocompatibility complex 
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PET-CT    Positron emission tomography-computed tomography 
PFA    Paraformaldeyhyde 
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PTHrP    Parathyroid hormone- related protein 
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RANK    Receptor activator of nuclear factor kappa beta 
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RPM    Rotations per minute 
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SA-HRP   Streptavidin horseradish peroxidase 
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shRNA    Short hair-pin RNA  
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TAE Trizma base, acetic acid and 
ethylenediaminetetraacetic acid 
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TIFF    Tagged image file format file 
Tm    Melting temperature 
TNF    Tumour necrosis factor 
TO-PRO-3   TO-PRO-3 iodide 
TRAIL Tumour necrosis factor-related apoptosis-inducing 
ligand 
TU    Transducing units 
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UV    Ultra violet 
VCAM    Vascular cell adhesion molecule 
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VEGF    Vascular endothelial growth factor 
VLA-4    Very late antigen 
WB    Western blotting 
WBC    White blood cell 
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Zn    Zinc 
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5’    Five prime end 
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5TGM1vt   5TGM1 in vitro 
5T33-GFP   5T33MM-green fluorescent protein 
5T33MMvt   5T33 multiple myeloma in vitro 
5T33-GFP   5T33MM-green fluorescent protein 
3’    Three prime end 
Α    Alpha 
Β    Beta 
β2M    Beta 2 microglobulin 
°C    Degrees Celsius 
Δ    Delta 
ΔCt    Delta cycle threshold 
γ    Gamma 
κ    Kappa 
∏    Pi 
µA    Microamperes 
µCT    Micro computed tomography 
µg    Microgram 
µl    Microlitre 
µm    Micrometre 
µmol    Micromolar 
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1.1 Multiple Myeloma 
 
1.1.1 Epidemiology of multiple myeloma 
Multiple myeloma (MM) is a haematological malignancy predominantly 
characterised by the uncontrolled expansion of plasma cells in the bone marrow 
(BM), resulting in bone disease (1). It accounts for 1.5% of all cancers (2) and for at 
least 13% of all haematological malignancies worldwide (3). In the UK, the incidence 
of MM is 6-8 diagnoses per 100,000 people with over 4500 people diagnosed with 
MM per year (2).  
 
MM is an age-dependent disorder where the mean age of diagnosis is 62 years for 
men (75% >70 years) and 61 years for women (79% >70 years) (4) and less than 15% 
are diagnosed before the age of 60 (5). It is the most common haematological cancer 
in African Caribbean ethnicities where twice as many are likely to develop myeloma 
compared to European Americans (6). There is also a higher incidence of MM in 
males rather than females (7). However, the genetic basis for any differences 
between specific ethnicities and sexes is unknown. When the frequency of 
immunoglobulin (Ig) heavy (IgH) translocations, translocation loci and genomic gain 
or loss were compared between European Americans and African Caribbeans, the 
only statistical difference observed was a greater frequency of IgH translocations in 
European Americans (6). 
 
1.1.2 Pathology of disease 
Myeloma cells (MCs) are classified as abnormal plasma cells. The primary role of a 
normal plasma cell is to provide a humoral immune response via the production of 
Igs when a foreign antigen is encountered. Plasma cells are typically un-dividing cells, 
which possess a distinct morphology, high endoplasmic reticulum and Golgi content, 
as well as the expression of specific molecules. Normal plasma cells express 
molecules such as syndecan-1 (also known as cluster of differentiation (CD) 138), 
very-late antigen (VLA)-4 and chemokine C-X-C motif receptor (CXCR) 4. Markers that 
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are down-regulated post plasma cell differentiation include B220, CD19, CD21, CD22, 
CXCR5 and the major histocompatibility complex (MHC) II (8).  
 
Plasma cells originate from B lymphocytes which are produced from differentiated 
BM haemopoietic stem cells (HSCs), discussed in Chapter I Section 1.2. Throughout 
the stages of differentiation, several significant genetic modifications occur, which 
include; rearrangements of the variable, diversity and joining (V(D)J) regions of the 
IgH chain during somatic hypermutation (8, 9) and Ig class switching in the centrocyte 
and plasmablast (10). Both somatic hypermutation and class switching use 
activation-induced deaminase (AID), which produces double strand deoxyribonucleic 
acid (DNA) breaks. The DNA breaks are usually repaired locally however, they may 
lead to chromosomal translocations, which can occur in up to 1000 cells a day (11). 
Therefore, each DNA modification that occurs within a cell throughout the stages of 
B cell differentiation increases the risk of chromosomal abnormalities, which are a 
common feature in myeloma (12). 
 
Several genetic mutations have been identified in myeloma patients and they are 
characterised into two cytogenetic categories, which include hyperdiploid or non-
hyperdiploid. Hyperdiploid patients have more than the normal diploid number of 
chromosomes such as trisomies of chromosomes (this may include chromosomes 3, 
5, 7, 9, 11, 15, 19), whereas non-hyperdiploid patients are hypodiploid, with fewer 
than the normal diploid number of chromosomes or may have chromosomal 
translocations, particularly of the IgH gene, which occurs in approximately 50% of 
monoclonal gammopathy of unknown significance (MGUS) patients (the pre-
malignant condition before asymptomatic or symptomatic myeloma) and 60-65% of 
symptomatic myeloma patients (13, 14).  
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1.1.3 Clinical features  
MM patients can present with several different clinical features, depending on the 
stage and severity of disease. Common features are haematological irregularities, 
renal disease and bone disease. 
 
Haematological irregularities include a reduction in erythrocytes, platelets and white 
blood cells (WBCs) as well as normochromic and normocytic anaemia (iron <8.5 
grams (g) per decilitre (dl)) which are exhibited as fatigue, abnormal bleeding and 
increased risk of infection. These signs are primarily caused by the rapid expansion 
of MCs in the BM (15).  
 
Renal disease is also common in MM patients and is “one of the most common causes 
of death, second to infection” (16). Up to 50% of newly diagnosed patients can 
present with renal abnormalities and 20% of patients are diagnosed with severe renal 
impairments which require dialysis (17). Renal failure is caused by the presence of 
malignant plasma cells in the BM. Clonal plasma cells secrete monoclonal antibody, 
also known as paraprotein or M protein (50% of patient MCs secrete IgG, 20% IgA 
and 20% light chains) (17), which cause lesion formation in the kidneys, known as 
cast nephrology. Lesions present in the kidneys have been associated with tubular 
rupture and nephritis, resulting in obstructions and poor filtration (16). In addition, 
amyloidosis caused by paraprotein or light chain secretion as well as hypercalcaemia, 
caused by the breakdown of bone (discussed in more detail in Chapter I section 1.1.5) 
also result in renal impairment (2). 
 
Bone disease and the development of osteolytic lesions, as a result of MC infiltration 
of the BM, are also a major cause of morbidity and occur in 40-50% of MM patients 
(18). Patients suffering from lesions may experience bone pain and have increased 
risk of pathological fractures (2), discussed in greater detail in Chapter I, Section 
1.1.5. 
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1.1.4 Diagnosis 
Several tests are performed to reach a diagnosis of MM. These include analysis of the 
blood, urine, BM and skeleton. 
 
Full blood counts, red blood cell (RBC) sedimentation rate and blood smears are used 
to assess abnormalities in the number of different cellular constituents in the 
peripheral blood, as well as to test iron and haemoglobin levels. Bone marrow 
aspirates or trephines may also be taken to determine the number of different 
cellular constituents, particularly the number of plasma cells, which is generally 
higher than 10% in MM patients (5). Plasma cell phenotyping can also be conducted 
using flow cytometry to characterise specific cell surface markers, as well as 
fluorescent in situ hybridisation (FISH) to determine cytogenetic abnormalities (19). 
Karyotyping can also be conducted to identify specific chromosomal abnormalities.  
 
Renal defects are detected by urine biochemistry or urine electrophoresis, which 
detect the presence of paraprotein or Ig light chains, also known as Bence Jones 
protein, in the urine. In addition, serum electrophoresis, immuno-fixation and 
biochemical tests are also conducted to determine the presence of paraprotein 
present in the circulation as well as levels of creatinine, calcium, beta (β) 2 
microglobulin (β2M) and albumin, which indicate severity of renal dysfunction (5, 
20). 
 
Positron emission tomography (PET)-computed tomography (CT) (PET-CT), magnetic 
resonance imaging (MRI) and X-rays are used to visualise the extent of bone lesions 
and fractures in MM patients (20).  
 
In early MM, it is often difficult to distinguish symptomatic MM from related 
disorders such as asymptomatic/smouldering MM and MGUS. Monoclonal 
gammopathy of unknown significance is the most common premalignant condition 
present in Western countries and is present in 3% of the general population over 50 
years of age (21, 22). It is diagnosed by the presence of paraprotein however, levels 
are less than 30 g/l and patients do not show signs of bone disease or organ-related 
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disorders. The risk of developing MM or plasma cell related disorders increases at a 
rate of 1% every year following diagnosis, and it is uncertain whether all patients 
have the premalignant condition prior to MM diagnosis. However, Landgren et al (22) 
found that “virtually all” MM patients in their studies (N=71) had a form of MGUS 
(diagnosed by the presence of paraprotein < 30 g/dl) prior to MM, but the trigger 
which initiates progression to MM is unknown.  
 
Smouldering/ asymptomatic MM is a precursor to MM, whereby approximately 3000 
cases are diagnosed per year in the United States of America and patients have an 
average annual risk of progression to MM of 10% in the first 5 years after diagnosis, 
which decreases to 3% annually for the following 5 years and 1% thereafter (23). 
Smouldering MM patients are diagnosed due to paraprotein levels above 30 g/dl and 
more than 10% of plasma cells present in the BM, however they do no present with 
any organ related impairment (5).  
 
An international diagnostic system to distinguish between MGUS, smouldering MM 
and symptomatic MM was developed by Smith et al (24), the International Myeloma 
Working Group (25) and the British Committee for Standards in Haematology (BCSH), 
as stated in the official Myeloma Guidelines (5), shown in Table 1.1. 
 
Table 1.1: The diagnostic criteria to differentiate between MGUS, asymptomatic MM and 
symptomatic MM  
Adapted from the Bird et al (5), permission from The British Journal of Hematology 04.08.14. l: Litre. 
 
In addition, a staging system was also designed by Durie and Salmon (26) and has 
been adapted by the BCSH in the MM guidelines (5), as shown in Table 1.2. This 
Monoclonal 
gammopathy of 
unknown significance 
Asymptomatic myeloma Symptomatic myeloma 
M protein in serum <30 
g/l 
M protein in serum >30 
g/l 
M protein present in 
serum and/or urine 
BM clonal plasma cells 
<10% 
And/or BM clonal 
plasma cells >10% 
BM plasma cells and 
plasmacytoma 
No myeloma related 
organ or tissue 
impairment 
No myeloma related 
organ or tissue 
impairment, bone 
lesions or symptoms 
Any myeloma related 
organ or tissue 
impairment including 
bone lesions 
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staging system was designed to categorise patient stage and severity of disease in 
order to reach a prognosis and to decide upon suitable treatment options. 
 
Table 1.2: The Durie and Salmon staging system of myeloma 
 
Adapted from Durie and Salmon (26) by the BCSH (5), permission from The British Journal of 
Hematology 04.08.14. nmol: nanomole, µmol: micromole, mg: milligram. 
 
1.1.5 Pathology of tumour-induced lytic bone disease 
The specific constituents of the BM and its microenvironment provide a suitable 
“soil” for the expansion and enhanced survival of MCs in MM, as explained by Paget 
(27) using the “seed and soil” hypothesis. Two specialised cells residing in the BM 
microenvironment, which are of importance with regards to the development of 
MM, are osteoblasts and osteoclasts. Osteoblasts are responsible for secreting the 
extracellular organic bone matrix known as osteoid, which is then mineralised to 
form new bone (28). Osteoclasts are able to secrete enzymes and proteins to digest 
the bone in the process of resorption (29). The mechanisms in which osteoblasts and 
osteoclasts work together to produce functioning bone is known as remodelling (30) 
and this balanced process is described in Figure 1.1.  
 
 
 
 
 
 
 
Stage Criteria Median survival 
(months) 
Stage I Serum β2M < 3.5 mg/l 
(296 nmol/l) 
 
Serum albumin ≥ 3.5 g/dl 
(35g/l or 532 µmol/l) 
 
62 
Stage II Remainder fitting 
neither Stage I or III 
45 
Stage III Serum β2M ≥ 5.5 mg/l 
(465 nmol/l) 
29 
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Figure 1.1: A schematic diagram representing the cycle of normal bone remodelling. The cycle 
consists of four phases: 1. Bone resorption occurs by the activation of osteoclasts, which release acid 
phosphatases and collagenases, which degrade bone. 2. The reversal phase in which apoptosis of 
osteoclasts occurs followed by recruitment of osteoblasts. 3. Subsequent bone formation where 
osteoblasts secrete osteoid, which is mineralised with hydroxyapatite to form new bone. 4. A resting 
phase in which neither resorption or formation occurs and osteoblastic cells become flattened bone 
lining cells (31). 
  
 
In MM, the process of bone remodelling is “uncoupled” (32) and the 
osteoclast/osteoblast axis is disrupted, favouring osteoclastic bone resorption and 
supressing osteoblastic bone formation, ultimately leading to lytic bone lesions and 
bone disease (18). This increase in bone loss is enhanced by what is known as “The 
Vicious Cycle” (33), where myeloma cells express or secrete factors such as nuclear 
factor kappa (κ) β ligand (RANKL) (32, 34), macrophage inflammatory protein 1 
(MIP1α) (35, 36), tumour necrosis factor α (TNFα) (37), interleukin 1 β (IL-1β) (38), IL-
3 (39) and IL-6 (40), which stimulate osteoclastic differentiation and activation. In-
turn, osteoclasts produce proteins including IL-6 (41), annexin II (42), osteopontin 
(43), B cell-activating factor belonging to the TNF family (BAFF) (44) and a 
proliferation-inducing ligand (APRIL) (44), which increase myeloma cell proliferation 
or prevent apoptosis. Overall, this cycle results in increased numbers of active 
osteoclasts and myeloma cells, leading to enhanced bone loss. This phenomenon is 
illustrated in Figure 1.2.  
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Figure 1.2: A schematic diagram representing “The Vicious Cycle”. Myeloma cells produce the factors: 
RANKL, MIP1α, TNFα, IL-3 and IL-6 that stimulate osteoclast differentiation. In-turn, osteoclasts 
produce: IL-6, annexin II, osteopontin, BAFF and APRIL, which induce myeloma cell proliferation. These 
events occur within a cycle, driving both myeloma cell expansion and osteoclastogenesis resulting in a 
net loss of bone. Adapted from Galson et al (33), permission from Nature Reviews 31.07.14.  
 
 
One of the main regulators of osteoclastogenesis in MM is the RANK/RANKL 
pathway. Receptor activator of nuclear factor κ β ligand is an essential cytokine for 
the differentiation of preosteoclasts to activated osteoclasts (45). Receptor activator 
of nuclear factor κ β ligand is expressed by stromal cells, osteoblasts and T cells and 
exists as a membrane bound form as well as soluble RANKL, when cleaved by 
metalloproteinases. Receptor activator of nuclear factor κ β ligand binds to its 
receptor RANK, expressed on preosteoclasts and activated osteoclasts. Receptor 
activator of nuclear factor κ β / RANKL interactions result in the differentiation of 
preosteoclasts, the fusion of polykaryons and the activation of resorption in mature 
osteoclasts. Osteoclastogenesis can however, be inhibited by a decoy receptor, 
known as osteoprotegerin (OPG), which is expressed by osteoblasts. Osteoprotegerin 
binds to RANKL, blocking the binding of RANK with RANKL, thus behaving as a 
paracrine inhibitor of osteoclast formation and activation (46). In MM, OPG is down 
regulated (47) therefore, osteoclastogenesis and thus bone resorption is not 
inhibited resulting in a disruption of normal bone remodelling.  
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As mentioned above, osteoblast number and bone formation are reduced in MM 
which may be due to inhibition of the wingless (Wnt) signalling pathway by MC 
secretion of soluble Wnt inhibitory factors including dickkopfs (DKKs) (48, 49) or 
secreted frizzled-related proteins (SFRPs) (50).  
 
1.1.6 Treatment options 
To date, MM remains an incurable disease and resulted in approximately 10,710 
deaths in the USA in 2012 (51) and approximately 2600 in the UK in 2011 
(http://www.cancerresearchuk.org/cancer-
info/cancerstats/keyfacts/myeloma/myeloma). Survival rates post-diagnosis vary 
from several weeks to several decades. However, the 5 year or more survival rate in 
myeloma patients in the USA between 2002-2004 was 45-57% in patients less than 
50 years of age, 39-48% in 51-59 year olds, 31-36% in 60-69 year olds and only 27-
29% in those over the age of 70 (52). This was similar to UK statistics in 2010 where 
only 37% of patients survived 5 years post diagnosis 
(http://www.cancerresearchuk.org/cancerinfo/cancerstats/types/myeloma/surviva
l/multiple-myeloma-survival-statistics#1_5_10_yr_survival). 
 
There are a variety of treatments available for MM patients however, current 
treatments are not curative, but alleviate the symptoms to improve quality of life. 
Current treatments include radiotherapy, chemotherapy, bisphosphonates, surgery 
and BM and stem cell transplants. The type of treatment administered is dependent 
on the age of the patient and the severity of disease. 
 
1.1.7 Treatments to reduce tumour burden 
Radiotherapy is generally administered locally at the site of pain to reduce tumour 
burden which in-turn reduces osteoclastic bone resorption to help prevent further 
bone loss. Radiotherapy is also used to treat spinal cord compression and this may 
be given in combination with surgery or kyphoplasty (53). 
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Chemotherapeutic drugs are administered to reduce tumour burden. These include 
chemotherapies (lenalidomide, pomalidomide, thalidomide), corticosteroids 
(dexamethasone (dex) and prednisone), and proteasome inhibitors (bortezomib and 
carfilzomib). Treatments are given in combination such as lenalidomide, dex and 
bortezomib (RVD), lenalidomide cyclophosphamide and dex or RVD plus 
cyclophosphamide (54). Lenalidomide, thalidomide and pomolidomide are thought 
to work by inducing apoptosis in MCs via caspase 8 and tumour necrosis apoptosis-
inducing ligand (TRAIL) signalling as well as down regulation of nuclear factor κ B (Nf-
κB), IL-6 and vascular endothelial growth factor (VEGF) (54-56). Proteasome 
inhibitors such as bortezomib and carfilzomib are thought to act by inhibiting the 26 
S proteasome, resulting in the inhibition of the degradation of proteins involved in 
cell proliferation (57). In addition, bortezomib was found to inhibit angiogenesis by 
reducing the production of VEGF, IL-6, IGF-1, Angiopoietin (Ang)-1 and Ang-2 by 
endothelial cells in vitro (58), which could contribute to a reduction in tumour burden 
in patients.  
 
1.1.8 Treatments to alleviate symptoms 
Bisphosphonates are the most commonly administered drug to reduce bone 
resorption and to prevent further formation of osteolytic lesions or osteopenia. 
There are several different bisphosphonates available which include the nitrogen-
containing bisphosphonates; zoledronic acid, pamidronate and ibandronate and 
non-nitrogen containing bisphosphonates; clodronate and etidronate. 
Bisphosphonates once administered, bind to hydroxyapatite in the bone and are 
released during bone resorption and internalised by osteoclasts. Once inside the cell 
they can either inhibit osteoclastic activity or induce osteoclast apoptosis (59). Non-
nitrogen containing bisphosphonates are able to inhibit adenosine triphosphate 
(ATP)-dependent enzymes (60), whereas nitrogen containing bisphosphonates 
inhibit the enzyme farnesyl pyrophosphate synthase, required in the mevalonate 
pathway, an essential pathway for the post-translational modification of proteins 
(61). In the clinic, standard therapy usually uses zoledronic acid or pamidronate to 
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reduce bone pain (62). In addition, bisphosphonates have also been reported to exert 
an anti-tumour effect in vitro (63) and in vivo (64).  
 
Autologous stem cell transplants may also act as standard therapy for newly 
diagnosed patients, however, transplants are usually only applied to younger 
patients and use also depends on the stage of disease. Other therapies that may be 
required to alleviate symptoms include dialysis, rehydration, blood transfusion, 
plasmaphoresis, antibiotics and Ig infusions (15).  
 
1.1.9 Recurrence of disease 
Despite continual development of novel therapies for MM, current treatments are 
unable to completely eradicate the disease and patient relapse is inevitable. Previous 
studies have proposed that residual MCs present in the BM following treatment are 
able to evade chemotherapy via (currently) unknown mechanisms; and some groups 
have categorised these cells as “cancer stem cells”(65). Several mechanisms have 
however been proposed. For example, previous studies have suggested that chemo-
evasion is a result of MC mediated alterations in immune surveillance (suppression 
and dysfunction of T cells and natural killer (NK) cells) (66, 67); a lack of optimal 
microenvironment for growth, and some have also suggested that MC adhesion to 
specific niches in the BM microenvironment results in MC dormancy (65, 68). 
Concerning the latter, previous reports have speculated that dormant MCs may in 
fact hijack or reside in similar niches to those occupied by HSCs and they therefore 
utilise similar mechanisms as HSCs to acquire cell dormancy. The concept of the HSC 
niche has been explored for approximately the last thirty-five years and previous 
studies have found that HSCs were maintained in these niches by the expression and 
interactions of specific molecules on the HSCs and other cells in the BM 
microenvironment (69) (discussed in more detail below). In support of a MC niche, a 
recent study by Chen et al (70) found early MCs (identified by a lipophilic dye known 
as Paul Karl Horan dye (PKH26)) preferentially resided in osteoblastic niches and 
homed and survived to a lesser extent in vascular and splenic niches, using murine 
MM in vivo models. In addition, PKH26 positive cells demonstrated increased 
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chemoresistance compared to PKH26 negative cells. in vitro (70). However, current 
data is still inconclusive as to the specific molecule interactions responsible for the 
adhesion of MCs to these niches and mechanisms of MC dormancy and therefore, 
further research is required to explore this. 
 
1.2 The HSC Niche 
 
1.2.1 Evidence for a HSC niche 
HSCs possess the ability for unlimited self-renewal and production of a variety of 
differentiated progeny by haematopoiesis (71), as illustrated in Figure 1.3. Schofield 
et al (72) proposed that HSCs reside in a specialised microenvironment or niche which 
is responsible for controlling self-renewal and differentiation of HSCs, required for 
maintenance of the different cell types within the BM. The HSC microenvironment is 
comprised of several supporting cells and components including stromal cells, 
extracellular matrix molecules and growth factors (73) all of which contribute to the 
maintenance of the stem cell pool size. 
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Figure 1.3: HSC differentiation into different cell lineages. A schematic diagram representing the 
process of haematopoiesis and the lineages in which each cell in the BM is derived. Haemopoietic stem 
cells differentiate into lymphoid and myeloid lineages. The lymphoid lineage produces B cells, T cells 
and NK cells. The myeloid lineage produces several progenitors which include colony forming unit 
(CFU), granulocyte erythroid monocyte and megakaryocyte (CFUGEMM), CFU granulocyte monocyte 
eosinophil (CFUGMEo), CFU eosinophil (CFUEo), CFU granulocyte monocyte (CFUGM), CFU granulocyte 
(CFUG), CFU monocyte (CFUM), CFU basophil (CFUB), CFU megakaryocyte (CFUMega), burst forming unit 
(BFU) and CFU erythrocyte (CFUE). These progenitors then differentiate into their corresponding 
mature cell type. Adapted from Hoffbrand A.V (15) and Reya et al (74). 
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It has been proposed that HSCs may reside in two different niches entitled the 
“osteoblastic niche” and the “vascular niche” (75, 76) which are responsible for the 
maintenance of HSCs and their ability to survive and proliferate in the BM, as shown 
in Figure 1.4 . However, the existence of either niche remains controversial (77). 
 
In addition to osteoblastic cells and ECs, several other cell types have been implicated 
in the HSC niche in the BM. These included the chemokine C-X-C motif ligand (CXCL) 
12 abundant reticular (CAR) cells, mesenchymal stem cells (MSCs), osteoclasts and 
adipocytes (76). However, evidence is limited with regards to their roles in the HSC 
niche. 
 
 
 
 
 
 
 
 
Figure 1.4: The HSC niche. A schematic diagram illustrating the HSC niche. a. Haemopoietic stem cells 
adhere to osteoblasts or bone lining cells on the bone surface, which has been proposed to result in 
HSC quiescence. b. Once activated, the HSCs are thought to mobilise to the blood vessels where they 
proliferate and differentiate. 
 
1.2.2 The osteoblastic HSC niche 
The osteoblastic niche is composed of osteoblasts or “osteoblastic-like” cells 
possessing an osteoblastic phenotype, which includes expression of alkaline 
phosphatase (Alp). It has been hypothesised that HSCs adhere and interact with 
osteoblasts or their growth factors on trabecular and endocortical surfaces of bone 
(73), resulting in G0 cycling quiescent HSCs and inhibition of their maturation. 
a b 
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Quiescent HSCs are often termed long term-HSCs (LT-HSCs) and possess a commonly 
recognised phenotype of c-kit positive, sca-1 positive and lineage negative (KSL) and 
possess the ability to self-renew unlike short-term HSCs (ST-HSCs) (69). 
 
Several in vivo studies have identified the importance of osteoblastic cells for HSC 
survival and self-renewal in the BM, investigated by manipulating osteoblastic 
number using transgenic mice or administration of hormones in murine models. In 
core binding factor 1 α (CBF1α) (an essential osteoblast differentiation transcription 
factor) knockout (KO) mice (a lethal mutation in homozygous mice), this resulted in 
a lack of BM cavity, little or no ossification of the skeleton and a decrease in 
osteoblast numbers. In addition, osteoblastic cells that were present seemed to be 
poorly differentiated with no osteocalcin (Ocn) expression and weak Alp expression 
(78). In CBF1α KO embryos, loss of CBF1α and therefore osteoblasts, correlated with 
a reduction in BM haemopoietic cells and also splenomegaly as a result of 
extramedullary haematopoiesis (79). These findings were also supported by Visnjic 
et al (71, 80) who noted a lack of BM cellularity and a reduction in KSL HSCs when 
osteoblast numbers were decreased using a thymidine kinase and 2.3 kilo base (kb) 
fragment of collagen type I α I (COL1A1) promotor, conditional KO mouse model. 
 
Osteoblast stimulation using a constitutively active parathyroid hormone (PTH)/ 
parathyroid hormone-related protein (PTHrP) receptor (PPR) mouse model (81) 
resulted in an increase in trabecular osteoblastic cells which correlated with a 
significant increase in HSCs in the long bones and increased HSC engraftment (82). In 
support of this, daily administration of PTH in C57Bl/6 mice, which increased 
osteoblast number, also resulted in an increase in HSC number in the BM and HSC 
engraftment in vivo (82). In addition, Zhang et al (83), also noted that when 
osteoblast number was increased using an inducible bone morphogenetic protein 
(BMP) receptor (BMPR) 1 α KO mouse model, LT-HSC number and HSC engraftment 
was also increased. 
 
The location of HSCs in the BM microenvironment is also important when defining 
the HSC niche. Xie et al (84) and Zhang et al (83) both noted HSC localisation and/or 
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adhesion to osteoblasts on the endosteal and trabecular bone surfaces by 
immunohistochemistry (IHC) or immunofluorescence (IF). The osteoblasts that the 
HSCs adhered to seemed to be a distinct sub-population of mononuclear “spindle-
shaped” osteoblasts, positive for neural cadherin (N-cad), a potentially important 
molecule for HSC proximity to osteoblasts and maintenance of HSC quiescence (83).  
 
Several studies have also reported that LT-HSCs specifically adhering to bone are less 
sensitive to stresses such as treatment with the chemotherapeutic fluorouracil (5-
FU) in vivo, which is potentially facilitated by their G0 phase of cell cycle (85).  
 
1.2.3 The vascular HSC niche 
HSCs have also been reported to reside at peri-vascular surfaces in the BM, 
implicating a vascular niche may also be in existence. The vascular niche is 
composed of single layered ECs forming sinusoids, which lack connective tissue and 
therefore are highly permeable (86). It is hypothesised that active HSCs adhere to 
the ECs, establishing a site for proliferation, differentiation and mobilisation from 
the niche into the blood. 
 
To illustrate the importance of ECs with regards to HSC maintenance, several in vitro 
studies have co-cultured tyrosine kinase (Tie)-2 positive murine ECs, (isolated from a 
variety of murine organs) with phenotypic HSCs (87). Co-culturing ECs with HSCs 
promoted HSC differentiation and cell expansion, compared to controls, illustrating 
the potential for ECs to provide an environment in which HSCs can survive and self-
renew. Several in vivo mouse models have also demonstrated the importance of 
sinusoids for maintenance of haematopoiesis in the liver (88) and HSCs were found 
adjacent to stem cell factor (SCF) expressing vessels in the BM (89). Furthermore, KO 
of SCF in both Tie-2 positive ECs and leptin receptor (LEPR) positive peri-vascular 
stromal cells, significantly reduced HSC frequency in the BM and reduced BM 
cellularity in the SCF-LEPR KO animals (89), demonstrating the importance of the 
vasculature and peri-vasculature for the maintenance of HSC numbers.  
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1.3 Key molecules in the osteoblastic niche 
 
Specific receptors expressed by HSCs and their complementary ligands expressed by 
either osteoblasts or ECs, may facilitate the adhesion of HSCs to the bone or 
vasculature. Adhesion to these two sites may also induce HSC dormancy or activation 
as well as influencing HSC homing to the BM or mobilisation into the circulation.  
 
Several molecules of potential importance have been identified which include CXCR4 
and CXCL12, Notch-1 and Jagged (Jag)-1, Tie-2 and Ang-1 and N-cad. Throughout this 
thesis CXCR4, Notch-1, Tie-2 and N-cad will be referred to as the HSC niche molecules, 
whereas CXCL12, Jag-1 and Ang-1 will be referred to as the complementary ligands 
to the HSC niche molecules. 
 
1.3.1 CXCR4/CXCL12 
Chemokines are a large family of cytokines associated with many chemotactic 
responses, particularly inflammation. The family consists of over 50 structurally-
related proteins which are 60-88 amino acids (AA) long and they are subdivided into 
four groups (90). They are classified upon their NH2 terminal cysteine structure, 
which contain either adjacent cysteine AAs (CC), two cysteines separated by one 
different AA (CXC), two cysteines separated by three different AAs (CX3C) (91) or 
contain only one cysteine (XC) (91). The chemokine CXCL12 or stromal-cell derived 
factor (SDF)-1, has two splice variants, α and β. It is expressed by several cell types 
such as ECs, peri-vascular cells, (92) as well as stromal cells residing on endosteal 
bone surfaces (93). CXCL12 is also expressed on CAR cells residing near sinusoids in 
the BM (94).  
 
CXCL12 binds to two receptors, CXCR4 and CXCR7 (95), which are known as hepta-
helical receptors as their chain of AAs “traverses” the membrane seven times (10) 
(Figure 1.5). They are also more commonly known as G-protein coupled receptors 
(GPCRs), which are the largest family of membrane proteins which “mediate cellular 
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responses to hormones, neurotransmitters and are also responsible for vision, 
olfaction and taste” (96). CXCR4, is one of nineteen known human chemokine 
receptors (97) and it is expressed in a variety of different tissues including neural, 
muscle, cord blood and stem cell populations (98), specifically HSCs (99). 
 
As a GPCR, CXCR4 activation is mediated by an “intracellular heterotrimeric G 
protein” which is bound to the cell membrane (100). The G protein is comprised of 
three subunits, Gα, Gβ and G gamma (γ), which bind to guanosine diphosphate (GDP) 
when the ligand CXCL12 is not bound. However, when CXCL12 is bound, GDP is 
replaced by guanosine triphosphate (GTP), resulting in the dissociation of the G 
protein into two separate subunits containing Gα which is bound to the GTP and a 
second subunit containing Gβ and Gγ (100). The Gα subunit can also be classified into 
4 separate families Gαs, Gαi, Gαq, and Gα12 (101, 102). Each Gα, and Gβ and Gγ 
subunit, transmits the GPCR signal down different signalling pathways, which include 
phospholipase-c (PLC), phosphatidylinositol 3-kinase (PI3-K), extracellular signal-
related kinase (ERK), protein kinase (PK) B (PKB/Akt), NF-κB, mitogen-activated 
protein kinases (MAPK) and B cell lymphoma (bcl)-2 associated death promoter 
(BAD) pathways. This results in different downstream effects, which may include 
chemotaxis, gene transcription and cell survival, required for wound healing, 
angiogenesis, metastasis, cell recruitment and inflammation, to name but a few (94, 
100, 103-107) (Figure 1.5). CXCR4 and CXCL12 signalling is also crucial for functioning 
tissues, as demonstrated by Nagasawa et al, who showed that KO of CXCL12 in a 
transgenic model resulted in foetal mortality and specifically defects in haemopoeitic 
cells, cardiac tissue and brain tissue (108) . 
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Figure 1.5: The structure of CXCR4 and activation with CXCL12. a. Diagram illustrating the general 
structure of CXCR4 in its unstimulated state, consisting of a hepta-helical structure bound to a G protein 
consisting of α, β, γ subunits bound to GDP. b. Activation of CXCR4 by CXCL12, causes the replacement 
of GDP with GTP, resulting in the dissociation of the Gα with Gβ and Gγ. c. Gα consists of 4 subfamilies, 
Gαi, p, s and 12. The α subfamilies and Gβ and Gγ subunit stimulate different signalling pathways 
resulting in different functions. Adapted from Sodhi et al (102), permission from Nature Reviews 
30.7.14. 
 
The requirement for CXCR4/CXCL12 in HSC homing and mobilisation have been 
illustrated using CXCL12 (109) and CXCR4 KO (94) mouse models. Ara et al (109) 
showed that KO of CXCL12 in mouse embryos resulted in a reduction of HSCs in the 
liver, spleen and BM. In addition, Tzeng et al (110) demonstrated that conditional KO 
of CXCL12 resulted in a reduction in LT-HSCs, an increase in ST-HSCs and fewer G0 
cycling HSCs, therefore, demonstrating that the CXCR4/CXCL12 interactions may 
promote HSC quiescence.  
 
These results were also consistent with the conditional KO of CXCR4, where fewer 
LT-HSCs and fewer G0 cycling HSCs were present in the BM and there was also an 
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increase in HSCs in the peripheral blood (94). Therefore, in addition the promoting 
quiescence, the CXCR4/CXCL12 axis is required for HSC homing to the BM, liver or 
spleen from the circulation.  
 
CXCR4/CXCL12 signalling can be inhibited using antibodies or the antagonist 
AMD3100. In vitro migration assays demonstrated that HSCs migrate in response to 
CXCL12-α enriched media (99) and this was inhibited upon treatment with an anti-
CXCR4 antibody (111). Pre-treatment of CD34 positive HSCs with anti-CXCR4 or anti-
CXCL12 antibodies also severely reduced CD34 positive HSC engraftment in the BM 
when injected into non-obese diabetic/severe combined immunodeficiency 
(NOD/SCID) mice (112). This therefore again, reiterates the importance of 
CXCR4/CXCL12 signalling for the migration and homing of HSCs. 
 
1.3.2 Notch-1/Jag-1 
Notch-1 and Jag-1 have both been reported to possess several roles in stem cell fate, 
self-renewal and differentiation into specific progeny from HSCs (113, 114). Notch 
molecules exist as a family of transmembrane glycoprotein receptors, which occur as 
four homologues, 1-4 (115). Their basic structure consists of an intracellular and an 
extracellular domain, which contain several different motifs (116-118) as shown in 
Figure 1.6. 
 
Notch-1 is expressed in a variety of different organs and tissues, such as the thymus, 
BM and foetal liver (119) as well as by various cell types which include BM precursors, 
lymphocytes, neutrophils (115) and CD34 positive HSCs (120). 
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Figure 1.6: The structure of Notch-1. A diagram demonstrating the extracellular and intracellular 
structure of Notch-1. Its extracellular region consists of epidermal growth factor (EGF) like proteins 
and Notch-1/ Lin-1 repeats and its intracellular domain consist of a recombination signal-binding 
protein 1 for J-κ (RBP-JK)-associated molecule (RAM), ankyrin repeats and a transcriptional activation 
domain (TAD) and a proline, glutamic acid, serine and threonine (PEST) region. Adapted from Swiatek 
et al (121). 
 
Notch-1 is activated by its complementary ligand Jag-1. The ligands were first 
characterised in Drosophila, which consist of two main groups of Notch ligands 
named Serrate and Delta. The mammalian homologues of each of these groups of 
ligands are Delta 1 and 2 and Jag-1 and 2 (113). Jag-1, illustrated in Figure 1.7, is 
expressed on several cell types, including primary BM stromal cells and human 
umbilical vein ECs (HUVECs) (114) as well as the murine preosteoblastic cell line 
MC3T3-E1 (122).  
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Figure 1.7: The structure of Jag-1. A diagram illustrating the structure of Jag-1, which consists of an 
extracellular domain containing a cysteine rich region, EGF-like repeats, a delta (Δ) and oncostatin-M 
(OSM)-11 (DOS)-like region, a Δ serrate lag-2 region (DSL) and a module at the N-terminus of Notch 
ligands (MNNL), with an N-terminus. Adapted from Kovall et al (123), permission from The Society of 
Developmental biology.  
 
The activation of Notch-1 is initiated through the binding of its ligand Jag-1 (117, 124) 
as shown in Figure 1.8. Activation of Notch-1 has been achieved using a 
recombination activation gene-1 (RAG-1) mouse model (115). This model resulted in 
a 15-fold increase in KSL HSCs and inhibition of HSC differentiation towards the B cell 
lineage. Interestingly T cell differentiation was not impaired, providing evidence that 
Notch-1 is required for HSC and progenitor fate. Walker et al (113) also found that 
Jag-1 activation of Notch-1 resulted in reduced proliferation of HSCs and an increase 
in G0/G1 cycling cells in vitro, therefore, Notch signalling potentially facilitates HSC 
quiescence.  
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Figure 1.8: The activation of Notch-1 by Jag-1: A schematic diagram illustrating the activation of 
Notch-1 through the binding of Jag-1 in a neighbouring cell. 1. Jag-1 binds to the EGF-like proteins in 
the extracellular region of Notch-1, causing a conformational change. 2. A disintegrin and 
metalloproteinases (ADAMs) cleave sites at the intracellular Notch-1 domain resulting in a membrane 
tethered intracellular Notch-1. 3. γ secretases cleave the membrane tethered intracellular Notch-1. 4. 
Jag-1 and extracellular Notch-1 detach from the cell and intracellular Notch-1 is released. 5. 
Intracellular Notch-1 translocates to the nucleus and binds to the DNA binding protein 
CBF1/RBPjk/Su9H) Lag-1 (CSL), resulting in the recruitment of mastermind and MED8, which induce 
up-stream target genes. These include hairy enhancer of split (HES), hairy-related (HRT) and hairy/ 
enhancer of split related with YRPW motif protein 1 (Hey1). Adapted from Kopan et al (125), permission 
from Cell Press 30.07.14. 
 
In addition, Karanu et al (114) reported an increase in stem cell self-renewal in the 
BM of mice that had received Jag-1 activated transplanted HSCs cells compared to 
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controls. This is further supported by Calvi et al (82) who demonstrated an increase 
in osteoblastogenesis using PPR, which resulted in an increase in Jag-1 expression as 
well as an increase in HSCs in the BM. In addition, Notch-1/ Jag-1 are essential 
molecules, as demonstrated using a Notch-1 KO mouse model (121). Embryos in this 
model died before birth suffering from necrotic tissue, cell death and developmental 
retardation from 8.5 days post-coitum (PC). Therefore, Notch-1 KO is a lethal 
mutation, potentially essential for long-term definitive haematopoiesis (119). To 
investigate the effects of Notch-1 in post embryonic development, a Notch-1 
inducible KO model was developed which knocked-out Notch-1 after administration 
of polyl-polyc (126). This resulted in a decrease in mature thymocytes, mature T cells 
and an increase in cells of the B cell lineage in the thymus. This therefore, highlights 
that Notch-1 signalling is required for the differentiation of cells in the T cell lineage 
and when Notch-1 is deficient, this process is diminished. In addition to this, these 
data also imply that Notch-1 signalling may be responsible for inhibition of B cell 
differentiation. 
 
1.3.3 Tie-2/Ang-1 
Tie-2 is a cell surface receptor, which exists in the “Tie” family of receptors also 
containing Tie-1. Tie-2 is expressed by ECs (127), HSCs (85) neutrophils (128), dorsal 
root ganglion cells (129) as well as synovial lining cells and pericytes in patients with 
rheumatoid arthritis (127). Its structure consists of an extracellular binding domain 
and an intracellular kinase domain, as demonstrated in Figure 1.9.  
 
Ang-1 is one of the primary ligands for Tie-2, which is expressed in several cell types 
such as BM stromal cells, MSCs (130), osteoblast and osteoblast progenitors (85), 
pericytes (131), neutrophils and monocytes (132). It belongs to a family of four of 
angiopoietins, known as Ang-1 to 4. Ang-1 and Ang-4 are both receptor agonists 
whilst, Ang-2 and Ang-3 are receptor antagonists and importantly, Ang-2 specifically 
blocks Tie-2 activation. The structure of Ang-1 consists of a small “super clustering 
region”, a coiled-coiled domain and a fibrinogen-like Tie-2 binding region (133) as 
illustrated in Figure 1.10.  
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Figure 1.9: The structure of Tie-2. A diagram illustrating the structure of Tie-2, which consists of an 
extracellular region containing Ig 1-3 domains, EGF-like repeats and fibrinogen type III repeats. The 
intracellular domain comprises of split tyrosine kinases. Adapted from Huang et al (133), permission 
from Nature Reviews 30.07.14. 
 
 
 
 
 
 
 
Figure 1.10: The structure of Ang-1. A diagram representing the structure of Ang-1, which contains a 
super clustering, coiled-coiled and fibrinogen-like region. Adapted from Huang et al (133), permission 
from Nature Reviews 30.07.14. 
 
 
The binding of Tie-2 to its ligand results in dimerisation and activation of the kinase 
domain by phosphorylation (134). The activation of Tie-2 by Ang-1 is essential for 
several functions, which relate primarily to angiogenesis, but also to inflammation 
and haematopoiesis. For example activation of Tie-2 results in downstream signalling 
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of ERK, NF-κB and PI3-K pathways which can result in cell survival, proliferation, 
migration, anti-inflammatory, anti-permeability and vessel sprouting/ reorganisation 
responses (85, 135-139). Tie-2/ Ang-1 signalling is also essential for the survival of 
functioning tissues. Knock-out of Tie-2 in murine models resulted in lethality before 
birth and specifically, embryos had impaired cardiac structures and underdeveloped 
vasculature (140). Similar defects were also noted in Ang-1 KO mouse embryos as 
well (141).  
 
Tie-2 is also essential for haematopoiesis and is expressed in KSL HSCs (142). When 
Tie-2 was knocked-out in transgenic mouse models, adult mice experienced a 
dramatic reduction in haemopoietic cell lineages, therefore, demonstrating that Tie-
2 is important for HSC differentiation and proliferation (143). In support of this, Arai 
et al (142) also showed that Tie-2 was important for cell cycling in HSCs. Tie-2 positive 
HSCs seemed to adhere to Ang-1 positive osteoblastic cells in an osteoblastic niche 
in vivo, resulting in HSC quiescence and evasion from chemotherapy (85). 
 
1.3.4 N-cad 
N-cad is a member of the cadherin superfamily. Typically, cadherins are single pass 
transmembrane, calcium dependent cell-cell adhesion glycoproteins (144). The 
cadherin superfamily can be categorised into four subfamilies, which are classical, 
desmosomal, proto-cadherin and cadherin-like proteins. N-cad is grouped into the 
category of classical Cadherins (145).  
  
The standard structure of a Cadherin molecule consists of an extracellular region, 
transmembrane helix and a cytosolic domain, as shown in Figure 1.11. The 
extracellular domain, which acts as the binding domain, contains cadherin repeat 
proteins, the number of which are dependent on the subtype of classical cadherin, 
which are entitled I, II and III. Type I and II consist of five cadherin repeats whereas 
III contain a variable number. N-cad is a type I classical cadherin (146). The homotypic 
binding of N-cad between cell junctions results in several cleavages of N-cad and 
subsequent activation, as shown and described in Figure 1.12.  
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Figure 1.11: The structure of N-cad. A diagram representing the cytosolic and extracellular structure 
of N-cad. The extracellular domain contains cadherin repeats whereas the intracellular cytosolic 
domain contains an α and, β catenin, vinculin portion, which binds to actin in the cytoskeleton of the 
cell. Adapted from Angst et al 2001 (147), permission from The Journal of Cell Science 30.07.14. 
 
N-cad possesses a number of roles throughout the body due to its expression in a 
variety of tissues including the heart, the nervous system and the BM. N-cad is an 
essential molecule in the body as demonstrated by N-cad KO mice which died before 
birth due to heart defects and malformed somites (148).  
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Figure 1.12: Cleavage of N-cad upon activation. 1. N-cad binds homotypically to another N-cad 
molecule, resulting in cleavage of the extracellular domain by metalloproteinases. 2. The extracellular 
domain dissociates from the cell membrane and the intracellular domain is subsequently cleaved by γ-
secretase. 3. The intracellular domain dissociates from the cell membrane resulting in the release of a 
soluble α, β and zinc (zn) complex used in MAPK, ERK and β-catenin signalling pathways resulting in 
cellular invasion and migration. Adapted from Reiss et al 2005 (149). 
 
One potential role for N-cad in the BM is its involvement in the HSC niche, where it 
may anchor HSCs to osteoblasts lining the surface of bone. However, whether N-cad 
is an essential molecule for HSC maintenance in an osteoblastic niche has been highly 
debated previously. Several studies reported that KO of N-cad had no effect upon 
haematopoiesis (77, 150, 151) and Kiel et al and Bromberg et al were also unable to 
detect N-cad in purified HSCs by polymerase chain reaction (PCR) and flow 
cytometry. In contrast, in support of the importance of N-cad in a HSC osteoblastic 
niche, N-cad was expressed in both human primary trabecular osteoblasts as well as 
the osteoblastic cell lines MG-63 and SAOS2 (152). N-cad was also found to be 
expressed in KSL HSCs (83, 84, 142), which specifically localised to N-cad positive 
osteoblasts with a distinct “spindle” shape. In addition, BMPR1A deficient mice 
demonstrated an increase in N-cad positive osteoblasts lining the cortical and 
trabecular bone surfaces, which correlated with an increase in HSCs. This therefore, 
implies that N-cad positive osteoblasts may be responsible for the self-renewal or 
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survival of LT-HSCs (83). In addition, knock-down (KD) of N-cad in HSCs reduced their 
localisation to the endosteum in the BM in vivo and significantly reduced HSC long-
term repopulating ability in recipient mice in the BM but not in the spleen (153). 
Whereas, over-expression of N-cad in HSCs, resulted in slower cycling of HSCs, 
promoted HSC quiescence, and a higher number of HSCs were also found in close 
proximity to the bone in vivo (154). 
 
1.4 A potential myeloma cell niche 
 
As described in Chapter I Sections 1.2 and 1.3, there is a large amount of evidence in 
support of a HSC niche. The osteoblastic niche results in quiescence of the HSCs via 
the interactions of molecules expressed on the HSCs themselves and complementary 
molecules expressed by osteoblasts as shown in Figure 1.13a. 
 
The concept of MCs existing within a niche and expressing the same molecules as 
those expressed by HSCs is a moderately new theory and as of yet little research has 
been conducted in order to support this hypothesis. As stated previously, Chen et al 
(70) found that MCs (identified by a PKH26 dye) seemed to home preferentially to 
osteoblastic niches compared to vascular or splenic niches in vivo. In addition, these 
cells had a higher capacity for chemoresistance compared to MCs that were PKH26 
negative, when isolated and analysed ex vivo. Several reports have also 
demonstrated the importance of osteoblastic cells for prostate cancer metastasis to 
bone. Specifically, Shiozawa et al (155) found that using confocal microscopy, 
prostate cancer cells metastasised to osteoblastic niches in bone where they 
competed with existing HSCs. Upon, treatment with PTH to increase bone, or 
reduction of osteoblastic cells using the inducible Col 2.3 KO mouse model, there 
were increases and decreases respectively in prostate cancer metastasis to vossicles 
in vivo. In addition, treatment of naïve mice with the CXCR4 antagonist AMD3100 
resulted in mobilisation of HSCs out of the BM, which increased metastatic potential 
upon injection of prostate cancer cells, due to reduced competition for the 
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osteoblastic niche. Similarly, when mice with prostate bone metastasis were treated 
with AMD3100, this caused mobilisation of prostate cancer cells from the niche. 
These results are also supported by Wang et al (156) who found that prostate cancer 
cells homed preferentially to the lateral surfaces of bone, which was potentially 
mediated by higher numbers of osteoblastic cells on that surface compared to the 
medial surface. As with Shiozawa et al (155), this interaction was also inhibited using 
the CXCR4 antagonist AMD3100.  
 
A potential myeloma cell niche is illustrated in Figure 1.13b, which shows the 
expression of CXCR4, Notch-1, Tie-2 and N-cad by the MCs and the interaction of 
these molecules with their complementary ligands CXCL12, Jag-1, Ang-1 and N-cad, 
expressed by osteoblastic cells lining bone surfaces. These interactions may result in 
the adhesion of MCs to bone surfaces and may also propagate quiescence in these 
cells, providing a mechanism for MC survival in the BM.  
 
Currently, there is some evidence, which demonstrates the expression of the HSC 
niche molecules CXCR4, Notch-1 and N-cad by MCs (which is discussed in the 
introductions of the individual results chapters). However, the expression of these 
molecules by MCs has not been reported in the context of an osteoblastic niche in 
the current literature. In order to determine the expression of these molecules in 
MCs, preclinical models are typically used. The most common existing preclinical 
myeloma models are described below in Section 1.5.  
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Figure 1.13: A diagram representing molecule interactions in the HSC osteoblastic niche and 
proposed MC niche. a. Molecules expressed by HSCs are CXCR4, Notch-1, Tie-2 and N-cad. The 
complementary niche molecules expressed by osteoblastic cells are CXCL12, Jag-1, Ang-1 and N-cad. 
b. A diagram representing a proposed MM osteoblastic cell niche, where MCs express the same 
molecules as HSCs, which interact with their complementary ligands expressed by osteoblastic cells.   
a 
b 
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1.5 Preclinical multiple myeloma models 
 
Several models of myeloma have been developed over the past 40 years to assess 
the efficacy of drugs used in the treatment of MM. Common models previously used 
include immune-deficient xenograft models using human cell lines such as HS-Sultan 
(157), ARH-77 (158-160) and RPMI-8226 cells (161) injected intravenously (IV) or 
intraperitoneally (IP), or S6B45 cells injected subcutaneously (SC) (162) into Severe 
combined immunodeficiency (SCID) mice. Multiple myeloma disease is recapitulated 
in these animals (with the exception of the SC tumours), displaying characteristics of 
MM which include expansion of MCs in the BM, paralysis due to spinal cord 
compression and production of paraprotein. In addition, primary patient samples 
have previously been injected into human foetal long bone chips and implanted into 
immunocompromised mice resulting in MC growth in the human bone implant in the 
SCID-hu model of MM (163, 164). More recently MC cell lines including U266 and 
RPMI-8226 have also been injected into NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ 
(NOD/SCID γ) mice intra-tibially and U266 cells have been injected IV (165). Also 
NOD.Cg-Rag1tm1Mom IL2rgtm1Wjl/SzJ mice, a radiation resistant alternative to 
NOD/SCID γ mice (166) have been used for recapitulation of MM by injection of U266 
and H929 cell lines as well as primary MCs, injected IV.  
 
Alternatively, immune-competent myeloma models are used. These include the 5T 
series of MM cells, where C57BL/KaLwRij mice are injected with murine “myeloma 
like cells” (167). The 5T series of murine MCs originated spontaneously in 0.5% of 
C57BL/KaLwRij mice older than two years, first reported by Radl et al (168). The 5T 
series of murine models of myeloma are maintained by the isolation of 5T cells from 
the BM of tumour bearing mice and re-injection into young syngeneic recipient mice, 
where cells typically home to the BM, which is the primary location of disease 
progression. The full list of 5T murine MCs and their characteristics are listed below 
in Table 1.3. Most commonly used are the 5T2MM (49, 169, 170) 5T33MM (171-173) 
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and 5TGM1 (a derivative of the 5T33MM model produced by continual in vivo 
passage of the 5T33MM cells (174)) models of myeloma (175-178).  
Table: 1.3: The 5T series of murine models of MM  
Adapted from Asosign et al (179), permission from The Hematology Journal, 31.7.14. 
 
In this thesis, the 5T33 and 5TGM1 murine myeloma models were used. These 
particular models are well characterised at The University of Sheffield and have the 
advantage of using immune competent animals. 5T33MM and 5TGM1 cells can be 
maintained in vitro (5T33MMvt and 5TGM1vt) and in addition to wild type (WT) cells; 
green fluorescent protein (GFP) transduced cells (5T33-GFP and 5TGM1-GFP), have 
been developed for visualisation by flow cytometry and fluorescent microscopy.  
 
1.6 Summary 
 
In conclusion, MM is a B cell malignancy that develops in a specialised 
microenvironment in the BM. The specific mechanisms as to how MCs home, 
colonise and survive in the BM are not fully understood and further research is 
required in order to understand these processes.  
 
Haemopoietic stem cells exist in BM niches whereby their proliferation and 
differentiation is maintained by molecules expressed by the HSCs themselves and 
complementary niche molecules expressed by constituents of the BM 
microenvironment, which include osteoblastic cells. Myeloma cells may potentially 
5TMM series Isotype paraprotein Osteolytic bone lesion Growth pattern 
5T2 IgG2a κ Pronounced Moderate 
5T7 IgG2b κ Sporadic Slow, smouldering 
5T13 IgG2b κ Sporadic Moderate 
5T14 IgG1 
Mainly osteolytic, some sub-
lines osteosclerotic 
Moderate, some sub-
lines aggressive 
5T21 IgD Not studied Aggressive 
5T30 IgG2a κ Not studied Moderate 
5T33 IgG2b κ Diffuse Aggressive 
5TF IgG3 Mainly peripheral Moderate 
5TGM1 IgG2b κ Pronounced Aggressive 
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exist within a similar niche where they express a similar repertoire of molecules as 
the HSCs, which interact with their complementary ligands expressed by osteoblastic 
cells located on the surface of bone. These interactions may in-turn result in MC 
dormancy and subsequent survival in the BM. However, currently, little research has 
been conducted to identify whether these molecules are expressed by the MCs and 
whether they are important for the development of MM. Therefore, within my thesis 
I have conducted further research using the 5T series of murine myeloma models to 
explore whether MCs utilise the same molecular mechanisms as HSCs to acquire cell 
dormancy.  
 
1.7 Aims, hypothesis and objectives 
 
1.7.1 Aims and hypothesis 
The aim of this project was to test the overall hypothesis that “Myeloma cells exist 
within an osteoblastic niche similar to that occupied by HSCs”.  
Within this main hypothesis, further sub-hypotheses were explored: 
1. Myeloma cells express the same repertoire of molecules as HSCs and their 
complementary ligands are expressed by osteoblastic cells in vitro. 
2. Myeloma cells express the same repertoire of molecules as HSCs when analysed 
ex vivo and in vivo. 
3. Treatment of murine primary osteoblast lineage cells (OLCs) with osteogenic 
media (OGM) will result in osteoblast differentiation and differences in MC 
adhesion to OLCs at different stages of differentiation. 
4. The knock-down (KD) of HSC niche molecules in MCs will result in reduced MC 
adhesion to primary OLCs in vitro and a subsequent reduction in tumour burden 
in vivo. 
 
1.7.2 Objectives 
In order to test these hypotheses the following objectives were devised: 
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1. To determine the expression and presence of the HSC niche molecules CXCR4, 
Notch-1, Tie-2 and N-cad by the 5T33-WT, 5T33-GFP and 5TGM1-GFP cell lines 
using endpoint and real-time reverse transcription (RT)-PCR, flow cytometry and 
immunofluorescence (IF) in vitro. To also establish the expression and presence 
of the complementary ligands CXCL12, Jag-1, Ang-1 and N-cad by the MC3T3-E1 
osteoblastic cell line and murine primary OLCs, using endpoint and real-time RT-
PCR, flow cytometry and IF in vitro. 
2. To identify the presence of protein for CXCR4, Notch-1, Tie-2 and N-cad and 
complementary ligands CXCL12 and Jag-1 by BM derived 5T33-GFP and 5TGM1-
GFP cells and spleen derived 5TGM1-GFP cell lines ex vivo using flow cytometry. 
To also determine the presence of protein for CXCR4 and N-cad in 5TGM1-GFP 
infiltrated BM sections in vivo using IHC. 
3. To examine the effect of differentiating primary OLCs with OGM on alkaline 
phosphatase (Alp) production, mineralisation, expression of differentiation 
markers and HSC niche molecules and ligands using real-time RT-PCR, and 
attachment to 5TGM1-GFP cells in vitro.  
4. To Knock-down (KD) HSC niche molecules in 5TGM1-GFP cells using short hair-
pin ribonucleic acid (RNA) (shRNA), and to establish the effect of this on MC 
attachment to primary OLCs in vitro and tumour burden in vivo. 
 
Chapter II: Materials and methods Page 37 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter II: Materials and methods 
 
 
 
 
 
 
 
 
 
 
Chapter II: Materials and methods Page 38 
 
2.1 General cell culture methods 
 
All equipment, materials and reagents used in tissue culture are outlined in Appendix 
1, Section 1.1, Table 1.1. 
 
2.1.1 Cells 
2.1.1.1 The 5T murine myeloma cell lines 
The murine 5T33MM and 5TGM1 cell lines were kindly provided by Dr Karin 
Vanderkerken (Vrije Universiteit Brussel, Belgium) and Prof. Babatunde Olukayode 
Oyajobi (University of Texas Health Science Centre at San Antonio, USA) via Dr Claire 
Edwards (The University of Oxford, UK), respectively.  
 
2.1.1.2 MC3T3-E1 osteoblast cell line 
The MC3T3-E1 osteoblast cell line was originally purchased from The American Type 
Culture Collection (ATCC). Cells were previously isolated from the calvaria of C57BL/6 
mice and sorted by Alp expression described by Kodama et al (180). The cell 
population exist primarily as preosteoblasts however, they are able to differentiate 
into mature osteoblasts using supplements such as β-glycerophosphate (BGP) and 
ascorbic acid (asc), described by Kitching et al (181). 
 
2.1.1.3 Primary osteoblast lineage cells 
Primary OLCs were isolated at The University of Sheffield from C57BL/6 mouse pups 
as described in Section 2.2.1.2, described previously by Bakker et al (182). Like 
MC3T3-E1 cells they are able to differentiate into mature osteoblasts using BGP and 
asc, explored thoroughly by Lian and Stein et al (183) using rat calvarial osteoblasts 
and described by Yang et al (184) using murine primary osteoblasts.  
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2.1.2 Cell culture 
2.1.2.1 5T murine myeloma cell line culture 
All 5T murine MC lines were grown in “complete” Roswell Park Memorial Institute 
medium (RPMI), containing 10% foetal bovine serum (FBS), 1% 
penicillin/streptomycin (100 units/100 micrograms (µg)/millilitre (ml) (PS), 1% non-
essential amino acids (NEAA) (1X) and 1% (1 millimolar (mM)) sodium pyruvate (NaP), 
pre-warmed to 37 degrees Celcius (°C). Cells were passaged every three days or when 
confluent to ensure viability. At passage, the cells were split at a 1:5 dilution by 
removing 3 ml of MCs in suspension and transferring them to a fresh T75 flask 
containing 12 ml complete RPMI media. Cells were not used experimentally beyond 
passage six. Cells were cultured at 37°C in 5% CO2. 
 
2.1.2.2 MC3T3-E1 cell line culture 
MC3T3-E1 cells were cultured in “complete” Minimum essential medium alpha 
(MEMα) medium in the absence of deoxyribonucleosides and ribonucleosides, with 
10% FBS and 1% PS, pre-warmed to 37°C. Cells were passaged every three to four 
days or when confluent. At passage, the MEMα medium was removed and the cells 
were washed twice in 10 ml phosphate buffered saline (PBS). The cells were 
dissociated from the flask using 1.5 ml pre-warmed trypsin/ 
ethylenediaminetetraacetic acid (EDTA) (0.25%) at 37°C for 3 min (min). The 
trypsin/EDTA was neutralised using 8.5 ml complete MEMα medium and the cell 
suspension was transferred to a universal and centrifuged. All centrifugation was 
conducted at 300 x gravitational acceleration (G) for 5 min at room temperature 
unless stated otherwise. The cells were re-suspended in 10 ml complete MEMα 
media and 2 ml was transferred to a T75 flask containing 10 ml MEMα media. Cells 
were not used experimentally beyond passage six. Cells were cultured at 37°C in 5% 
CO2. 
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2.1.2.3 Primary osteoblast lineage cell culture 
All primary OLCs were cultured in “complete” MEMα, containing 
deoxyribonucleosides and ribonucleosides (MEMα-Nuc), 10% FBS, 1% PS and 1% 
fungizone anti-mycotic liquid (FZ), pre-warmed to 37°C. Primary OLCs not undergoing 
differentiation were not used beyond passage six, whereas cells for differentiation 
experiments were not used beyond passage two. Primary OLCs when passaged were 
split as described in Section 2.1.2.2 for the MC3T3-E1 cells. Cells were cultured at 
37°C in 5% CO2. 
 
2.1.2.4 Cell counting 
All cells were counted using a Neubauer haemocytometer, where 10 microlitres (µl) 
of a cell suspension was combined with 10 µl trypan blue. Ten µl of the mixture was 
placed under a coverslip attached to the haemocytometer and the cells were 
counted as shown in Figure 2.1.  
 
 
 
 
 
 
Figure 2.1: A schematic diagram of a haemocytometer: a. The dimensions and volume of each 
individual square. b. The volume of each 4x4 square grid. c. Cell number calculation. d. An example of 
cell number calculations.  
 
2.1.2.5 Cell thawing 
Each vial of cells was removed from liquid nitrogen and rapidly thawed by partial 
emersion in a 37°C water bath. The thawed cells were transferred to a universal 
containing 4 ml pre-warmed appropriate media, centrifuged and washed in 5 ml of 
a b 
c 
d 
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media. The wash step was repeated twice to ensure removal of dimethylsulphoxide 
(DMSO). After the final wash, the MCs were seeded at 1x106 cells per 12 ml of media 
into a T75 flask and the MC3T3-E1 and primary OLCs were seeded at 5x105 cells per 
12 ml of media into a T75 flask.  
 
2.1.2.6 Cell freezing 
Cells were counted, centrifuged and resuspended in 1 ml 10% DMSO/90% FBS per 
1x106 cells. Each ml was transferred to a cryovial and added to a freezing chamber 
containing 2-propanol. Cells were left over-night at -80°C, after which the vials were 
transferred to a liquid nitrogen dewar. This method allowed for uniform slow freezing 
of the cells and prevented ice crystal formation.  
 
2.1.2.7 Primary osteoblast lineage cell differentiation 
For all differentiation experiments, primary OLCs were seeded at a density of 
6000/cm2, into a variety of different sized wells and flasks depending on the analysis. 
The design of the individual aspects of the differentiation experiments are described 
in the methods section in Chapter V. Three days after seeding, the cells were cultured 
with or without media containing fresh BGP (10 mM) and asc (50 µg/ ml) (aliquoted 
at 100X and 1000X concentrations respectively and frozen at -20°C prior to use), 
referred to as OGM. When the cells were replenished, the old media was removed, 
the cells were washed twice in PBS and standard MEMα-nuc or OGM was then added. 
The cells were cultured in this manner every two-three days. 
 
2.2 Primary animal cells and tissues 
 
2.2.1 Animal cell isolation 
All equipment, materials and reagents used for animal cell isolation are listed in 
Appendix 1, Section 1.2, Table 1.2.  
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2.2.1.1 Animals 
C57BL/6 and C57BL/KaLwRij mice were purchased from Harlan (Leicester, UK) and 
the University of Leeds, respectively. All mice were housed in the University of 
Sheffield’s Biological Services. All animal work was approved by the local ethical 
committee and carried out under Home Office project licence numbers 40/2901 and 
40/3462. 
 
2.2.1.2 Primary osteoblast lineage cell isolation 
Two to four day old C57BL/6 pups were sacrificed by cervical dislocation per the Code 
of Practice for the Humane Killing of Animals under Schedule 1 (Scientific Procedures 
Act 1986). The calvaria from each pup was dissected free of soft tissue under sterile 
conditions and transferred into sterile PBS containing 1% PS. Each calvaria was 
washed three times in 5 ml of sterile Hank’s balanced salt solution (HBSS), containing 
1% FZ, by inversion. The calvariae were cut into small pieces and digested to release 
the osteoblastic cells. Firstly, 1 ml sterile collagenase II (1 mg/ml) per calvaria was 
added to the universal with the calvariae and incubated at 37°C for 15 min, inverting 
the tube every 5 min. The supernatant was removed and discarded (fraction 0). The 
calvariae were then digested in a further ml of collagenase II (1 ml per calvaria) for 
30 min at 37°C, inverting every 10 min. The supernatant was removed, centrifuged 
at 300 x g for 10 min, and re-suspended in 1 ml complete MEMα-Nuc medium and 
stored at 4°C (fraction 1). The calvariae were washed twice in 1 ml PBS and further 
digested in 1 ml sterile EDTA in PBS (4 mM, pH 8.0) per calvaria and incubated at 37°C 
for 30 min, inverting the tube every 10 min. The supernatant was removed and 
treated as with fraction 1 (fraction 2). The calvariae were then washed twice in 1 ml 
HBSS followed by digestion using 1 ml collagenase II (per calvaria) and incubated at 
37°C for 30 min, inverting the tubes every 10 min. The supernatant was removed and 
treated as with fraction 1 and 2 (fraction 3). All the fractions from each of the pups 
was pooled and divided between an equal number of T25 flasks to the number of 
pups. An additional 2 ml of media was added to each of the flasks to make a total 
volume of 5 ml. The cells were incubated until confluent (3-4 days), then pooled, 
counted and frozen down as described in Section 2.1.2.6. 
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2.2.1.3 Bone marrow isolation for RNA extraction 
The BM from 9-10 week old C57BL/6 mice was isolated to act as a positive control in 
PCR and flow cytometry experiments for the detection of HSC niche molecules and 
ligands. Mice were sacrificed under the Schedule 1 Code of Practice for the Humane 
Killing of Animals (Scientific Procedures Act 1986) by IP injection of 100 µl 
pentobarbitone (200 mg/ml) followed by cervical dislocation. The hind limbs were 
carefully dissected free of soft tissue and the femora and tibiae were separated at 
the knee joint. The proximal and distal ends of each bone were cut using a scalpel to 
expose the BM. To isolate the BM, each hind limb was flushed using a sterile needle 
(27 Gauge) containing 500 µl PBS and the content of each bone was transferred to a 
1.5 ml Eppendorf. The samples were centrifuged, the supernatant removed and the 
cell pellets were used for RNA extraction as described in Section 2.3.1 1. 
 
2.2.1.4 Bone marrow, splenocyte and blood isolation for flow cytometry 
Bone marrow, splenocytes and blood were isolated from 9-10 week old C57BLK/6 
mice to act as a positive control for initial antibody optimisation experiments. In 
addition, the BM and spleen were isolated from 6-8-week-old C57BL/KaLwRij mice 
injected with 5T33-GFP or 5TGM1-GFP cells for the detection of HSC niche molecules 
and ligands in experimental flow cytometry experiments. 
 
Bone marrow was isolated as described in Section 2.2.1.3. However, after the 
samples were centrifuged and the supernatant removed, 2 ml RBC lysis buffer (1X, 
diluted in distilled water (H2O) (dH2O)), was added to each cell pellet and incubated 
at room temperature for 10 min. Lysed RBCs were removed from the sample 
supernatant by centrifugation and the sample was subsequently washed twice in 1 
ml wash buffer (1X diluted in dH2O), provided in the RBC lysis kit. Bone marrow cells 
isolated from C57BL/6 mice were counted and 1x106 cells were used per flow 
cytometry sample for the detection of HSC niche molecules and ligands. Whereas, 
only 100,000 BM cells, isolated from C57BL/KaLwRij mice were used per flow 
cytometry sample, due to the large numbers of samples required.  
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To isolate the splenocytes, the spleen was carefully dissected and torn into 5 ml 
Dulbecco's Modified Eagle Medium (DMEM) into a petri dish. The suspension was 
filtered through a 70 µm cell strainer, to remove large pieces of tissue, followed by 
centrifugation. Red blood cells were lysed and 1x106 splenocytes, isolated from the 
C57BL/6 mice and 100,000 splenocytes isolated from the C57BL/KaLwRij mice were 
used per flow cytometry sample.  
 
Blood was extracted from pentobarbitone-sedated mice via cardiac puncture using a 
sterile needle (27 Gauge). The blood was immediately transferred to a vacutainer 
coated in EDTA to prevent coagulation and 1 ml RBC lysis buffer was added per 100 
µl of extracted blood for 10 min at room temperature. Red blood cells were removed 
from the supernatant following centrifugation at 600 x g for 8 min at room 
temperature and the remaining cells were washed twice in RBC lysis wash buffer. 
Flow cytometry was then conducted using 100,000 blood cells per sample isolated 
from the C57BL/6 mice and 10,000 isolated from C57BL/KaLwRij mice. 
 
2.2.2 In vivo models of multiple myeloma 
 
2.2.2.1 The 5T33-GFP and 5TGM1-GFP models of multiple myeloma for detection 
of HSC niche molecules and ligands 
Six to eight week old C57BL/KaLwRij mice were injected IV via the tail vein with either 
1x106 5T33-GFP or 2x106 5TGM1-GFP cells. All mice were sacrificed upon 
presentation of hind limb paralysis (a clear indicator of tumour load). In the 5T33MM-
GFP model this occurred within 4-6 weeks post-injection (P-I), whereas in the 
5TGM1-GFP model this occurred at 21-23 days P-I. Tumour burden and the presence 
of protein for HSC niche molecules and ligands in the tibiae were assessed by flow 
cytometry as described in Sections 2.2.1.4 and 2.4.1.2. Further details of study design 
are outlined in the methods section in Chapter IV and Chapter VI.  
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2.2.2.2 Gene knock-down experiments in the 5TGM1-GFP model 
For N-cad KD studies, a pilot experiment was firstly conducted where 11 week old 
female C57BL/KaLwRij mice were injected IV with either 2x106 un-transduced 
5TGM1-GFP, scrambled control cells (CTRL 25) or N-cad KD (KD 25) cells. At the first 
signs of illness, the entire cohort of mice was sacrificed. Tumour burden was 
determined by flow cytometry and CD138 IHC, as described in Sections 2.4.1.2 and 
2.4.3.3 respectively, and bone disease was analysed using micro CT (µCT) as 
described in 2.7.1.1. Further details of the study design are outlined in the methods 
sections in Chapter VI. 
 
2.3 Molecular biology methods 
 
2.3.1 RNA extraction 
All equipment, materials and reagents used for RNA extraction are outlined in 
Appendix 1, Section 1.3, Table 1.3. 
 
2.3.1.1 RNA methodology 
To detect the gene expression of each HSC niche molecule, ligand and the plasma cell 
marker CD138 from the desired tissue or cell type, the messenger RNA (mRNA) was 
firstly extracted using a phenol/chloroform method (Ultraspec reagent). Myeloma 
cells, MC3T3-E1 and primary OLCs were set-up in culture 24 hours prior to extraction, 
as described in the method sections in the individual results chapters. After 24 hours, 
the MC cells were centrifuged, washed once in 5 ml PBS and re-suspended in 1 ml 
Ultraspec RNA isolation solution. Whereas, for the MC3T3-E1 cells and primary OLCs, 
the media was removed, the cells were washed once in 5 ml PBS, and 1 ml Ultraspec 
was added directly to each flask. In addition, the cell pellets from the murine BM 
samples, following their isolation, as described in Section 2.2.1.3, were re-suspended 
directly into 1 ml of Ultraspec solution. All cells were then transferred to a 1.5 ml 
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RNase and DNase free tube and vigorously vortexed for homogenisation for 5 min at 
4°C. 
 
To each sample, 200 µl of chloroform was added and incubated at 4°C for 5 min. This 
was followed by centrifugation at 12,000 x g for 15 min at 4°C after which the content 
of each tube had separated into three phases; a lower organic phase, an inter-phase 
and an upper aqueous phase containing the RNA. The aqueous phase was transferred 
to a new 1.5 ml RNase and DNase free tube and an equal volume of isopropanol was 
added. The samples were then incubated for a further 20 min at 4°C and centrifuged 
again at 12,000 x g for 5 min at 4°C to precipitate the RNA. The samples were then 
washed twice in 70% ethanol diluted in diethylpyrocarbonate (DEPC) water and 
centrifuged at 7,500 x g for 5 min in between washes. The RNA pellet was air dried 
and solubilised in 30-50 µl of DEPC water. The samples were then stored at -80°C 
until required for RT. 
 
2.3.1.2 Quantification of RNA 
The purity and concentration of all RNA samples were determined using a NanoDrop 
2000 and its dedicated software. The purity of each sample was determined using 
the 260/280 nanometre (nm) and 260/230 nm absorption ratios. Ribonucleic acids 
absent of protein contamination (260/280 nm) had a value above 1.8 and RNA which 
did not contain impurities such as phenol or ethanol (260/230 nm) had a value of 
between 2.0-2.2. An example of the curves generated using the NanoDrop 2000 
software are shown in Appendix 2, Section 2.1. The concentration of the RNA, which 
was usually between 200-600 nanograms (ng)/µl, was also calculated using the 
NanoDrop 2000 software.  
 
2.3.1.3 RNA fragment-length analysis 
Fragment length analysis of each RNA sample was established using an Agilent 
Bioanalyser 2100 and analysed using 2100 Expert Software by Paul Heath at The 
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University of Sheffield. An RNA integrity number between 9.0 and 10 indicated 
suitable RNA fragment length. Examples of fragment length analysis are shown in 
Appendix 2, Section 2.2. 
 
2.3.2 Reverse transcription 
All equipment, materials and reagents used for RT are outlined in Appendix 1, Section 
1.4, Table 1.4. 
 
2.3.2.1 Reverse transcription methodology 
Reverse transcription was conducted to convert mRNA into complementary DNA 
(cDNA), for subsequent PCR experiments. To remove any contamination before 
conducting RT, the required number of 0.5 ml RNase and DNase free tubes for the RT 
reaction were irradiated for 30 min in an ultra violet (UV) hood. Two micrograms of 
RNA was calculated and the required volume was transferred to an irradiated 0.5 ml 
tube and DEPC H20 was added to make a final volume of 11 µl. For each RNA sample, 
a superscript positive (a sample with reverse transcriptase enzyme) (RT+) and 
superscript negative (a sample without reverse transcriptase enzyme) (RT-) replicate 
was prepared, to control for genomic contamination.  
Reverse transcription was conducted by combining random primers, 
deoxynucleotide triphosphates dNTPs and DEPC H20 together in a 0.5 ml tube. The 
volumes required of each reagent for one sample is shown in Table 2.1. Two 
microlitres of this mixed was added to each tube containing the RNA and DEPC H20 
to make a 13 µl solution. The samples were then placed in a MJ Research PTC 200 
thermal cycler for 5 min at 65°C to allow for the binding of the random primers to 
the RNA template. After 5 min, the samples were removed from the thermal cycler 
and cooled at 4°C for at least 1 min.  
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Table 2.1: Reagents required for one sample in the first phase of reverse transcription 
 
 
 
 
This was followed by combining first strand buffer, dithiothreitol (DTT), RNase 
inhibitor (RNasin) together and then adding either SuperScript RT enzyme (RT+) or 
DEPC H20 (RT-). The volumes added are shown in Table 2.2. 
 
Table 2.2: Reagents required to make one RT+ and RT- sample in the second phase of reverse 
transcription 
 
The entire 7 µl of the mix was then added to each RNA sample and placed in the 
thermal cycler. The RT samples were heated at 25 °C for 5 min, followed by 50 °C for 
55 min, 70 °C for 15 min and 4 °C thereafter, as described in Table 2.3. The cDNA 
samples were then removed from the thermal cycler, diluted approximately to 20 
ng/µl, using nuclease free water and stored at -20°C until required for PCR. 
 
 
Reagent 
Stock solution Working solution Volume 
(µL) 
DEPC H2O n/a n/a 0.5 
Random primers 500 ng/ µl 250 ng 0.5 
dNTPs 10 nM 5 nM 1 
Reagent 
Stock solution Working solution RT- 
volume 
(µL) 
RT+ 
Volume 
 (µL) 
First strand buffer 5X 1X 4 4 
DTT 0.1 M 5 mM 1 1 
RNasin 
1 unit/ µl 1 unit 1 1 
SuperScript III, 
Reverse transcriptase 
enzyme 
200 units/ µl 200 units 0 1 
DEPC H2O 
n/a n/a 1 0 
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Table 2.3: Temperatures and times used for reverse transcription 
Temperature (°C) Time (Min) 
25 5 
50 55 
70 15 
4 Thereafter 
 
 
2.3.3 Endpoint PCR 
All equipment, materials and reagents used for endpoint PCR are outlined in 
Appendix 1, Section 1.5, Table 1.5. 
 
2.3.3.1 Principals of endpoint PCR 
Endpoint PCR is a tool used for the amplification of a sequence of DNA from a 
particular gene of interest (GOI). Once amplified, the gene product can be visualised 
by agarose gel electrophoresis. The basic principle of PCR, which is displayed in Figure 
2.2, involves the use of a heat stable enzyme known as Taq polymerase, isolated from 
the bacterium Thermus Aquaticus. Within the PCR reaction, specific primers bind to 
their complementary nucleotides on the cDNA template, initiating the binding of Taq 
polymerase and subsequent transcription of a complementary strand of the 
template by the binding of dNTPs to their complementary nucleotides. After a 
number of cycles, the desired product is amplified sufficiently for visualisation in the 
agarose gel.  
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Figure 2.2: A 
schematic diagram 
displaying the 
process of gene 
amplification using 
PCR. 1. DNA is 
denatured to form 
two complementary 
strands. 2. Primers 
then anneal to their 
complementary 
sequence on each 
strand of DNA, which 
initiates binding of 
Taq polymerase. 3. 
Taq polymerase then 
transcribes the 
complementary 
strand by addition of 
dNTPs and 
elongation of the 
strand. This cycle is 
repeated to amplify 
the gene of interest 
(GOI). 
 
 
 
 
 
 
2.3.3.2 Endpoint PCR methodology 
An endpoint PCR mix was made by combining magnesium chloride (MgCl2), 
ammonium buffer, dNTPs, sense and anti-sense primers, Taq polymerase and RT-PCR 
H2O. Forty-eight microlitres of the PCR mix was added to 2 µl of cDNA (approximately 
40 ng) to make a final volume of 50 µl. The volume required of each reagent for one 
sample is described in Table 2.4. 
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Table 2.4: Reagents required for one endpoint PCR sample 
 
 
 
 
 
 
Samples were loaded into the thermal cycler. The standard settings for the PCR 
reactions were as follows; denaturation at 95⁰C for 5 min, annealing for 1 min 
(temperatures varied for each set of primers, see Appendix 2, Section 2.4, Table 2) 
and elongation at 72⁰C for 1 min. These steps were then repeated for the number of 
cycles required; see Appendix 2, Section 2.4, Table 2 for cycle numbers. This was 
followed by a final elongation step at 72⁰C for 10 min and the samples were then 
cooled to 4⁰C. The end PCR product was either stored at 4°C short-term or at -20°C 
long-term. 
 
2.3.3.3 Primer design 
Primers were designed using the following guidelines: 20 base pair (BP) in length, 
G+C content between 40%-60%, no repeated lengths greater than 3 BP, no repeat 
dinucleotides e.g. ATATATATA, primers must not be complementary to avoid primer 
dimer, must cross exon boundaries, the melting temperatures (Tm) must not differ 
by >5°C between the primers, the 3’ end should contain a G or C (G/C Clamp). 
The full sequence of each set of primers and their Tms are shown in Appendix 2, 
Section 2.5, Table 2.2.  
 
Reagent Stock solution 
Working 
solution 
Volume (µL) 
MgCl2  50 mM 3 mM 3 
Ammonium 
buffer 
10X 1X 5 
dNTPS 10 nM 1 nM 5 
Sense and anti-
sense primers  5 µm 0.2  µm 2 
Taq polymerase 
5 units/ µ 2.5 units 0.5 
RT-PCR H20 
n/a n/a 30.5 
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2.3.4 Gel electrophoresis 
All equipment, materials and reagents used for gel electrophoresis are outlined in 
Appendix 1, Section 1.6, Table 1.6. 
 
2.3.4.1 Principals of gel electrophoresis 
Gel electrophoresis allows for the separation and subsequent visualisation of PCR 
products. The amplified DNA is loaded into an agarose gel and when a current is 
applied, the negatively charged DNA moves through the gel towards the anode. The 
larger the size of DNA product, the slower it moves through the gel due to the 
restriction of the agarose pore size. Therefore, larger products are visualised nearer 
to the top of the gel. A DNA ladder is also used to estimate the BP size of the DNA 
product. Ethidium bromide in the agarose binds to DNA present in the sample and 
subsequently fluoresces upon exposure to UV light. Therefore, gene expression of 
the sequences amplified by PCR are visualised as a white band. 
 
2.3.4.2 Gel electrophoresis methodology 
The agarose gel for the electrophoresis was made using trizma base, acetic acid, EDTA 
(TAE) buffer (pH 8.0) and agarose. The quantities of each reagent required to make 
one litre of 50X TAE buffer demonstrated in Table 2.5.  
 
Table 2.5: Reagents and the quantities required to make 1 litre of 50X trizma base, acetic acid and 
EDTA buffer 
Reagent Stock solution Working solution Amount required 
Trizma base n/a 2 M 242 g 
EDTA pH 8.0 0.5 M 50 mM 100 ml 
Glacial acetic acid  Glacial 1 M 57.1 ml 
dH2O n/a n/a 842.9 ml 
 
The 50X solution was then diluted 1:50 using dH2O before use, to produce a solution 
containing 40 mM tris base, 20 mM glacial acetic acid and 1 mM EDTA, pH 8.0. To 
make the gel, agarose was added to the TAE buffer at a 1.6% concentration and then 
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dissolved by heating in a microwave. The agarose was then cooled to approximately 
60°C and ethidium bromide was added at a final concentration of 0.5 µg/ ml. The 
agarose was then poured into a gel mould and electrophoresis combs were added to 
form wells. The gel was then left to cool to room temperature for 45 min. Once 
cooled the gel was transferred to an electrophoresis tank containing 1X TAE buffer, 
which covered the surface of the gel. The combs were removed to allow for the 
addition of PCR products into the wells. Twenty microlitres of PCR product and 5 µl 
of loading buffer (1X) were added to an irradiated 0.5 ml RNase and DNase free tube. 
Fifteen microlitres of RT+ and RT- samples were loaded into neighbouring wells 
preceded by 15 µl of RT-PCR H2O and 15 µl of the hyperladder IV. The DNA was then 
separated at 120 Volts using a power pack for 40 min and visualised using a Bio-rad 
Gel Doc XR+ Imager system and Quantity One 4.6.8 software. 
 
2.3.4.3 Gene sequencing 
To confirm the specificity of the PCR products, each PCR sample was sequenced in-
house by the University of Sheffield Medical School Genomics Facility. After 
sequencing, the exact homology was analysed by comparing the sequencing results 
with the expected template and GenBank archives.  
 
2.3.5 Real-time PCR 
All equipment, materials and reagents used for real-time PCR are outlined in 
Appendix 1, Section 1.7, Table 1.7. 
 
2.3.5.1 Principals of real-time PCR 
Real-time PCR uses the basic principles of PCR however, rather than displaying the 
results in an agarose gel the results are assessed quantitatively in “real-time”. In 
addition, rather than using primers, intercalating dyes or fluorescent hydrolysis 
probes are used. The intercalating dyes bind directly to the DNA whereas, the 
fluorescent probes, bind to complementary nucleotides on the cDNA template. 
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Fluorescent probes are made of DNA oligonucleotides with a 5 prime end (5’) bound 
to a reporter molecule (such as 6-carboxyfluorescein (FAM)) and a 3 prime end (3’) 
bound to a quencher molecule, such as minor groove binder (MGB), Their use in real-
time PCR is shown in Figure 2.3.  
 
 
 
 
 
 
 
 
 
 
Figure 2.3: A schematic diagram displaying binding of a probe to its DNA target sequence and 
sequential fluorescence emission. The probe consists of a DNA sequence complementary to its target 
gene, in addition to a reporter (R) and quencher (Q) molecule. a. The probe binds to the complementary 
nucleotides on the cDNA template. At this point, when the molecules are in close proximity, the 
fluorescent out-put is low. b. The reporter is cleaved by Taq polymerase. c. Separation of the reporter 
and quencher molecules result in an increase in fluorescent out-put. With every cycle the fluorescence 
increases producing a cycle threshold (Ct) value, which indicates the number of cycles required to cross 
the set threshold. The greater the abundance of target sequence, the greater the fluorescence and 
fewer cycles required to cross the threshold, resulting in a lower Ct value. 
 
2.3.5.2 Real-time PCR methodology 
To remove any contamination, a 384 well plate, 0.5 ml RNase and DNase free tubes, 
RT-PCR H20, a microseal adhesive cover and tips were placed in the UV hood for 30 
min. For each reaction, a mix containing RT-PCR H20, Master Mix and probes was 
made using the volumes for one sample demonstrated in Table 2.6.  
 
a 
b 
c 
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Table 2.6: Reagents and the quantities required for one real-time PCR sample 
Reagent Stock solution Working solution Volume (µl) 
RT-PCR H2O n/a n/a 2.5 
Master Mix  5X 1X 5 
Probe   0.5 
 
The entire 8 µl mix was transferred into a well of the 384 well plate and to this, 2 µl 
of cDNA (approximately 40 ng) was added. The plate was covered using the microseal 
adhesive cover and centrifuged at 300 x g for 1 min at room temperature to ensure 
all liquid was combined at the bottom of the well. The probes used were designed to 
bind to complementary nucleotides on the cDNA template for the GOI and 
housekeeping (HK) genes, which included β2M, hypoxanthine-guanine 
phosphoribosyltransferase (HPRT) or transferrin receptor (TFRC) designed by Life 
Technologies. The list of probes used and their reference numbers are in Appendix 2, 
Section 2.6, Table 2.4. The plate was analysed using the HT 7900 real-time PCR 
machine and SDS 2.3 software. Cycle conditions, which were standard for all real-
time PCR machines per Applied Biosystems, are described in Figure 2.4. 
 
 
 
 
Figure 2.4: A diagram describing the conditions used for real-time PCR. At stage one the reaction 
mixture containing the probes, Master Mix and cDNA was heated to 50°C for 2 min to activate all 
reaction reagents, followed by specific Taq activation for 10 min at 95°C, at stage 2. Stage 3 and 4 
conditions were repeated for 40 cycles whereby the cDNA and complementary strands were denatured 
at 95°C for 0.15 min followed by annealing of probes and elongation at 60°C for 1 min. 
 
Gene expression of each molecule was either presented using their Ct values or 1/ΔCt 
value (calculated by normalisation to a HK gene), or using the fold change or 
percentage of gene expression using the ΔΔCt method. The latter is shown in greater 
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detail in Table 2.19. Genes which were not expressed and had a Ct value of greater 
than 35 were referred to as undetermined (UD).  
 
2.3.5.3 Probe efficiency 
Probe efficiency experiments were conducted before use of the probes, the results 
for which are shown in Appendix 2, Section 2.6, Figure 2.3. Serial dilutions of control 
murine BM cDNA (101-104), were added as in the reactions described above. The data 
was presented graphically using the Ct values and trend lines were plotted. Primer 
efficiency was calculated using this formula: Efficiencyx = 10(-1/slope) -1 * 100. The 
percentage efficiency values for each of the probes is shown in Appendix 2, Section 
2.6, Table 2.6. All probes were within the acceptable range of efficiency of between 
90-110% as advised by the manufacturer, with the exception of TFRC, which was not 
used in future experiments. 
 
2.4 Cell biology 
 
2.4.1 Flow cytometry 
All equipment, materials and reagents used for flow cytometry are outlined in 
Appendix 1, Section 1.8, Table 1.8. 
 
2.4.1.1 General principles of flow cytometry 
Flow cytometry is a technique which allows for the quantification of protein on a per 
cell basis, as illustrated in Figure 2.5. In summary, a fluorescently labelled antibody 
binds to its antigen if present on the cell. The cell with the bound fluorescent 
antibody or a cell absent of fluorescent antibody moves through the pressurised 
system passing through beams of light and subsequent detectors, which detect the 
forward scatter (cell size) and side scatter (granularity) and therefore providing 
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information with regards to the general structure of the cell. In addition, a series of 
lasers excite the fluorochromes attached to the bound antibodies and the light 
reflected passes through dichromic mirrors to the detectors, which detect specific 
wavelengths dependent on the fluorochrome used. The results are then analysed 
using specialised computer software. If fluorescence is detected by the software, this 
implies that an antibody is bound, and the software expresses the results as a 
percentage of the cells with bound antibody. Therefore, this provides information 
about the percentage of the cell population, which are positive for the antigen of 
interest. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.5: A schematic diagram illustrating the principles of flow cytometry a. The cells are 
incubated with a fluorescent antibody. b. Upon flow cytometry, the cells travel through the flow 
cytometry machine via the flow cell and the antibodies are excited by a series of lasers. c. Their 
emission wavelengths are reflected by dichroic mirrors and pass through various filters (FL-1 to FL-4, 
forward scatter (FSC) and side scatter (SSC)). d. The emission signal detected is analysed and 
interpreted by computer software. Adapted from Brown et al (185) (2000), permission from The 
Journal of Clinical Chemistry. 
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2.4.1.2 Flow cytometry methodology 
The murine BM, splenocytes and blood samples were prepared for flow cytometry 
as described in Section 2.2.1.4. All cell lines were counted and set-up in tissue culture, 
24 hours prior to flow cytometry as described for RNA extractions in Section 2.3.1 1.  
 
On the day of flow cytometry, the MCs were harvested directly from the 6 well plate, 
transferred to a universal, centrifuged and washed twice in 10 ml PBS. The media 
from the MC3T3-E1 cells and primary OLC samples in the T75 flasks was removed and 
the cells were washed twice in 10 ml PBS before 5 ml cell dissociation solution was 
added. Flasks were then incubated at 37⁰C for 3 min to gently detach the cells from 
the surface of the flask without impairing surface protein expression. The remaining 
cells were gently scraped from the surface using a cell scraper and 10 ml of 
appropriate medium was added to the harvested cells. The cells were centrifuged 
and re-suspended in 10 ml of media, which was transferred to a T25 flask. This 
suspension of cells was then left standing upright in the incubator at 37⁰C for 3 hours 
to restore any receptor activity that may have been impaired. After the allocated 
time, the cells were harvested and washed twice in 10 ml PBS.  
 
All cell types (which included the BM, splenocytes, blood cells, MCs and osteoblastic 
cells) were centrifuged and 200 µl 10% goat serum diluted in 0.5% bovine serum 
albumin (BSA) in PBS was added per sample, transferred to a well in a V-bottomed 
96 well plate and incubated for 20 min at 4°C to block Fc receptors. After which, the 
cells were centrifuged as normal for the myeloma, osteoblastic, BM and spleen 
derived cells or 600 x g for 8 min at room temperature for the blood. They were then 
re-suspended in 100 µl 0.5% BSA and surface staining of CXCR4, Jag-1, Tie-2 and 
CD138 was conducted by adding an optimum concentration of antibody and matched 
dose of isotype control antibody (shown in Table 2.7) to each sample re-suspended 
in 100 µl 0.5% BSA. Samples were incubated at 4⁰C for 30 min in the dark. After 
incubation, the samples were washed three times in 200 µl 0.5% BSA, using the 
centrifugation settings described previously. After the final wash, the samples were 
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re-suspended in 300 µl 0.5% BSA, passed through a 70 µM cell strainer and 
transferred to flow cytometry tubes.  
 
Notch-1 and CXCL12 protein detection required an intracellular staining technique, 
whereby the cells were centrifuged after blocking and fixed in 100 µl 4% 
paraformaldehyde (PFA) per sample, provided in the permeablisation kit, for 10 min 
at room temperature. After fixation, the samples were centrifuged as before, washed 
once in 200 µl PBS and then washed twice in 200 µl permeablisation buffer, provided 
in the permeablisation kit (diluted to 1X using dH2O). The cells were then re-
suspended in 100 µl permeablisation buffer, the optimum antibody concentration 
was added to the cells and the samples were incubated at 4⁰C for 30 min in the dark. 
After incubation, the cells were washed three times in 200 µl permeablisation buffer, 
re-suspended in 300 µl 0.5% BSA and the cells were passed through a 70 µm strainer 
and transferred to flow cytometry tubes.  
 
Table 2.7: Antibodies used in flow cytometry 
Antibody 
specificity 
Host Isotype Fluorochrome 
Amount of 
antibody 
Supplier 
Anti-CXCR4 Rat IgG2b ĸ APC 0.5 µg eBioscience 
CXCR4 isotype Rat IgG2b ĸ APC 0.5 µg eBioscience 
Anti-CXCL12 Mouse IgG1 APC 0.25 µg R&D Systems 
CXCL12 isotype Mouse IgG1 APC 0.25 µg R&D Systems 
Anti-Notch-1 Mouse IgG1 ĸ PE 1.0 µg eBioscience 
Notch-1 isotype Mouse IgG1 ĸ PE 1.0 µg R&D Systems 
Anti-Jag-1 
Armenian 
hamster 
IgG PE 0.5 µg eBioscience 
Jag-1 isotype 
Armenian 
hamster 
IgG PE 0.5 µg 
Cambridge 
Bioscience 
Anti-Tie-2 Rat IgG1 ĸ PE 0.5 µg eBioscience 
Tie-2 isotype Rat IgG1 ĸ PE 0.5 µg 
Cambridge 
Bioscience 
Anti-N-cad Mouse IgG1 Dylight 650 0.25-1.0 µg 
Novus 
Biologicals 
N-cad isotype Mouse IgG1 APC 0.25-1.0 µg R&D Systems 
Anti-CD138 Rat IgG2a ĸ APC 0.5 µg 
BD 
Pharmingen 
CD138 isotype Rat IgG2a ĸ APC 0.5 µg eBioscience 
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To detect the viability of cells, where possible, cells were stained with 2 µl of either 
TO-PRO 3 iodide (TO-PRO-3) (final concentration of 2 nM) or propidium iodide (PI) 
(final concentration of 50 µg/ml). The samples were analysed using a Fluorescence-
Activated Cell Sorting (FACS) Calibur machine (Becton Dickinson) (BD). The laser and 
detectors used for analysis were dependent on the absorbance and emission spectra 
of each fluorochrome. The lasers used to excite each fluorochrome and the detector 
used to analyse their emissions are displayed in Table 2.8. In order to prevent spectral 
overlap between the GFP in FL-1 and the PI or PE in FL-2, compensation was applied. 
Compensation used to prevent FL-1/FL-2 overlap was 20%, established using naïve 
BM or WT myeloma cell samples by comparing it to GFP positive samples. 
Compensation to prevent FL-2/FL-1 overlap was 4.5%, established using PI and PE 
negative BM or cell samples, which were compared to PI and PE positive samples. 
These settings were consistently used throughout all experiments with GFP 
expressing cells and PE and PI fluorochromes.  
 
The percentage of cells which were positive for each fluorochrome and therefore, 
positive for tumour burden or each molecule in 10,000-100,000 events was then 
calculated using the Cell Quest software. These were calculated by drawing a gate 
around the GFP or fluorochrome positive population based on naïve BM or isotype 
control samples, to ensure that less than one percent of staining was evident in the 
gated region. The settings for the gates then remained the same throughout each 
experiment.  
 
The Cell Quest software can also analyse mean fluorescent intensity (MFI), however, 
the main focus within these experiments was the number of positive cells in the 
population rather than intensity on a per cell basis, therefore, MFI was not 
calculated. 
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Table 2.8: Laser, absorbance, emission and detector information for each fluorochrome used in flow 
cytometry 
 
 
 
 
 
2.4.2 Immunofluoresence staining 
All equipment, materials and reagents used for IF are outlined in Appendix 1, Section 
1.9, Table 1.9. 
 
2.4.2.1 Principles of immunofluorescence staining 
Immunofluorescence was used for the visualisation and quantification of the 
presence of protein by the 5T33-GFP and 5TGM1-GFP MCs. The general principals 
are similar to flow cytometry whereby a fluorescent antibody binds to the antigen of 
interest on cells however; the cells are bound to a fixed surface rather than in 
suspension. When the cells are placed under a fluorescent microscope, bound 
fluorescent antibodies attached to the cells, are excited by a light source, and light 
emitted passes through a series of filters and detectors to produce an image using 
the computer software. 
 
2.4.2.2 Immunofluorescence staining methodology 
The 5T33-GFP and 5TGM1-GFP cells were grown in culture as described in 2.1.2.1 and 
subsequently stained for the HSC niche molecules, ligands and CD138 by IF. On the 
day of IF staining, 1x105 cells per sample were transferred to a universal and washed 
once in 5 ml PBS before fixation in 500 µl 4% PFA for 10 min at room temperature. 
After fixation, the cells were washed twice in 5 ml PBS and re-suspended in 200 µl 
 
Laser 
excitation 
(nm) 
Absorbance 
Max (nm) 
Emission Max 
(nm) 
Detector 
GFP 488 490 515 FL-1 
Phycoerythrin 
(PE) 
488 496 578 FL-2 
Allophycocyanin 
(APC) 
633 650 660 FL-4 
PI 488 540 620 FL-2 
TO-PRO-3 633 640 657 FL-4 
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PBS. The cells (1x105) were then cytospun at 500 rotations per min (RPM) for 5 min 
on a medium acceleration on to a super-frost slide and then left to dry for 5 min at 
room temperature before beginning the staining the procedure. 
 
The cells were isolated using a hydrophobic barrier pen to contain staining solutions 
and the slides were placed in PBS. They were then added to a humidified immuno-
tray where they were blocked in approximately 200 µl 10% goat serum in PBS for 20 
min at room temperature. For cell surface staining of CXCR4, Notch-1 and CD138, the 
block was “tapped” off and approximately 200 µl primary fluorescent antibody or 
matched dose isotype antibody diluted in PBS was added. The dilution of each 
antibody is displayed in Table 2.9. The antibodies were incubated for 45 min at room 
temperature in the dark, followed by washing in PBS three times for 5 min.  
 
For intracellular staining of CXCL12, the cells were permeablised after blocking by 
washing the slides twice in a bath containing 0.5% tween diluted in PBS (PBST) for 5 
min per wash. After which the slides were stained with the appropriate dilution of 
antibody in 0.5% PBST for 45 min at room temperature in the dark. The slides were 
then washed three times in a bath containing 0.5% in PBST, 5 min per wash.  
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Table 2.9: Antibodies used for immunofluorescence staining 
 
After extracellular and intracellular staining and subsequent washing, the slides were 
cover-slipped using the aqueous Prolong Gold mount containing 4',6-Diamidino-2-
phenylindole, dihydrochloride (DAPI) and 22 x 22 millimetre (mm) cover slips. The 
edges were then sealed with nail varnish and the slides were left to dry for an hour 
before examining by fluorescent microscopy. 
 
2.4.2.3 Fluorescent microscopy 
Immunofluorescence staining was visualised using a Leica AF6000 microscope and 
LAS-AF software. The settings forvisualising both the DAPI and APC are displayed in 
Table 2.10. The settings differed slightly depending on the molecule being analysed. 
 
 
 
 
 
 
Antibody 
specificity 
Host 
 
Isotype Fluorochrome Concentration Dilution Supplier 
Anti-
CXCR4 
Rat IgG2b ĸ APC 0.2 mg/ml 1:300 eBioscience 
CXCR4 
isotype 
Rat IgG2b ĸ APC 0.2 mg/ml 1:300 eBioscience 
Anti-
CXCL12 
Mouse IgG1 APC 20 µg/ml 1:5 R&D Systems 
CXCL12 
isotype 
Mouse IgG1 APC 10 µg/ml 1:2.5 R&D Systems 
Anti-
Notch-1 
Mouse IgG2a ĸ APC 0.2 mg/ml 1:20 eBioscience 
Notch-1 
isotype 
Mouse IgG2a ĸ APC 0.2 mg/ml 1:20 eBioscience 
Anti-
CD138 
Rat IgG2a ĸ APC 0.2 mg/ml 1:300 BD Pharmingen 
CD138 
isotype 
Rat IgG2a ĸ APC 0.2 mg/ml 1:300 eBioscience 
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Table 2.10: Leica AF6000 microscope and LAS-AF settings used to visualise immunofluorescence 
staining of the HSC niche molecules, ligands and CD138 in the 5T33-GFP and 5TGM1-GFP cells 
Molecule Fluorochrome 
Filter 
cube 
Exposure time 
millisecond 
(ms) 
Gain Intensity Binning 
CXCR4 
DAPI A4 250 3.1 4 1x1 
APC Y5 590 10 5 1x1 
CXCL12 
DAPI A4 300 3.1 4 1x1 
APC Y5 590 10 5 1x1 
Notch-1 
DAPI A4 220 3.1 4 2x2 
APC Y5 480 10 5 2x2 
CD138 
DAPI A4 220 3.1 4 2x2 
APC Y5 480 10 5 2x2 
 
After visualisation, the pictures were exported as tagged image file format files 
(TIFFs) and imported into Volocity software (Perkin Elmer) for image analysis. 
Volocity software was used to manually spot count the number of DAPI stained nuclei 
and APC labelled cells to calculate the percentage of cells positive for each molecule 
of interest. An example of this is shown in Figure 2.6.  
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Figure 2.6: 
Quantification of 
immunofluorescence 
using Volocity 
software. The 5T33-
GFP cells were stained 
with an anti-CXCR4 
antibody and DAPI. 
Staining was visualised 
and analysed using 
Volocity software. This 
was conducted by 
manually spot counting 
DAPI and APC positive 
cells to calculate the 
number of cells positive 
for each molecule of 
interest. a. Manual 
spot counting of DAPI 
stained nuclei (blue) 
using 5T33-GFP cells. 
Numbers represent 
each DAPI positive cell. 
b. Manual spot 
counting of the CXCR4 
staining (red) using 
5T33-GFP cells. 
Numbers represent 
each DAPI positive cell. 
 
 
 
 
 
2.4.3 IHC staining 
All equipment, materials and reagents used for IHC are outlined in Appendix 1, 
Section 1.10, Table 1.10. 
 
2.4.3.1 Principles of IHC 
Immunohistochemical techniques were developed to visualise the expression of the 
HSC molecules of interest ex vivo. A “sandwich” IHC system was optimised to 
visualise the presence of protein for N-cad, CXCR4 and CD138 in BM histological 
a 
b 
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sections taken from mice injected with 5TGM1-GFP cells. The basic IHC method used 
is displayed in Figure 2.7. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.7: A schematic diagram demonstrating a sandwich IHC technique. In IHC, a sandwich 
antibody technique can be used to detect proteins of interest. To do this a primary antibody binds to 
the antigen of interest. This is followed by the binding of a biotinylated secondary to its complementary 
antibody species. The biotin on the secondary antibody then binds to the streptavidin horseradish 
peroxide (SA-HRP), which binds to the peroxidase substrate 3'-Diaminobenzidine (DAB). This then 
produces a brown colour, which can be visualised using light microscopy. 
 
2.4.3.2 Preparation of bones for IHC 
Tibiae were dissected free of soft tissue from C57BL/KaLwRij mice which had been 
injected with 5TGM1-GFP cells after 10, 14, 17 and 21 days P-I. The bones were fixed 
in 4% PFA for 24 hours and then decalcified in 0.4 M EDTA pH 8.0 containing 0.5% 
PFA for 2 weeks, changing the solution every other day. The bones were placed into 
tissue processor cassettes and washed three times, an hour per wash, in PBS to rinse 
away residual EDTA. The bones were placed into the Leica TP2010 processor to 
dehydrate the tissues and infiltrate them with wax using the programme as described 
in Table 2.11. 
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Table 2.11: Processing schedule for bones using the Leica TP2010 processor 
 
 
 
 
 
 
 
 
 
 
After processing, the bones were embedded into wax in a specific orientation, which 
was the same for each tibia. The wax blocks were trimmed using a Leica microtome 
to expose the length of the BM (approximately 900 µm) and 3 µm sections were cut 
in serial, and put on to a 45°C water bath to “float-out” for 30 min. They were then 
attached to super-frost positively charged slides and placed onto a hot plate at 45°C 
to remove residual creases. Finally, they were placed in an oven at 37°C to fully 
adhere to the slides over-night before they were used for IHC. 
 
2.4.3.3 IHC methodology for CD138 
On the day of staining, sections were deparaffinised twice in xylene for 4 min 
followed by rehydration through a series of alcohols (99%, 99%, 95% and 70% 
industrial methylated spirits (IMS)) for 4 min each. The sections were then washed in 
tap water for 5 min and transferred to PBS for a further 5 min. Antigen retrieval (A. 
Menarini kit) was performed by diluting trypsin 1:4 in the buffer provided. The trypsin 
was pre-warmed for 45 min at 37°C before adding approximately 200 µl of solution 
STATION SOLUTION TIME VACUUM 
1 70% Ethanol 2 hours No 
2 70% Ethanol 2 hours No 
3 70% Ethanol 2 hours No 
4 95% Ethanol 2 hours No 
5 95% Ethanol 2 hours No 
6 100% Ethanol 2 hours No 
7 100% Ethanol 2 hours No 
8 Xylene 2 hours No 
9 Xylene 2 hours No 
10 Wax 2 hours Yes 
11 Wax 2 hours Yes 
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to each slide and incubating for 10 min at room temperature. The sections were then 
washed twice in PBS, with agitation for 4 min per wash. To reduce non-specific 
staining, the sections were blocked by adding 200 µl 10% goat serum in PBS to each 
slide for 1 hour at room temperature. The block was tapped off and the slides were 
then incubated with 200 µl primary or concentration matched isotype control 
antibody diluted in PBS, for 1 hour at room temperature (as shown in Table 2.12). 
The sections were then washed twice in PBS for 4 min with gentle agitation. To block 
endogenous hydrogen peroxidase, 200 µl 3% hydrogen peroxide (H2O2) (1:10) in PBS 
was added to each slide for 30 min at room temperature, followed by washing twice 
in PBS with gentle agitation. Two hundred microlitres of goat anti-rat secondary 
antibody, diluted 1:300, was added to the slides for 30 min at room temperature and 
slides were subsequently washed twice in PBS. This was followed by incubation with 
200 µl SA-HRP at a dilution of 1:300 for 30 min at room temperature followed by 
washing twice in PBS. Finally, the peroxide substrate reagent was prepared by adding 
1 ml of diluent to 1 drop of DAB in the Immpact DAB kit. Two hundred microlitres of 
this solution was then added to the slides for 10 min at room temperature. The slides 
were washed in tap water to remove excess DAB, followed by counter staining in 
Gill’s haematoxylin for 20 seconds to visualise the nuclei. The slides were then left to 
“blue” in running tap water for 3 min after which they were dehydrated through a 
series of alcohols (70%, 95% and 99% IMS) for 10 seconds each and a final 99% IMS 
for 30 seconds. This was followed by two xylene washes, the first for 1 min and the 
second for a further 3 min. The slides were then cover-slipped using 22 x 22 (mm) 
coverslips with Di-N-Butyl Phthalate in Xylene (DPX). Staining was visualised by 
scanning the slides using an Aperio Scan Scope scanner and images were captured at 
a 2X and 40X magnification using Image Scope Software.  
 
2.4.3.4 IHC methodology for N-cad 
The method for staining N-cad in the 5TGM1-GFP infiltrated bone sections by IHC 
was similar to the protocol used for CD138 (Section 2.4.3.3). However, there were 
some differences with regards to buffers, antigen retrieval and the antibodies used. 
The wash buffer and diluent throughout the protocol was 0.1% PBST. For antigen 
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retrieval, the trypsin was diluted 1:1 and was used at room temperature immediately 
without pre-heating, for 15 min. In addition, an anti-N-cad antibody and dose 
matched isotype control antibody was used at a 1:100 dilution (as shown in Table 
2.12) and incubated for 1 hour at room temperature. The secondary antibody used 
was a goat anti-rabbit, at a 1:200 dilution, incubated for 30 min at room temperature. 
All other details were the same as in the CD138 protocol. 
 
2.4.3.5 IHC methodology for CXCR4 
The method for staining CXCR4 in the 5TGM1-GFP infiltrated bone sections by IHC 
was similar to the protocol used for CD138 IHC. However, antigen retrieval was not 
required and an anti-CXCR4 and dose matched isotype control antibody was used at 
a 1:50 dilution (Table 2.12). The slides were then treated in the exact same manner 
as in the CD138 protocol.  
 
Table 2.12: Antibodies used for IHC 
*This was initially at a 15 mg/ml concentration, which was subsequently diluted to 1mg/ml to match 
the primary antibody and then further diluted 1.100 as indicated in the table.  
 
2.4.3.6 CD138 staining quantification 
To quantify CD138 staining in tumour bearing 5TGM1-GFP infiltrated bone sections, 
an Aperio Scan Scope slider scanner and Image Scope software were used. An image 
of an example bone section, which has been analysed, is shown in Figure 2.8. To 
analyse the bones, the total area of BM space, trabecular bone and CD138 stained 
Antibody 
specificity 
Host Isotype Concentration Dilution Supplier 
Anti-CD138 
primary  
Rat IgG2a 0.5 mg/ml 1:300 BD Pharmingen 
CD138 isotype  Rat IgG2a 0.5 mg/ml 1:300 BD Pharmingen 
Anti-N-cad 
primary  
Rabbit IgG 1.0 mg/ml 1:100 Pierce Antibodies 
N-cad isotype Rabbit IgG *1.0 mg/ml 1:100 Dako cytomation 
Anti-CXCR4 
primary  
Rat IgG2b 0.5 mg/ml 1:50 BD Pharmingen 
CXCR4 isotype Rat IgG2b 0.5 mg/ml 1:50 BD Pharmingen 
Chapter II: Materials and methods Page 70 
 
tumour colonies were calculated (mm2). As only the cellular BM space was required, 
the area of trabecular bone was subtracted from the total BM area. To calculate the 
percentage of tumour burden, the total area of tumour was then divided by the 
cellular BM area and multiplied by 100. This technique has also been successfully 
used by others at the University of Sheffield (Dr S. Lawson personal communication). 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.8: An example image using the Aperio Scan Scope slide scanner and analysis of tumour 
burden using Image Scope software. A representative section of a tibia (2X magnification) infiltrated 
with 5TGM1-GFP cells stained for CD138 (brown). Image Scope software was used to measure the 
tumour burden (yellow outline) the marrow space (green outline and bone (red outline). 
 
2.4.4 Western blotting 
All equipment, materials and reagents used for Western blotting (WB) are outlined 
in Appendix 1, Section 1.11, Table 1.11. 
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2.4.4.1 Principals of Western blotting 
Western blotting was used to determine the protein levels of N-cad in 5T33-GFP and 
5TGM1-GFP cells, which had been knocked-down for N-cad (method described in 
2.6.4). Western blotting is a technique whereby proteins are separated through an 
acrylamide gel, transferred on to a nitrocellulose membrane and visualised using a 
sandwich antibody reaction similar to IHC. However, rather than using a biotinylated 
secondary antibody, a HRP conjugated secondary antibody and enhanced 
chemoluminescence substrate (ECL) is used. Enhanced chemoluminescence 
substrate consists of H2O2 and luminol, which binds to HRP on the secondary 
antibody, resulting in oxidation of the luminol and emission of iridescent light. 
Chemo-luminescence is visualised by standard x-ray development and the protein 
appears as a band on an x-ray film.  
 
2.4.4.2 Cell lysis  
For whole cell lysis, a nonyl phenoxypolyethoxylethanol (NP-40) substitute buffer 
containing tris buffer, sodium chloride (NaCl) and NP-40 was used. This was made 
using the quantities in Table 2.13. The buffer was then stored at 4°C until required.  
 
Table 2.13: Reagents and the quantities required to make 10 ml NP-40 buffer 
Reagent Stock solution 
Working 
solution 
Amount 
required 
Tris 
hydrochloride 
(pH 8.0) 
1 M 50 mM 500 µl 
NaCl 3 M 150 mM 500 µl 
NP-40 n/a n/ 100 µl 
dH2O n/a n/a 8.9 ml 
 
The 5T33-GFP or 5TGM1-GFP cells were lysed by transferring 1x107 cells per sample 
into a universal, followed by centrifugation and washing once in 10 ml PBS. A 
protease inhibitor cocktail (PIC) (1X) was added to the NP-40 buffer at a 1:100 dilution 
and the cell pellet was re-suspended in 200 µl of NP-40/PIC solution. The samples 
were then water sonicated to produce ultrasound waves that mechanically disrupt 
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cells to further release proteins in addition to breaking down interfering cellular DNA. 
The lysates were then frozen at -20°C and stored until required.  
 
2.4.4.3 Protein quantification 
Protein quantification was conducted using a bicinchoninic acid (BCA) assay. The 
assay produces a purple colour in the presence of protein, which is analysed by 
spectrophotometry. The colour reaction is produced by the reduction of copper (Cu) 
2+ ions to Cu+ ions by peptide bonds present in proteins. The Cu+ ions interact with 
the BCA, which produces a purple by-product. The intensity of the purple is measured 
by the absorbance at 562 nm using a spectrophotometer and the optical density (OD) 
readings of the samples are then extrapolated from the OD readings of a set of 
protein standards to calculate the quantity of protein present. 
 
2.4.4.4 Bicinchoninic acid assay methodology 
Firstly, a 100 mg/ml BSA stock was made in NP-40 buffer and this was subsequently 
diluted at a 1:100 dilution to 1 mg/ml using NP-40 buffer. The concentrations used 
for the standards and the volume of BSA and NP-40 diluent required are shown in 
Table 2.14 and those volumes were loaded into a 96 well plate. 
 
Table 2.14: Volumes of bovine serum albumin and NP-40 required for the bovine serum albumin 
standards  
 
 
 
 
 
Protein from the 5T33-GFP and 5TGM1-GFP cells was loaded into the wells at either 
a 1:5 or 1:10 dilution with NP-40 buffer, making a total volume of 10 µl, as with the 
Standard Concentration 
(µg/ml) 
Volume of BSA 
(µl) 
Volume of 
NP-40 (µl) 
1000 10 0 
800 8 2 
600 6 4 
400 4 6 
200 2 8 
100 1 9 
0 0 10 
Chapter II: Materials and methods Page 73 
 
Concentration
0 100 200 300 400 500 600 700 800 900 1000
0.11
0.21
0.31
0.41
0.51
StandardCurve
Linear Fit: y = A + Bx: A B R^2
STD01 (Standards: Concentration vs MeanODValue) 0.125 0.000429 0.999
protein standards. Bicinchoninic acid and copper II sulphate were combined at a 50:1 
ratio respectively and 200 µl of this solution was added to the wells containing either 
10 µl of BSA standard or 5T33-GFP or 5TGM1-GFP lysates. The plate was then 
incubated at 37°C for 30 min to catalyse the colour change reaction and read using 
the SpectraMax plate reader at 562 nm. A standard curve was plotted, as shown in 
Figure 2.9. 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.9: Increasing amounts of bovine serum albumin resulted in a standard curve using a 
bicinchoninic acid assay. Increasing amounts of BSA (0-1000 µg/ml) were added to a 96 well plate 
followed by a BCA and copper II sulphate solution and incubated for 30 min at 37°C. A colour change 
reaction was measured using a SpectraMax plate reader at 562 nm and the curve was plotted using 
SoftMax Pro software.  
 
The concentrations of the unknown sample proteins were calculated by 
extrapolation of their ODs from OD and concentration values in the BSA standard 
curve using the following formula: 
y=a+bx 
a= The intercept 
b= Slope 
x= Unknown concentration 
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y= Known OD 
Rearrangement of formula= x=(y-a)/b 
Using this equation the concentration of the unknown protein was calculated, as 
shown in the example below using the slope and intercept values calculated from the 
standard curve in Figure 2.9. 
0.396 (OD)-0.125 (Intercept)/0.000429 (Slope) =631  
This concentration was then multiplied by 5 or 10 to account for the dilution factors 
and to provide a concentration in µg/ml.  
 
2.4.4.5 Acrylamide gel methodology 
To make the acrylamide gel, firstly, the separator and cover plates were placed in the 
casting frames and added to the casting stand. The plates were then tested for 
leakages before loading the gel into them.  
 
A 7% resolving gel was made using tris buffer, acrylamide, sodium dodecyl sulphate 
(SDS), ammonium persulphate (APS) and tetramethylethylenediamine (TEMED). The 
gel was made using the volumes shown in Table 2.15. The resolving gel was added to 
casting plates and left to set for 45 min, at room temperature. 
 
Table 2.15: Reagents and volumes required to make one 7% resolving acrylamide gel.  
 
 
 
 
 
 
A 4% stacking gel was then made using the same reagents as for the resolving gel 
however; 0.5 M tris buffer pH 6.8 was used rather than 1.5 M tris buffer pH 8.0. The 
gel was made using the volumes shown in Table 2.16. The stacking gel was then 
Reagent Volume 
dH2O 4 ml 
30% Acrylamide 1.87 ml 
1.5 M tris pH 8.0 2 ml 
10% SDS 80 µl 
10% APS 80 µl 
(TEMED) 8 µl 
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added to the top of the resolving gel, ensuring there were no bubbles and was left to 
set for approximately 45 min.  
 
Table 2.16: Reagents and volumes required to make one 4% stacking acrylamide gel 
 
 
 
 
 
 
2.4.4.6 Sodium dodecyl sulphate-polyacrylamide gel electrophoresis 
In initial experiments, different amounts of protein were loaded and run using sodium 
dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-PAGE) to determine which 
protein amount was sufficient to visualise a band for N-cad in the 5TGM1-GFP cells as 
shown in Appendix 2, Section 2.7, Figure 2.4. The optimum amount of protein used was 
20 µg and this was used in subsequent experiments. 
 
The desired quantity of protein (20 µg) per sample was calculated using the 
concentrations determined using the BCA assay in Section 2.4.4.4. Prior to use, laemmli 
buffer (4X) was added to β-mercaptoethanol at a 1:20 dilution and the laemmli buffer 
was then added to the protein samples to make a total volume of 20 µl. The biotinylated 
protein ladder was also diluted 1:10 using the laemmli buffer. The samples and 
biotinylated marker were then denatured by heating in a hot block at 90°C for 10 min 
after which they were cooled at 4°C. Before loading, the gel (in the glass plates) was 
added to the electrophoresis assembly kit and inserted into an electrophoresis tank 
containing 1X running buffer. The running buffer was initially made as a 10X solution 
containing tris base, glycine and SDS and diluted 1:10 in dH2O upon use. The amounts 
and volumes of reagents required to make 10X running buffer and the final working 1X 
solution are displayed in Table 2.17.  
 
 
Reagent Volume 
dH2O 3 ml 
30% Acrylamide 0.67 ml 
0.5 M tris pH 6.8 1.25 ml 
10% SDS 50 µl 
10% APS 50 µl 
TEMED 5 µl 
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Table 2.17: Amounts and volumes of reagents required to make a litre of 10X running buffer and 
final amounts of reagent present in 1 litre of 1X running buffer 
 
 
 
 
 
 
The biotinylated protein ladder (10 µl), a pre-stained protein ladder (5 µl) and the 
samples (20 µl) were then loaded in the gel. Using the Biorad power pack, a current was 
applied at 80 Volts to allow for the separation of the pre-stained marker through the 
stacking layer followed by 150 V for approximately 1 hour and 30 min for separation of 
the proteins through the resolving gel. 
 
2.4.4.7 Protein transfer 
Following loading and separation of the proteins through the acrylamide gel, the 
proteins in the gel were transferred to a hybond nitrocellulose membrane. Firstly, 
the nitrocellulose membrane, which was cut to the same size as the gel, was soaked 
in methanol for 5 min followed by 1X transfer buffer. Ten times transfer buffer was 
made using tris base, glycine and dH20, which was diluted 1:10 to 1X using d H20 and 
methanol. The amounts required for the 10X transfer buffer stock solution and final 
amounts present in working 1X solution are shown in Table 2.18.  
 
Table 2.18: Amounts and volumes of reagents required to make a litre of 10X transfer buffer and 
final amounts of reagent present in 1 litre of 1X transfer buffer 
 
Reagent 
10X transfer 
buffer stock 
solution  
Amounts 
required for 
10X transfer 
buffer 
1X transfer 
buffer 
working 
solution 
Tris base 250 mM 30.3 g 25 mM 
Glycine 1920 mM 144 g 192 mM 
Methanol n/a n/a 20% 
dH2O n/a 1000 ml n/a 
 
Reagent 
10X running 
buffer stock 
solution  
Amounts 
required for 
10X running 
buffer 
1X running 
buffer 
working 
solution 
Tris base 250 mM 30.3 g 25 mM 
Glycine 1920 mM 144 g 192 mM 
SDS (20%) 1% 50 ml 0.1% 
dH2O n/a 950 ml n/a 
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Per gel, two teflon pads and four pieces of filter paper cut to the same size as the gel 
were soaked in 1X transfer buffer and were then used to form a sandwich between 
the gel and nitrocellulose membrane which was placed onto a transfer cassette in 
the correct orientation so that the proteins would transfer on to the membrane. The 
gel and membrane sandwich was placed in a transfer cassette facing towards the 
anode. The cassette was placed in a tank containing transfer buffer and the tank was 
surrounded by ice. The proteins were transferred onto the membrane at 50 Volts for 
7 hours.  
 
2.4.4.8 Immuno-blot 
After transfer, the membrane was removed from the transfer cassette for immuno-
blotting. Firstly, the membrane was blocked in 5% skimmed milk diluted in 0.25% 
PBST for 45 min at room temperature with agitation. After blocking, the membrane 
was cut to separate the biotinylated protein ladder, β-actin (42 kDa) and N-cad (135 
kDa) areas, using the pre-stained marker as a guide. The pieces of membrane were 
placed in separate universals containing either PBST for the biotinylated marker, β-
actin antibody in PBST at a 1:3000 dilution or N-cad antibody (used previously for the 
IHC staining in Section 2.4.3.5) at a dilution of 1:1000 in PBST for 1 hour, room 
temperature with agitation. The membranes were then washed three times in PBST 
for 5 min per wash with agitation, followed by an incubation with an anti-rabbit HRP 
secondary at a dilution of 1:10000 in PBST for the β-actin and N-cad or the anti-biotin 
HRP secondary antibody at 1:1000 in PBST for the biotinylated ladder for 45 min at 
room temperature with agitation. The membranes were then washed three times in 
PBST for 5 min per wash on a tube roller.  
 
2.4.4.9 Immuno-blot development 
After the final wash, the membranes were pieced back together onto a sheet of 
plastic. Using the ECL kit, solution A was combined with an equal quantity of solution 
B and this was then added to the membrane, which was then covered in plastic and 
smoothed down to remove air bubbles. Chemo-luminescence was then visualised in 
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a dark room. The membrane in the plastic was placed inside a developing cassette 
with the film. The membrane was exposed for a series of different times to optimise 
the exposure. Two different ECL kits were used, a Thermo Scientific kit (30 seconds 
of exposure) and a Santa Cruz kit (5 min of exposure). The film was then placed into 
a developing solution until bands began to appear (approximately 30 seconds), 
followed by washing in running tap water for 1 min after which the film was fixed 
(fixer solution) for 2 min and washed in running tap water for 5 min. The film was 
then left to air-dry over-night.  
 
2.4.4.10 Western blotting quantification 
After immuno-blotting and developing, the bands were quantified. This was 
conducted by scanning the film using the Epson 4990 scanner and software using a 
16-bit grey-scale. Once scanned, the bands were measured by densitometry using 
ImageJ software, which provided a density value for each band present on the film. 
Data was displayed as a fold change and percentage of protein KD. This was 
calculated by normalising the band density of N-cad protein to the HK (β-actin) band 
density, followed by comparing this value between the CTRL and N-cad known-down 
samples to provide a fold change and percentage of protein KD. An example of these 
calculations are shown in Table 2.19.  
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 Table 2.19: Calculations to determine the percentage of protein knock-down between the CTRL and 
KD transduced cells 
 
2.4.5 Myeloma cell growth curves 
2.4.5.1 Growth curve methodology 
To assess the effect of the N-cad KD upon cell proliferation in vitro, growth curve 
experiments were conducted. The untreated, CTRL and KD 5TGM1-GFP cells were 
seeded at a density of 5x103 cells into a 96 well plate in 200 µl complete RPMI media. 
Cells were counted every 2 days and media was replenished on days 0, 2, 4, 6, 8 and 
10. Cell proliferation was presented in a graphical format to visualise each phase of 
growth, which included the lag, exponential, stationary and death phase as 
demonstrated in Figure 2.10. The doubling-time in the exponential phase was 
calculated using the following formula:  
 
1/ ((log cell number at the end of the exponential phase- log cell number at the 
beginning of the exponential phase) 3.32/ time) 
 
 
 
 
Treatment β-actin N-cad Normalisation 
Mean of 
normalisation 
Fold 
change 
% 
 HK 
Protein of 
interest 
(POI) 
POI/HK 
Mean of all 
replicates 
KD/CTRL 
1- 
KD/CTRL*
100 
CTRL 17.21 19.34 1.12377964    
CTRL 17.50 24.13 1.37873507    
CTRL 15.12 28.65 1.89420087    
CTRL 
Mean 
   1.46557187  100 
       
KD 20.03 8.19 0.40905687    
KD 16.77 9.54 0.56843925    
KD 13.36 10.16 0.75999102    
KD mean    0.57916238 0.40 40 
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Figure 2.10: A typical cell growth curve. When cells expand in media over-time, they go through a 
series of growth phases. Firstly when seeded there is an initial phase of slow growth (lag phase) which 
is followed by a rapid proliferation phase (exponential phase). As nutrients and media decrease, 
division occurs at a steady rate and there are equal numbers of cells dying as there are dividing 
(plateaux phase). However, when nutrients and space become too depleted less division and an 
increase in cell death occur (death phase).  
 
2.5 Primary osteoblast lineage cell differentiation 
 
All equipment, materials and reagents used for all primary OLC differentiation 
experiments are outlined in Appendix 1, Section 1.12, Table 1.12. 
 
2.5.1 Alkaline phosphatase production analysis 
2.5.1.1 Principals of alkaline phosphatase analysis 
Alkaline phosphatase is a well-known marker of osteoblast differentiation and is up 
regulated in the early differentiation of preosteoblasts to mature osteoblasts. 
Alkaline phosphatase production by a cell can be determined using a p-nitrophenyl 
phosphate (PNPP) reaction based on a colour change described by Sabakbar et al 
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(186). This reaction can be detected using a plate reader by spectrophotometry 
(Figure 2.11).  
 
 
 
 
Figure: 2.11: The chemistry of the reaction between alkaline phosphatase and p-nitrophenyl 
phosphate. Alkaline phosphatase hydrolyses PNPP, resulting in the formation of nitrophenolate, which 
produces a yellow colour. The more Alp present the quicker the reaction and colour change occurs. 
 
 
2.5.1.2 Alkaline phosphatase assay methodology 
Alkaline phosphatase assays were conducted on days 0, 3, 7, 10, 14, 21 and 28 post-
OGM treatment. On the day of the assay, the media was removed and the cells were 
washed twice in 150 µl of ice cold PBS. The cells were lysed in 0.1% triton in PBS and 
shaken on a rotating platform for 20 min. Whilst the cells were lysing, one PNPP 
tablet and one tris buffer tablet were dissolved in 20 ml of dH20, forming a final 
solution containing 1 mg/ml PNPP and 0.2 M tris buffer. Two hundred microlitre of 
this solution was then added to the lysed cells, avoiding production of air bubbles 
and the plate was immediately read using the SpectraMax plate reader. The plate 
was read using the kinetic settings, every 5 min for 90 min, to provide a read out of 
OD readings. The higher the intensity of the colour reaction, the higher the OD, as 
shown in the example in Figure 2.12. 
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Figure: 2.12: Alkaline phosphatase production in primary osteoblast lineage cells cultured in 
standard MEMα-nuc media compared to those in osteogenic media. Primary osteoblast lineage cells 
were cultured with standard MEMα-nuc or OGM. After 14 days, the cells were lysed using 0.1% triton 
and incubated with PNPP. This resulted in a colour reaction when in the presence of Alp. Results were 
analysed by spectrometry using a SpectraMax plate reader, which provided OD readings over the 
course of 90 min. Cells that were cultured in OGM had higher OD readings, which plateaux before those 
cultured with the standard MEMα-nuc media.  
 
 
2.5.1.3 DNA quantification methodology 
After conducting the Alp experiments, the DNA of the same cells was quantified using 
a PicoGreen® assay. This was conducted to enable normalisation of the Alp 
production to DNA concentration. The DNA standard (100 µg/ml) in the Quant-it 
PicoGreen® kit was diluted 1:50 (2.0 µg/ml) with tris/EDTA buffer. The DNA standards 
were then set up in duplicate at 0, 50, 100, 200, 400, 600, 800 and 1000 ng/ml of 
DNA in a 100 µl volume and transferred into a 96 well plate. Fifty microlitres of each 
sample used for Alp detection was then transferred into the 96 plate and to this, 50 
µl of tris/EDTA buffer was added. The PicoGreen® reagent was prepared by thawing 
a 25 µl aliquot and diluting it with 9975 µl of tris/EDTA buffer. One hundred 
microlitres of this solution was then added to each well. The plate was wrapped in 
foil to avoid bleaching and mixed gently on a rocker for 5 min before reading on a 
SpectraMax plate reader with an excitation at 488 nm and emission at 535 nm. 
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A standard curve was generated and the unknown DNA concentrations were 
calculated as with the BCA assay described in Section 2.4.4.4. The DNA concentration 
of each sample was multiplied by 4 to take into account the dilution factor and the 
final concentration was expressed as ng/ml. 
 
2.5.1.4 Calculating alkaline phosphatase activity 
To calculate Alp activity, Beer-Lambert Law was used:  
 
U= (ODt1-ODt0) x V 
t X ε X l 
 
 OD t1: The OD at the end of the reaction where the reaction reaches a 
plateaux 
 OD t0: The OD at the beginning of the linear part of the reaction 
 V: Volume of reaction (220 µl) 
 t: Reaction time (min) 
 ɛ: Molar coefficient of the PNPP (18.5 M-1 centimetre (cm)-1) 
 l: Light path (0.635 cm) 
 
The light path, which is the length in cm in which light travels in the plate reader to 
reach the reaction, was calculated as follows: 
V=πR2h 
Or: H= V/ πR2 
 V= the volume= 0.2 cm3 
 H= Height of the well or light path 
 R2= Radius of the well 0.3175 cm2= 0.1008 cm 
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 ∏= Pi= 3.142 
Therefore, light path= 0.63 cm 
 
This calculation was then normalised to the amount of DNA in µg by dividing the Alp 
calculation by the amount of DNA present in the sample. This was then presented as 
U/µg of DNA, a common way to present the data in recent literature (187). An 
example of the full calculations for this are shown in Appendix 2, Section 2.9, Table 
2.6. 
 
2.5.2 Primary osteoblast lineage cell mineralisation analysis 
2.5.2.1 Primary osteoblast lineage cell mineralisation assay methodology 
Osteoblast mineralisation assays were conducted on days 7, 14, 21 and 28 post-
differentiation. Media was removed from the 24 well plates and washed twice in 1 
ml PBS. The cells were fixed in 100% IMS over-night at 4°C and then washed twice in 
PBS. The wells were stained with 1 ml 40 mM pH 4.2 alizarin red (a calcium binding 
dye) in dH20 per well for 90 min at room temperature. Following this, the cells were 
washed in 95% IMS, approximately four times to remove excess alizarin red. All of 
the liquid was then removed and the cells were air-dried over-night. Plastic discs 
were then added to each well and the intersections of the wells were filled with 
cotton wool to allow for contrast when scanned using an Epson 4990 scanner using 
the settings of: reflective, 24-bit colour and 2400 dots per inch (dpi). Mineralisation 
was analysed using ImageJ software. This was conducted by opening the 
mineralisation image file (TIFF) and setting it as a grey scale image. The threshold was 
then adjusted so that no mineralisation nodules were excluded or over-exposed and 
the threshold was then the same for each well within that plate. The software then 
calculated the percentage of nodules in the well area. 
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2.5.3 Myeloma and primary osteoblast lineage cell co-cultures 
2.5.3.1 Myeloma and primary osteoblast lineage cell co-culture methodology 
To establish whether MCs adhere to primary OLCs in culture and whether the stage 
of differentiation affects this adhesion, co-culture experiments were conducted. 
Primary OLCs were set up and cultured with OGM as described previously in Section 
2.1.2.7. On days, 3, 14 and 28 post-differentiation the media was removed and the 
cells were washed twice in 150 µl PBS. Un-transduced, CTRL and KD 5TGM1-GFP cells 
were seeded at a density of 5x104 into wells with or without primary OLCs, in a total 
volume of 200 µl complete RPMI media per well. The plates were incubated for 1 
hour and 6 hours after which, the media was removed and the wells were washed 
four times in 200 µl PBS. This number of washes was sufficient to remove the majority 
of cells from the wells, which did not contain primary OLCs. After the fourth wash a 
final 200 µl of PBS was added to the wells and the adhesion of the 5TGM1-GFP cells 
to the primary OLCs was visualised using fluorescent microscopy to quantify the 
number of GFP positive cells present. 
 
2.5.3.2 Co-culture analysis 
The GFP positive MCs were visualised using the Leica AF6000 microscope and the 
settings are demonstrated in Table 2.20.  
 
Table 2.20: Settings used for the Leica AF6000 microscope 
 
 
 
*To detect primary osteoblast lineage cells. **To detect 5TGM1-GFP cells. 
 
Contrast/ 
fluorochrome 
Filter 
cube 
Exposure 
time 
millisecond 
(ms) 
Gain Intensity Binning 
*Phase  
EMP 
(phase) 
11 2.9 32 1x1 
**GFP L5 262 7.9 4 1x1 
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Five pictures were taken over the entire area of the well as shown in Figure 2.13 and 
each image was exported as a TIFF and analysed using automated Volocity software, 
which calculated the number of GFP positive cells in each image, as shown in Figure 
2.14. 
 
Figure 2.13: Analysis of adherent 5TGM1-GFP cells 
after 1 and 6 hours co-culture with primary 
osteoblast lineage cells. Fifty thousand 5TGM1-GFP 
cells were seeded on to primary OLCs, which had 
been differentiated for 3, 14 and 28 days. After 1 and 
6 hours, images were taken of adherent 5TGM1 cells 
in each well in five different areas (0.012 cm2 per tile) 
using the Leica AF6000 microscope.  
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Figure 2.14: An example of automated green fluorescent protein positive cell counting using Volocity 
software. The TIFF files of 5TGM1-GFP and primary OLC co-culture tile images were loaded into 
Volocity. The number of GFP positive cells were counted automatically using the volocity software. This 
converts the TIFF files to grey scale images and analyses the contrasting images to the background. 
Each positive cell is annotated with an X and the number of positive cells are calculated per TIFF image. 
a. GFP positive 5TGM1-GFP cells after 6 hours of adhesion onto 14 day differentiated primary OLCs, 
before analysis. b. GFP positive 5TGM1-GFP cells after 6 hours of adhesion onto 14 day differentiated 
primary OLCs after Volocity software automated counting, where the out-put number of cells deemed 
positive were tagged with an X. 
a 
b 
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2.6 Knock-down of key HSC niche molecules 
 
All equipment, materials and reagents used for all KD experiments are outlined in 
Appendix 1, Section 1.13, Table 1.13. 
 
2.6.1 Short hair-pin RNA gene knock-down technology 
2.6.1.1 Principals of RNA interference technology 
Ribonucleic acid interference (RNAi) technology was used to KD key HSC niche 
molecules in the MCs. Different forms of RNAi technology are available for silencing 
genes, which include silencing RNA (siRNA), shRNA and micro RNA (miRNA). Specific 
sequences for siRNAs, shRNAs and miRNAs can be packaged into lentiviral particles 
for effective delivery into cells. Short hair-pin RNAs are usually designed to be 
between 19 and 23 nucleotide BPs long on both the sense and anti-sense strands 
with a 9 BP loop and are identical to the target mRNA sequence (188). 
 
Lentiviral particles are commonly produced in HEK293T cells, a type of renal epithelial 
cell line, which are notably easy to transfect. In third generation shRNA containing 
lentiviral particles, these cells are transfected with 3-4 vectors, which contain: 
1. A transgene expression cassette vector, which contains packaging genes as 
well as the shRNA sequence and resistance genes e.g. pLu-green 
2. A packaging vector, which encodes packaging genes such as pol, gag, rev, tat 
3. An envelope expression vector, required for the formation of the viral 
envelope encoding for the G-protein vesicular stomatitis virus envelope gene 
 
The viral particles are then produced by the HEK293T cells and collected in the cell 
supernatants (189), as shown in Figure 2.15. The lentiviral particles are transduced 
into the host cells where the shRNA is integrated into the hosts DNA. The shRNA is 
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then transcribed by Polymerase II or III and translocated from the nucleus to the 
cytoplasm where the hairpin loop is cleaved by an enzyme known as dicer to form 
siRNA. The siRNA is then incorporated into the RNA induced silencing complex (RISC), 
which cleaves the double stranded (Ds) shRNA to single stranded siRNA and guides 
the single strand towards the target mRNA (190). The binding of siRNAs to their 
complementary mRNA results in degradation of the complementary mRNA strand by 
the enzyme argonaute-2, as shown in Figure 2.15. This therefore, removes any mRNA 
for the GOI and stops subsequent translation to protein (191). As the shRNA is 
directly integrated into the genome, there is permanent silencing of the gene 
compared to siRNA, which has a short half-life, is also easily degraded and less than 
1% of the siRNA duplex is usually present 48 hours after transduction (191).  
 
 
 
 
 
 
 
 
 
Figure 2.15: The principals of lentiviral short hair-pin RNA, to knock-down N-cad and CXCR4 in the 
5TGM1-GFP cells. a. The production of lentiviral particles from HEK293T cells. HEK293T cells can be 
transfected with plasmids for the transgene, which contains the shRNA and resistance sequences, a 
packaging vector and the enveloped cassette. The particles produced are then collected for use from 
the cell supernatant. b. The transduction of the lentiviral shRNA particles into the MCs to KD the GOI. 
The lentiviral particles are transduced into the MC and the transgene is incorporated into the hosts 
DNA. The shRNA is transcribed and transported from the nucleus to the cytoplasm. The hairpin is then 
removed by the enzyme dicer to produce siRNA. The siRNA then enters the RISC complex where the 
double stranded (ds) RNA is cleaved to form a single strand, which binds to the complementary mRNA, 
resulting in degradation by argonaute-2. This removes the mRNA and prevents protein translation. 
Adapted from Manjunath et al (189), permission from The Journal of Advanced Drug Delivery Reviews 
30.07.14.  
a b 
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2.6.2 Puromycin killing curves 
 
2.6.2.1 Principals of puromycin selection 
Puromycin is an aminonucleoside antibiotic, derived from the bacterium 
Streptomyces alboniger which is able to kill cells via disruption of protein synthesis. 
However, if the cells possess a puromycin n-acetyle-transferase (PAC) gene, they are 
able to produce PAC, which is able to inactivate puromycin; resulting in viable cells.  
Prior to conducting GFP transduction or KD experiments, puromycin killing curves 
were conducted to establish the lowest dose of puromycin required to kill 100% of 
cells within four days of treatment. The optimum dose was then used to select for 
cells containing the transduced PAC gene, acquired from the control or shRNA vector. 
 
2.6.2.2 Puromycin killing curve methodology 
5T33-WT or 5TGM1-GFP cells were seeded at a density of 1x105 cells into a 12 well 
plate in 2 ml complete RPMI media and incubated for 24 hours. The following day, 
the cells were centrifuged and re-suspended in 2 ml of fresh complete RPMI media 
followed by treatment with 0 (PBS), 0.5, 1.0, 2.5, 5.0, 7.5 and 10 µg/ ml of puromycin. 
After 2 and 4 days following treatment, the viability of the cells were tested by 
centrifuging the cells and re-suspending them in 300 µl of PBS before staining the 
dead cells with TO-PRO-3 as described in Section 2.4.1.2. The lowest dose required 
for 100% cell death over a 4-day period was then established by analysing the 
number of viable cells remaining at the different concentrations of puromycin at the 
2 and 4 day time points. 
 
2.6.3. Polybrene optimisation 
The reagent polybrene was used to aid the binding of the viral capsid to the cells 
being transduced by neutralising the charge on the sialic acid present on the cell 
membrane. The optimum concentration of polybrene per the data sheet was 5 
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µg/ml, however, as some concentrations of polybrene can be toxic in certain cells 
optimisation was required. 
 
2.6.3.1 Polybrene optimisation methodology 
The effect of polybrene upon cell viability after 24 hours was established before use 
in the GFP transduction or KD experiments. Before use, polybrene was immediately 
diluted to 1 mg/ml in sterile H20 and frozen in 1 ml aliquots, which were thawed as 
required. For polybrene optimisation, the 5T33-WT and 5TGM1-GFP cells were 
counted and seeded into a 48 well plate at a density of 5x104 in 500 µl complete RPMI 
media containing 0, 2.5, 5.0, 7.5 and 10 µg/ml polybrene and incubated for 24 hours. 
After 24 hours, the number of cells present in each well were counted to establish 
whether the polybrene had prevented proliferation or caused cell death after 24 
hours. Viability staining could not be used in this instance as polybrene treatment 
resulted in false positives by allowing the DNA binding dye to enter viable cells.  
 
2.6.4 Green fluorescent protein transduction in 5T33-WT cells and 
knock-down of CXCR4 and N-cad in 5TGM1-GFP cells 
 
2.6.4.1 Green fluorescent protein transduction and knock-down of CXCR4 and N-
cad in the 5TGM1-GFP cells methodology 
To transduce GFP and to KD CXCR4 and N-cad in the MCs, a lentiviral particle 
transduction system was used which contained replication incompetent viral 
particles. The particles contained the shRNA sequences for CXCR4 and N-cad or 
scrambled sequence for the CTRL particles or GFP sequence. In addition, they also 
contained the PAC gene to enable puromycin resistance. The sequences of the 
hairpin loop and subsequent siRNA are shown in Table 2.21. 
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Table 2.21: The hairpin loop sequences and subsequent siRNA sequences provided in the lentiviral 
particles, for CXCR4 and N-cad knock-down 
 
 
 
 
 
 
 
 
 
 
 
The 5T33-WT and 5TGM1-GFP cells were seeded at a density of 2x104 cells in 100 µl 
complete RPMI media containing 5 µg/ ml polybrene (optimised using the method in 
Section 2.6.3.1) and the cells were transferred to a 96 well plate. To this, lentiviral 
particles were added at a range of multiplicity of infections (MOIs), which is defined 
as the number of transducing lentiviral particles per cell. The formula calculating the 
MOI is shown below: 
MOI calculations: 
Total number of cells per well X desired MOI= total transducing units (TU) required 
Total TU required / TU/ml in vial of lentiviral particles = volume of lentiviral particles 
required. 
E.g. MOI=20,000 cells x MOI 5.0= 100,000 
100,000/5x106= 0.02 ml= 20 µl 
Gene shRNA SiRNA Sense siRNA anti-sense 
CXCR4 A 
5’GATCCCCACGCCACCAA
CAGTCAATTCAAGAGATT
GACTGTTGGTGGCGTGGT
TTTT 
 
5’CCACGCCACCAACAGUC
AAtt 
5’UUGACUGUUGGUGGC
GUGGtt 
CXCR4 B 
5’GATCCCCTCAAGATCCT
TTCCAAATTCAAGAGATTT
GGAAAGGATCTTGAGGTT
TTT 
 
5’CCUCAAGAUCCUUUCC
AAAtt 
5’UUUGGAAAGGAUCUUG
AGGtt 
CXCR4 C 
5’GATCCGAGACTGACCA
GTCTTGTATTCAAGAGAT
ACAAGACTGGTCAGTCTC
TTTTT 
 
5’GAGACUGACCAGUCUU
GUAtt 
 
5’UACAAGACUGGUCAGU
CUCtt 
N-cad 
A 
5’GATCCGGAACCACATGA
AATTGAATTCAAGAGATT
CAATTTCATGTGGTTCCTT
TTT 
 
5’GGAACCACAUGAAAUU
GAAtt 
5’UUCAAUUUCAUGUGGU
UCCtt 
N-cad 
B 
5’GATCCGAACCCAACTCA
ATTAACATTCAAGAGATG
TTAATTGAGTTGGGTTCTT
TTT 
5’GAACCCAACUCAAUUA
ACAtt 
5’UGUUAAUUGAGUUGG
GUUCtt 
N-cad 
C 
5’GATCCGGAAGCTGGTAT
CTATGAATTCAAGAGATT
CATAGATACCAGCTTCCTT
TTT 
 
5’GGAAGCUGGUAUCUA
UGAAtt 
5’UUCAUAGAUACCAGCU
UCCtt 
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MOIs of 5, 15 and 25 were used and the correct volume of lentiviral particles was 
added to each well. The cells were incubated for 20 hours after which they were 
centrifuged and washed twice in 1 ml complete RPMI, re-suspended in 200 µl 
complete RPMI and incubated. After three further days of incubation, the cells were 
centrifuged and re-suspended in 500 µl complete RPMI media containing 7.5 µg/ml 
puromycin for the 5T33-WT cells and 5 µg/ml puromycin for the 5TGM1-GFP cells. 
The cells were then incubated until resistant colonies were visualised, approximately 
5 days after selection. The 5T33-WT resistant colonies were expanded and analysed 
to detect GFP expression using flow cytometry. The method for this was the same for 
GFP detection in the cell lines using flow cytometry in Section 2.4.1.2. The 5TGM1-
GFP cells transduced with shRNA, were set-up for RNA extraction as described in 
Section 2.3.1 1 to confirm KD of the genes. Cells were also frozen down for future 
experiments as described in 2.1.2.6 or they were also isolated for WB to confirm KD 
of protein, as described in Section 2.4.4.2. 
The cells which had been successfully knocked-down for CXCR4 and N-cad were also 
cultured in the absence of puromycin for 4 weeks to mimic the time in which they 
would not be under selection when in vivo. Real-time PCR and WB were conducted 
in these cells to confirm the stability of the KD. 
  
2.6.4.2 PCR analysis 
PCR analysis of the KD of CXCR4 and N-cad was performed by conducting RNA 
extraction (Section 2.3.1 1), RT (Section 2.3.2.1) and real-time PCR (Section 2.3.5.2) 
using the CTRL and KD cells at the various MOIs. The fold change and percentage of 
KD was calculated by normalising the GOI Ct values to the HK gene β2M and the KD 
was then calculated using the comparative ΔΔCt method as shown in Table 2.22.  
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Table 2.22: An example of calculations used to quantify the knock-down of CXCR4 and N-cad 
compared to CTRLs using real-time PCR 
 
2.7. Bone parameter analysis 
 
All equipment, materials and reagents used for bone parameter analysis are outlined 
in Appendix 1, Section 1.14, Table 1.14. 
 
2.7.1 Micro-computed tomography 
 
2.7.1.1 Principals of micro-computed tomography 
To determine any differences between the bone parameters in the mice injected 
with 5TGM1-GFP cells, CTRL or KD cells, micro-computed tomography (µCT) was 
used. Micro-computed tomography was introduced in the 1980s by Feldcamp et al 
for the evaluation of the bone micro-architecture in mice and small rodents (192). 
However, the concept of producing three-dimensional images of bone originated in 
Treatment β2M N-
cad 
Δct ΔΔCt SD Fold 
change 
SD % 
  HK GOI GOI-
HK 
2^-ΔCT 
SD 
KD/ 
CTRL 
SD 
control/ 
control 
average 
amount   
CTRL 15 15.38 23.10 7.71 
0.00476492 0.00112332 1.00 
0.195709
40 100 
CTRL 15 15.37 22.88 7.51 0.00548611         
CTRL 15 15.62 22.78 7.17 0.00696819         
Mean 15.46 22.92 7.46 0.00573974         
                  
        
      
SD 
treatment
/ control 
amount   
KD 15 16.01 24.61 8.60 
0.00257122 0.00073240 0.30 
0.127601
74 30 
KD 15 15.60 25.42 9.81 0.00111210         
KD 15 15.50 24.68 9.18 0.00173001         
Mean 15.70 24.90 9.20 0.00170390         
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1917 and was proposed by John Radon. Micro-computed tomography is a non-
invasive and non-destructive technique using X-rays. X-ray photons are generated by 
accelerated electrons in the source (usually an X-ray tube) which strike the tungsten 
within the tube. X-rays are emitted as a polychromatic beam, which pass through a 
rotating sample within the sample holder. X-rays are then absorbed or scattered 
depending on the density of the sample, dense samples such as bone which contain 
calcium cause x-ray absorption whereas soft tissues result in x-ray scattering. The 
images are detected and projected as two-dimensional image slices, which are 
reassembled to produce three-dimensional images. The main advantage of µCT is the 
spatial resolution of the machine, which can be as low as 4 µm producing highly 
accurate and detailed images. The main constituents of a CT machine are shown in 
Figure 2.16. A number of parameters can be analysed using µCT and the most 
informative are trabecular bone volume normalised to tissue volume (BV/TV), 
trabecular thickness (tb.th), trabecular number (tb.n), trabecular pattern factor 
(tb.pf) and cortical thickness (ct.th). In addition, lesion number and lesion area can 
be calculated. 
 
 
Figure 2.16: A diagram demonstrating the main constituents of a micro-computed tomography 
machine. Micro-computed tomography works by producing x-rays from electrons interacting with 
tungsten in the x-ray tube. The x-rays emitted exist as a polychromatic beam, which passes through 
the collimator and specific filters to the sample in the sample holder. X-rays are then either absorbed 
or scattered and these differences are detected. The results can then be re-constructed using specific 
software to produce 3D images. Adapted from Bouxsein et al (192), permission from The Journal of 
Bone and Mineral Research.  
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2.7.1.2 Micro-computed tomography methodology 
The right tibia from each mouse was fixed in 10% formalin prior to scanning. Formalin 
was made using the reagents and volumes shown in Table 2.23. Bones were then 
scanned using a SkyScan 1172 at 50 kilo volts (Kv), 200 microamperes (µA), using an 
aluminium filter of 0.5 mm and pixel size of 4.3 µm2 and images were then 
reconstructed using N-Recon software. Trabecular bone, 0.2 mm below the growth 
plate, was analysed using Ct-an and Batman software to provide data for bone 
parameters including BV/TV, tb.n and tb.th. All bones were scanned in-house by Holly 
Evans, a trained µ-CT technician.  
 
Table 2.23: Reagents and quantities required to make 10% formalin 
Item Supplier 
Sodium dihydrogen orthophosphate dihydrate 8 g 
Disodium hydrogen orthophosphate dihydrate 13 g 
Concentrated formaldehyde (i.e. 37-41%) 200 ml 
dH2O 1800 
 
2.7.1.2 Lesion counting 
To count the number of lesions and lesion area, data sets for each bone were resized 
from a 4.3 µm2 pixel size to 12.9 µm2. The cortical bone was hollowed out and files 
were imported into Drishti I, rendering software. Using this software, a 3D model of 
each bone was produced and each plane of bone (3 in total) was imaged and saved 
as a separate file. These files were resized using Picassa 3 software and the files were 
imported into ImageJ software. Lesions were then counted using the grey scale 
automated analysis function to count the number and the area of each hole (pixels 
2). 
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2.8. Statistics 
 
All data throughout are presented as the mean using the standard error of the mean 
(SEM) unless stated otherwise in the figure legend. All data were analysed statistically 
using GraphPad Prism Version 6. Where relevant, statistical analysis was conducted 
with guidance from the University of Sheffield Maths and Statistics Help group and 
advice from a senior clinical scientist with expertise in statistics. Throughout all 
experiments, non-parametric tests were used, as Gaussian distribution could not be 
assessed, as N numbers were not above the required number of eight. Mann-
Whitney U tests were used to compare values between two groups of unpaired data 
and a Wilcoxon matched pairs signed rank test was used to compare two groups of 
paired data. In addition, a Kruskal-Wallis test followed by Dunn’s post test was used 
to compare more than two groups of unpaired data and a Friedman test followed by 
Dunn’s post test was used to compare more than two groups of paired data.  
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3.1 Introduction 
 
HSCs reside in BM microenvironmental niches in which their proximity to certain BM 
constituents influences their behaviour. Their proximity to osteoblasts is thought to 
inhibit HSC proliferation and promote entry into the G0 phase of cell cycle, whereas, 
their proximity to the vasculature stimulates proliferation and differentiation into a 
variety of cell lineages (82, 83, 85). Molecules which have been implicated in the 
physical interaction between HSCs and osteoblastic cells, are the receptors CXCR4, 
Notch-1, Tie-2 and the adherin molecule N-cad, expressed by the HSCs, and their 
complementary ligands, CXCL12, Jag-1, Ang-1 and N-cad, expressed or secreted by 
the osteoblastic cells. The BM and its cellular constituents also play an important role 
in MC homing, growth and survival. Previous studies have largely focussed upon the 
influence of the BM microenvironment in the later stages of disease and current 
research is particularly limited with regards to early myeloma development as well 
as MC survival following chemotherapy. It has been suggested that MCs may exist 
within a BM microenvironmental niche, distinct but similar to that occupied by HSCs, 
or, MCs may in fact “hijack” the HSC niche. As with HSCs, occupancy of the niche may 
result in MC quiescence if located in close proximity to osteoblasts. Currently, little 
research has been conducted to test this hypothesis. However, previous papers have 
identified the expression of some of the HSC niche molecules by MCs in vitro.  
 
There is substantial evidence in support of the CXCR4/ CXCL12 axis as part of the 
mechanism for MC homing and mobilisation to the BM. Previous data have described 
the in vitro expression of CXCR4 by various patient cells and human myeloma cell 
lines including MM.1S, U266, OPM-2, Kas/61, RPMI-8226, KMS-12BM, KMS-12PE and 
KHM-1B cells (193-195) and murine cell lines such as the 5T2MM and 5T33MMvt 
(170). In addition, its ligand CXCL12 is widely known to be expressed by human 
osteoblast cell lines including MBA-15, MG63 (111) and MC3T3-E1 (196) as well as 
primary human osteoblasts (111) in vitro. 
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The interactions of Notch-1 and Jag-1 have also been investigated in MM. Notch-1 
was expressed by several human MC lines in vitro including; NCI H929, RPMI-8226, 
HS-Sultan, ARH-77, IM-9, MC/CAR and MM.1S (197) as well as primary human MCs 
(198). The ligand Jag-1 was also expressed by human primary BM stromal cells (199) 
and MC3T3-E1 osteoblastic cells (200) in vitro. 
 
Currently there is limited data available in support of the expression of Tie-2 by MCs 
compared to that published for CXCR4 and Notch-1. However, Tie-2 expression was 
determined in the human cell line XG-1 and in 4 out of 23 MM patient plasma cell 
samples by RT-PCR. Ang-1 expression was identified in numerous myeloma cell lines 
in vitro, including RPMI-8226, U266, OPM-2, XG-1, and XG-6 as well as 11 out of 22 
patient samples (201). Ang-1 was also expressed by murine primary osteoblastic 
cells, ST-2 cells and C2C12 myoblastic cells (202) in vitro. 
 
A role for N-cad in metastasis has been explored in several cancers including prostate 
and breast cancer. Prostate cell lines PC-3 and LAPC4 and LAPC9 cells (203) and breast 
carcinoma cell lines BT549, Hs578t, SUM159PT, MDA-MB-435 and MDA-MB-436 
expressed N-cad (204). N-cad expression has also been determined in human patient 
MM cells (205) and in human MC lines; LME-1, UM-1, OPM-1, NCI-H929 (206), U266 
and RPMI (207) in vitro. N-cad was also expressed by C2C12 myoblasts and the MSC 
progenitor cell line C3H10T1/2 (which undergo osteoblast differentiation once 
treated with BMP-2 and 7), KS483 osteoblastic cells (206) as well as murine MC3T3-
E1 cells (208) in vitro. 
 
Taken together the studies above provide evidence for a myeloma and osteoblastic 
cell axis in which the MCs express the HSC niche molecules CXCR4, Notch-1, Tie-2 and 
N-cad and the osteoblastic cells express the ligands CXCL12, Jag-1, Ang-1 and N-cad.  
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Currently there is no data, which systematically determines the expression of these 
molecules in the 5TGM1-GFP cell line and limited data for the 5T33MMvt model. In 
my studies, I have determined the in vitro expression profile of CXCR4, Notch-1, Tie-
2 and N-cad by the 5T33-WT, 5T33-GFP and the 5TGM1-GFP cells and the expression 
of the complementary ligands CXCL12, Jag-1, Ang-1 and N-cad by murine osteoblastic 
cells, cultured in vitro. 
 
3.2 Hypothesis, aims and objectives 
 
3.2.1. Hypothesis and aims 
The aim of these studies was to test the hypothesis that “Myeloma cells express the 
same repertoire of molecules as HSCs, and their complementary ligands are 
expressed by osteoblastic cells in vitro”. 
 
3.2.2 Objectives 
The hypothesis will be tested by the following objectives:  
1. To determine the expression of CXCR4, Notch-1, Tie-2 and N-cad by the 5T33-
WT, 5T33-GFP and 5TGM1-GFP cell lines using endpoint and real-time PCR 
and to evaluate the presence of each protein by flow cytometry, 
immunofluorescence (IF) and Western blotting (WB). 
2. To determine the expression of CXCL12, Jag-1, Ang-1 and N-cad by the 
MC3T3-E1 cells and murine primary osteoblast lineage cells (OLCs) using 
endpoint and real-time PCR and to evaluate the presence of each protein by 
flow cytometry. 
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3.3 Methods 
 
3.3.1 Gene expression analysis  
3.3.1.1 Endpoint PCR 
Murine BM was isolated from C57BL/6 mice (N=3) as described in Chapter II, Section 
2.2.1. The 5T33-WT, 5T33-GFP, 5TGM1-GFP, MC3T3-E1 cells and primary OLCs were 
prepared 24 hours prior to RNA extraction to ensure experimental consistency. One 
million MCs were seeded in triplicate into a 6 well plate with 3 ml complete RPMI 
media. The MC3T3-E1 cells and primary OLCs were seeded in triplicate at a density 
of 1x106 into a T75 flask in 12 ml of complete media, appropriate for the cell type. 
Each cell type was incubated for 24 hours before RNA extraction, followed by cDNA 
synthesis and PCR as described in sections 2.3.1, 2.3.2, 2.3.3 and 2.3.4. The process 
from seeding the cells to PCR was repeated three times to produce three biological 
replicates. The Genomics Facility at The University of Sheffield then sequenced all 
PCR products and the homology was analysed by comparing the sequencing results 
with the expected template and GenBank archives.  
 
3.3.1.2 Real-time PCR 
The cDNA from each cell type, generated as described above was also used for real-
time PCR analysis as described in section 2.3.5. Expression was analysed using an 
Applied Biosystems 7900HT real-time PCR machine to produce a Ct value, which was 
normalised to the HK gene β2M to produce the ΔCt value. As with endpoint PCR, the 
process from RNA extraction to PCR was repeated three times to produce three 
biological replicates (N=3). 
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3.3.2 Protein quantification analysis 
3.3.2.1 Flow cytometry 
The murine BM, splenocytes and blood were isolated and processed for flow 
cytometry as described in section 2.2.1 and the MCs and murine osteoblastic cells 
were set-up as described above for RNA extraction (N=3-6). Cells were then 
processed for flow cytometry as described in section 2.4.1. The percentage of 
positive viable cells (using PI or TO-PRO-3 staining) was measured using a FACS 
Calibur and analysed using Cell Quest software by gating against the negative isotype 
control, which demonstrated less than 1% positive staining. Each cell type was set-
up in triplicate and repeated three times (N=3) to produce a mean percentage of cells 
positive for each molecule.  
 
3.3.2.2 Immunofluorescence 
Immunofluorescence was used to quantify and visualise the protein for the HSC niche 
molecules, ligands and CD138 by the 5T33-GFP and 5TGM1-GFP cells as described in 
section 2.4.2. Positive cells were visualised using a Leica AF6000LX microscope, a 40X 
magnification and LAS LF software. Analysis was conducted using Volocity software 
to calculate the percentage of cells, which were positive for each molecule. Each 
experiment was set-up in triplicate (using three slides) and repeated three times 
(N=3) to calculate a mean percentage of cells which were positive for each molecule. 
 
3.3.3. Statistics 
Where relevant non-parametric statistical tests were used. A Kruskal-Wallis test 
followed by a Dunn’s post test (P<0.05) was used to determine any differences in 
gene expression between the MCs and the presence of protein for the HSC niche 
molecules and ligands between the murine constituents and MCs. Where relevant, 
error bars were displayed on all graphs using the SEM unless stated otherwise in the 
legend. 
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3.4 Results 
 
3.4.1 Qualitative assessment of gene expression for the HSC niche molecules, 
ligands and CD138 by normal murine constituents and murine multiple myeloma 
cells, determined using endpoint PCR 
Endpoint PCR was used to determine the qualitative gene expression of the HSC 
niche molecules, their ligands and the plasma cell marker CD138 by murine BM (to 
act as a positive control for the primers), 5T33-WT, 5T33-GFP and 5TGM1-GFP cells. 
As demonstrated in Figure 3.1, endpoint PCR of the murine BM generated products 
of expected size for the HK gene GAPDH (354 BP) and the HSC niche molecules; CXCR4 
(711 BP), Notch-1 (348 BP), Tie-2 (648 BP) and N-cad (560 BP) and ligands; CXCL12 
(205 BP), Jag-1 (370 BP), Ang-1 (401 BP) and CD138 (559 BP). These results therefore, 
confirmed that endpoint PCR primers were working effectively. 
Endpoint PCR was also used to determine the qualitative gene expression of the HSC 
niche molecules, ligands and CD138 by the MCs. Endpoint PCR of the 5T33-WT, 5T33-
GFP and 5TGM1-GFP cells generated products of expected size for the HK gene 
GAPDH and the HSC niche molecules CXCR4 and Notch-1. In addition, the 5T33-WT 
and 5TGM1-GFP samples also generated a band for N-cad but the 5T33-GFP cells did 
not (Figure 3.1). A band for CD138 was visualised in each MC type. Endpoint PCR 
analysis of MC lines did not generate products for the ligands CXCL12, Jag-1, Ang-1 
or the receptor Tie-2. Therefore, the MCs expressed some HSC niche molecules and 
no ligands by endpoint PCR.  
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Figure 3.1: Murine bone marrow and myeloma cells expressed HSC niche molecules, ligands and 
CD138 by endpoint PCR. Endpoint PCR reactions were run using approximately 40 ng of RT+ cDNA 
samples. An equal volume of RT- and H2O control samples were used to assess genomic and reagent 
contamination. The PCR reactions were run for 25 cycles for GAPDH and 35 cycles for the HSC niche 
molecules, ligands and CD138. The PCR products were separated by electrophoresis in a 1.6% agarose 
gel and visualised using a Bio-rad Gel Doc XR+ Imager system and Quantity One 4.6.8 software. Each 
row depicts an individual gel electrophoresis for GAPDH and each HSC molecule and ligand. The base 
pair (BP) number on the right corresponds to the size of bands visualised and band products were 
confirmed by in-house sequencing. Results are representative of three independent experiments. 
 
3.4.2 Quantitative assessment of gene expression for the HSC niche molecules, 
ligands and CD138 by normal murine constituents and murine multiple myeloma 
cells, determined using real-time PCR 
Real-time PCR was used to determine the quantitative expression of the HSC niche 
molecules, their ligands and CD138 by the murine BM, 5T33-WT, 5T33-GFP and 
5TGM1-GFP cells. Table 3.1 demonstrates a summary of the absolute gene 
expression values (Ct values) generated using real-time PCR. The BM expressed the 
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HK genes β2M and HPRT, HSC niche molecules CXCR4, Notch-1, Tie-2 and N-cad and 
ligands CXCL12, Jag-1 and Ang-1. In addition, they also expressed CD138. This 
confirmed that all probes were effective. 
Table 3.1 also shows the absolute gene expression of the HK, HSC niche molecules 
and ligands by the 5T33-WT, 5T33-GFP and 5TGM1-GFP cells and in addition, Figure 
3.2 shows the 1/ΔCt values relative to the HK gene β2M. The 5T33-WT, 5T33-GFP and 
5TGM1-GFP samples highly expressed the HK genes β2M and HPRT, the HSC niche 
molecules CXCR4 and Notch-1 and plasma cell marker CD138 but demonstrated low 
expression of the ligand CXCL12. The 5T33-WT expressed N-cad, as did the 5TGM1-
GFP, though at a higher level, whereas, N-cad was undetermined (UD) in the 5T33-
GFP samples. The 5TGM1-GFP samples also had marginal expression of Tie-2 and 
Ang-1, which were absent in both the 5T33-WT and 5T33-GFP samples. Each cell type 
did not express the ligand Jag-1. When the data was analysed statistically to compare 
the expression between the MCS, there were no significant differences. However, it 
was clear from the data that N-cad expression was higher in the 5TGM1-GFP cells 
compared to both the 5T33-WT and 5T33-GFP cells but because some of the values 
were UD this was unable to be analysed statistically. 
 
In summary, as with the endpoint PCR analysis, the MCs expressed only some of the 
HSC niche molecules and ligands using real-time PCR and the pattern of expression 
was broadly similar to the endpoint PCR analysis where absent expression 
corresponded with high or UD Ct values.  
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Table 3.1: A summary of the absolute gene expression of the HSC niche molecules, ligands and CD138 
by murine bone marrow and myeloma cells using real-time PCR  
Gene BM 5T33-WT 5T33-GFP 5TGM1-GFP 
β2M 17 ± 0.16 15 ± 0.11 15 ± 0.06 12 ± 0.22 
HPRT 22 ± 0.17 20 ± 0.24 20 ± 0.04 17 ± 0.17 
CXCR4 21 ± 0.08 21 ± 0.05 21 ± 0.25 19 ± 0.08 
Notch-1 23 ± 0.23 24 ± 0.09 25 ± 1.38 22 ± 0.34 
Tie-2 29 ± 0.07 UD UD 34 ± 0.56 
N-cad 27 ± 0.44 33 ± 0.33 UD 20 ± 0.06 
CXCL12 21 ± 0.55 31 ± 0.99 33 ± 1.38 30 ± 0.51 
Jag-1 28 ± 0.51 UD UD UD 
Ang-1 27 ± 0.17 UD UD 34 ± 0.75 
CD138 28 ± 0.81 21 ± 0.06 21 ± 0.10 18 ± 0.20 
Mean Ct values ± SEM UD= Undetermined, Ct value > 35. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.2: The murine bone marrow and myeloma cells expressed the HSC niche molecules and 
complementary ligands at varying levels using real-time PCR analysis. Gene expression was assessed 
by normalising the Ct values produced in real-time PCR for CXCR4 & CXCL12 (a), Notch-1 & Jag-1 (b), 
Tie-2 & Ang-1 (c) and N-cad & CD138 (d) to the HK gene β2M to produce the 1/ΔCt (y-axis) value. Data 
was analysed statistically using a Kruskal-Wallis test followed by Dunn’s post test (P<0.05) to compare 
expression between the MCs. Results were determined from three independent experiments (N=3) 
using the SEM. 
 
a b 
c d 
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3.4.3 Protein quantification of HSC niche molecules, ligands and CD138 by normal 
murine constituents and murine multiple myeloma cells using flow cytometry 
Flow cytometry was used to determine the number of murine BM, splenocytes, blood 
cells and MCs, which were positive for the HSC niche molecules, ligands and CD138. 
Figure 3.3a demonstrates an example of the flow cytometry plots produced for the 
staining of CD138 and the viability dye PI in samples of control BM, splenocytes and 
peripheral blood. The mean percentage of cells which were positive for each HSC 
niche molecule and ligand (excluding Ang-1 and N-cad) are shown in Figure 3.3.b and 
summarised in Table 3.2. The BM, splenocytes and blood were positive for the HSC 
niche molecules; CXCR4, Notch-1 and Tie-2 and the ligands; CXCL12 and Jag-1. CD138 
positive staining was also detected in the BM, splenocytes and blood. When the 
results were compared statistically, a significantly greater number of BM cells were 
positive for CXCR4 compared to the splenocytes (P<0.05) and there were no other 
statistically significant differences between the remaining HSC niche molecules and 
ligands when comparing the different cell types.  
 
Ang-1 was not analysed by flow cytometry due a lack of directly conjugated antibody 
and unsuccessful use of an indirect antibody method using the murine constituents 
(data not shown). In addition, when the work was originally conducted there were 
no directly conjugated N-cad antibodies available and indirect methods failed to stain 
the murine positive controls (data not shown). However, more recently a directly 
conjugated N-cad antibody became available and this was tested using the 5TGM1-
GFP cells and the 5T33-GFP cells as a negative control as shown later in Figure 3.5. 
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Figure 3.3: The control murine BM, 
splenocytes and blood samples 
were positive for the HSC niche 
molecules, complementary ligands 
and CD138 by flow cytometry. 
Murine BM, splenocytes and blood 
cells were incubated with directly 
conjugated primary antibodies for 
the HSC niche molecules; CXCR4, 
Notch-1 and Tie-2, ligands; CXCL12 
and Jag-1 and CD138 or dose 
matched isotype control antibodies. 
This was followed by flow cytometry 
using a FACS Calibur and Cell Quest 
software. a. An example of a 
representative scatter plot for CD138 
using the isotype or primary antibody 
for the murine BM (i-ii), splenocytes 
(iii-iv) and blood (v-vi). Positive 
staining for CD138 and negative PI 
staining is shown in the bottom right 
hand side of the quadrant. b. 
Quantitative analysis for the 
percentage of viable cells which were 
positive for CXCR4/CXCL12, (i), 
Notch-1/Jag-1 (ii) and Tie-2 & CD138 
(iii) by the BM, splenocytes and blood 
cells. Data was analysed statistically 
using a Kruskal-Wallis test followed 
by Dunn’s post test (P<0.05). Results 
were determined from three to six 
animals (N=3-6). 
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Table 3.2: A summary of the quantitative analysis for the percentage of control murine constituents, 
which were positive for the HSC niche molecules, ligands and CD138 using flow cytometry 
Protein BM Splenocytes Blood 
CXCR4 65.75 ± 5.08 37.24 ± 4.70 49.06 ± 3.04 
Notch-1 2.79 ± 0.81 4.87 ± 0.69 3.00 ± 2.98 
Tie-2 11.95 ± 2.37 11.09 ± 4.34 1.89 ± 0.16 
CXCL12 11.29 ± 2.39 5.44 ± 1.12 7.19 ± 3.09 
Jag-1 13.18 ± 13.18 1.48 ± 1.48 4.57 ± 0.20 
CD138 10.01 ± 4.03 6.68 ± 3.36 7.87 ± 3.06 
Mean percentage of positive cells ± SEM 
 
Figure 3.4.a. shows an example of the flow cytometry plots produced for the staining 
of CD138 and the viability dye PI in the 5T33-WT, 5T33-GFP and 5TGM1-GFP cells. 
The mean percentage of cells which were positive for each HSC niche molecule and 
ligand are shown in Figure 3.4.b. Table 3.3 also summaries the percentages and SEM 
values for the mean number of 5T33-WT and GFP and 5TGM1-GFP cells which were 
positive for the HSC niche molecules, ligands and CD138. Each MC was positive for 
the HSC niche molecules CXCR4, CXCL12, Notch-1, Tie-2 and CD138. In addition, the 
5TGM1-GFP cells were positive for the ligand Jag-1. When the proportion of positive 
cells were compared between the MCs statistically, a greater number of 5T33-WT 
cells were positive for CXCR4 (P<0.05) and Notch-1 (P<0.05) compared to the 5T33-
GFP cells. In addition a greater number of 5TGM1-GFP cells were positive for CXCL12 
(P<0.05), Notch-1 (P<0.05) and Jag-1 (P<0.05) compared to the 5T33-GFP cells. 
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Figure 3.4: The MM cells were 
positive for the HSC niche 
molecules, some of the 
complementary ligands and 
CD138 at varying degrees using 
flow cytometry. 5T33-WT, 5T33-
GFP and 5TGM1-GFP cells were 
incubated with directly conjugated 
primary antibodies for the HSC 
niche molecules CXCR4, Notch-1 
and Tie-2, ligands CXCL12 and Jag-
1 and, CD138 or dose matched 
isotype control antibodies. This 
was followed by flow cytometry 
using a FACS Calibur and Cell Quest 
software. a. An example of a 
representative scatter plot for 
CD138 using the isotype control 
and primary antibody by the 5T33-
WT (i-ii), 5T33-GFP (iii-iv) and 
5TGM1-GFP cells (v-vi). Positive 
staining for CD138 and negative PI 
staining is shown in the bottom 
right hand side of the quadrant. b. 
Quantitative analysis for the 
percentage of viable cells which 
were positive for CXCR4/ CXCL12 
(i), Notch-1/Jag-1 (ii) and Tie-2 & 
CD138 (iii) by the 5T33-WT, 5T33-
GFP and 5TGM1-GFP cells. Data 
was analysed statistically using a 
Kruskal-Wallis test followed by 
Dunn’s post test (P<0.05) Results 
were determined from three 
independent experiments (N=3). 
 
 
 
 
 
 
 
 
 
i iii v 
a 
bi 
ii iv vi 
iii 
ii 
Chapter III: The in vitro expression of HSC niche molecules and their complimentary ligands by 
myeloma and osteoblastic cells Page 112 
 
Table 3.3: A summary of the quantitative analysis for the percentage of myeloma cells, which were 
positive for the HSC niche molecules, ligands and CD138 using flow cytometry 
Protein 5T33-WT 5T33-GFP 5TGM1-GFP 
CXCR4 97.19 ± 0.06 90.59 ± 0.32 94.79 ± 1.41 
Notch-1 96.45 ± 0.10 64.43 ± 1.68 97.91 ± 0.26 
Tie-2 4.15 ± 0.67 0.34 ± 0.07 4.97 ± .0.78 
CXCL12 32.19 ± 4.15 3.76 ± 1.40 64.20 ± 3.00 
Jag-1 0.10 ± 0.03 0.03 ± 0.01 6.99 ± 1.18 
CD138 89.56 ± 0.93 89.59 ± 0.38 98.65 ± 0.20 
Mean percentage of positive cells ± SEM 
 
As stated previously, in more recent experiments a directly conjugated N-cad 
antibody was used to stain the 5T33-GFP (used as a negative control due to the 
endpoint and real-time PCR data) and 5TGM1-GFP cells for N-cad. A dose matched 
isotype control was also used however; the isotype control did not have the same 
conjugate as the primary antibody (Dylight 650) as this was unavailable. Therefore, 
the results between the isotype and primary antibody are not completely 
comparable. Figure 3.5 demonstrates the percentages of 5T33-GFP and 5TGM1-GFP 
cells, which were positively stained for N-cad using increasing amounts of primary 
antibody. As demonstrated in the graph, there was an increase in the number of 
positive 5T33-GFP and 5TGM1-GFP cells as the amount of primary antibody increased 
and using 1.0 µg of antibody, nearly all of the 5T33-GFP and the 5TGM1-GFP cells 
were positively stained (98% and 96% respectively). In addition, there were no 
differences between the number of 5T33-GFP or 5TGM1-GFP cells, which were 
positive for N-cad, when the percentages were examined. As these data were 
contradictory to the endpoint and real-time PCR data, where 5T33-GFP cells did not 
show any expression of N-cad, the reliability of the antibody is questionable.  
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Figure 3.5: An increase in the concentration of N-cad antibody correlated with an increase in positive 
staining in both the 5T33-GFP and 5TGM1-GFP cells using flow cytometry. 5T33-GFP and 5TGM1-
GFP cells were incubated with increasing doses of primary conjugated antibodies for N-cad or dose 
matched isotype control antibodies. This was followed by flow cytometry using a FACS Calibur and Cell 
Quest software. Quantitative analysis for the percentage of positive viable cells for N-cad by the 5T33-
GFP and 5TGM1-GFP was conducted. No statistical analysis was conducted. Results were determined 
from three independent experiments (N=3). 
 
3.4.4 N-cad protein detection by 5T33-GFP and 5TGM1-GFP cells using Western 
blotting 
As the flow cytometry data for N-cad did not seem reliable due to the linear increase 
in positive staining as the amount of antibody increased using the 5T33-GFP and 
5TGM1-GFP cells, WB was used as an alternative. This was conducted using a 
different unconjugated primary antibody, described in Section 2.4.4.  
 
Figure 3.6 demonstrates the WB produced to detect N-cad in the 5T33-GFP and 
5TGM1-GFP lysates. Two different ECL solutions were used, one was purchased from 
Thermo Scientific, as shown in Figure 3.6a and b respectively and the other was 
purchased from Santa Cruz Biotechnology as shown in Figure 3.6c and d. The ECL 
purchased from Thermo Scientific, despite a significantly shorter exposure time than 
the Santa Cruz Biotechnology ECL (30 seconds), over-exposed the protein bands, 
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particularly in the protein ladder, which made the ladder difficult to interpret. 
Whereas, the Santa Cruz Biotechnology ECL which needed a longer exposure time (5 
min), produced clearer WBs with a distinguishable protein ladder and clear bands for 
β-actin and N-cad. Therefore, this ECL was the most desirable to use in future 
experiments.  
 
 
 
 
 
 
 
 
 
 
Figure 3.6: N-cad protein was present in the 5TGM1-GFP cells but not in the 5T33-GFP cells using 
Western blotting. 5T33-GFP or 5TGM1-GFP cell lysates (20 µg) or biotinylated protein ladder (1:10) 
were run in a 7% polyacrylamide gel and the separated proteins were transferred on to a nitrocellulose 
membrane. The membranes were blotted with primary antibodies for N-cad and β-actin followed by 
HRP-conjugated secondary antibodies and an anti-biotin-HRP antibody. The blots were developed 
using ECL supplied by Thermo Scientific (exposure time of 30 seconds) and Santa Cruz Biotechnology 
(exposure time of 5 min). The experiment was repeated three times using three biological lysate 
replicates and representative images were produced. As shown above, lane 1 demonstrates the protein 
ladder and lane 2 shows the cell lysates. Proteins are labelled and the size of the protein is labelled on 
the left (kDa) a. 5T33-GFP lysates and Thermo Scientific ECL. b. 5TGM1-GFP lysates and Thermo 
Scientific ECL. c. 5T33-GFP lysates and Santa Cruz Biotechnology ECL. d. 5TGM1-GFP lysates and Santa 
Cruz Biotechnology ECL.  
 
Figure 3.6 also demonstrates differences in the presence of N-cad between the 5T33-
GFP (Figure 3.6a and c) and 5TGM1-GFP cells (Figure 3.6b and d). Using both the 
Thermo Scientific ECL and Santa Cruz ECL, clear β-actin bands were produced of the 
correct size for both the 5T33-GFP and 5TGM1-GFP lysates. However, there was no 
band for N-cad using the 5T33-GFP lysates whereas, clear bands of the correct size 
a b 
c d 
Protein 
ladder 
Lane 1 Lane 2 
Lane 1 Lane 2 Lane 1 Lane 2 
Lane 1 Lane 2 
5T33-GFP 
5T33-GFP 
5TGM1-GFP 
5TGM1-GFP 
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were detected using the 5TGM1-GFP lysates. Therefore, this implies that N-cad 
protein is not present in the 5T33-GFP cells but is present in the 5TGM1-GFP cells. 
 
3.4.5 Protein visualisation of HSC niche molecules, ligands and CD138 by 5T33-GFP 
and 5TGM1-GFP cells using immunofluorescence 
Immunofluorescence was used to confirm the presence of protein for the HSC niche 
molecules, ligands and CD138 by the 5T33-GFP and 5TGM1-GFP cells as well as to 
visualise the protein within the cells. Figures 3.7 and 3.8 demonstrate the images 
taken of 5T33-GFP and 5TGM1-GFP cells respectively, stained for CXCR4, Notch-1, 
CXCL12 and CD138. Images of Tie-2 and Jag-1 were not shown, as primary antibody 
staining was not apparent in either cell type compared to the isotype control. From 
the images, it was clear that both cell types were positive for CXCR4, CXCL12, Notch-
1 and CD138 and the positive staining appeared to locate to specific regions of the 
cells depending on the molecule. CXCR4 and CD138 staining was visualised on the 
membrane of the cells whereas Notch-1 seemed to be stained within membranous 
and cytoplasmic regions and CXCL12 was present inside the cell cytoplasm as discrete 
foci.  
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Figure 3.7: 5T33-GFP cells were positive for HSC niche molecules CXCR4, Notch-1, the ligand CXCL12 
and the plasma cell marker CD138 by immunofluorescence. 5T33-GFP cytospins were incubated with 
directly conjugated primary antibodies for the HSC niche molecules CXCR4 and Notch-1, the ligand 
CXCL12 and CD138 (right-hand side) and dose matched isotype control antibodies (left-hand side). This 
was followed by visualisation using a Leica AF6000LX microscope at a 40X magnification using LAS LF 
software. Nuclei are blue (DAPI) and positive antibody staining is red (APC). Images are representative 
of three independent experiments. Scales bars represent 50 µM. 
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Figure 3.8: 5TGM1-GFP cells were positive for HSC niche molecules CXCR4, Notch-1, the ligand 
CXCL12 and the plasma cell marker CD138 by immunofluorescence. 5TGM1-GFP cytospins were 
incubated with directly conjugated primary antibodies for the HSC niche molecules CXCR4 and Notch-
1, the ligand CXCL12 and CD138 (right-hand side) and dose matched isotype control antibodies (left-
hand side). This was followed by visualisation using a Leica AF6000LX microscope at a 40X 
magnification using LAS LF software. Nuclei are blue (DAPI) and positive antibody staining is red (APC). 
Images are representative of three independent experiments. Scales bars represent 50 µM. 
 
Using the images generated from IF, the percentage of 5T33-GFP and 5TGM1-GFP 
cells, which were positive for each molecule, was calculated, shown graphically in 
Figure 3.9 and summarised in Table 3.4. From the data, there were no differences 
between the number of cells 5T33-GFP and 5TGM1-GFP cells, which were positive 
CXCR4 
Notch-1 
CXCL12 
CD138 
Isotype antibody Primary antibody Primary antibody 
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for CXCR4, Notch-1 or CD138, but a greater number of 5TGM1-GFP cells, were 
positive for CXCL12 compared to the 5T33-GFP cells. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.9: The 5T33-GFP and 5TGM1-GFP cells were positive for the HSC niche molecules CXCR4 and 
Notch-1, ligand CXCL12 and CD138 using quantitative analysis of immunofluorescence staining. 
5T33-GFP and 5TGM1-GFP cytospins were incubated with directly conjugated primary antibodies for 
the HSC niche molecules CXCR4 (a) and Notch-1 (c), the ligand CXCL12 (b) and CD138 (d) or dose 
matched isotype control antibodies. This was followed by visualisation using a Leica AF6000LX 
microscope at a 40X magnification and LAS LF software. Volocity spot counting software was then used 
to calculate the mean percentage of cells, which were positive for each molecule. Results were 
determined from three independent experiments (N=3). 
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Table 3.4: A summary of the quantitative analysis for the percentage of 5T33-GFP and 5TGM1-GFP 
cells, which were positive for the HSC niche molecules; CXCR4 and Notch-1, ligand CXCL12, and 
CD138 using immunofluorescence 
Protein 5T33-GFP 5TGM1-GFP 
CXCR4 95.70 ± 1.21 96.33 ± 0.34 
Notch-1 98.70 ± 0.89 98.67 ± 0.34 
CXCL12 20.30 ± 3.78 71.00 ± 5.55 
CD138 97.00 ± 0.58 99.90 ± 1.01 
Mean percentage of positive cells ± SEM 
 
3.4.6 Qualitative assessment of gene expression for the HSC niche molecules and 
ligands by MC3T3-E1 and primary osteoblast lineage cells using endpoint PCR 
Endpoint PCR was used to determine the qualitative gene expression of the HSC 
niche molecules and their ligands by the murine MC3T3-E1 cells and murine primary 
osteoblast lineage cells (OLCs). As demonstrated in Figure 3.10, both the MC3T3-E1 
cells and primary OLC samples produced bands for ligands; CXCL12, Jag-1 and Ang-1, 
and HSC niche molecules; Notch-1 and N-cad. In addition, the primary OLCs produced 
a band for Tie-2. Therefore, the osteoblastic cells were positive for all ligands and 
some of the HSC niche molecules using endpoint PCR. 
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Figure 3.10: The murine osteoblastic cells expressed the complementary ligands and some of the 
HSC niche molecules using endpoint PCR. The endpoint PCR reactions were run using approximately 
40 ng of RT+ cDNA samples. An equal volume of RT- and H2O control samples were used to assess 
genomic and reagent contamination. The PCR reactions were run at 25 cycles for GAPDH and 35 cycles 
for the HSC niche molecules and ligands. The PCR product was separated by electrophoresis in a 1.6% 
agarose gel and visualised using a Bio-rad Gel Doc XR+ Imager system and Quantity One 4.6.8 
software. Each row depicts an individual gel electrophoresis for GAPDH and each HSC molecule and 
ligand. The base pair (BP) number on the right corresponds to the size of bands visualised and band 
product was confirmed by in-house sequencing. Results are representative of three independent 
experiments. 
 
3.4.7 Quantitative assessment of gene expression for the HSC niche molecules and 
ligands by MC3T3-E1 and primary osteoblast lineage cells using real-time PCR 
Real-time PCR was used to determine the quantitative expression of the HSC niche 
molecules and their ligands by MC3T3-E1 cells and OCLs. Table 3.5 demonstrates a 
summary of the absolute gene expression values (Ct values) and Figure 3.11 shows 
the 1/ΔCt values generated using real-time PCR. 
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Table 3.5: A summary of the absolute gene expression for the HSC niche molecules and ligands by 
MC3T3-E1 cells and primary osteoblast lineage cells using real-time PCR 
Gene MC3T3-E1 Primary OLCs 
β2M 19 ± 0.94 17 ± 0.12 
HPRT 25 ± 0.90 23 ± 0.08 
CXCR4 UD UD 
Notch-1 28 ± 1.26 25 ± 0.34 
Tie-2 UD 29 ± 0.37 
N-cad 24 ± 1.28 23 ± 0.16 
CXCL12 22 ± 1.18 17 ± 0.21 
Jag-1 25 ± 0.98 22 ± 0.13 
Ang-1 28 ± 1.31 25 ± 0.16 
Mean Ct values ± SEM UD= Undetermined, Ct value > 35. 
 
Both cell types expressed the HK genes β2M and HPRT as well as the ligands CXCL12, 
Jag-1 and Ang-1. In addition, they both expressed the HSC niche molecules Notch-1 
and N-cad. The primary OLCs, also expressed Tie-2, whereas this was absent in the 
MC3T3-E1 cells. Both cell types did not express CXCR4. It is clear from these data that 
the primary OLCs expressed CXCL12 at a greater level than the MC3T3-E1 cells and 
also had slightly higher expression of Notch-1, Jag-1, Tie-2 and Ang-1, whereas, N-
cad was more highly expressed in the MC3T3-E1 cells, however, statistical analysis 
was unable to be conducted.  
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Figure 3.11: The murine osteoblastic cells expressed the complementary ligands and some of the 
HSC niche molecules using real-time PCR. Gene expression was assessed by normalising the Ct values 
produced in real-time PCR for CXCR4 & CXCL12 (a), Notch-1 & Jag-1 (b), Tie-2 & Ang-1 (c) and N-cad 
(d) to the HK gene β2M to produce the 1/ΔCt value (y-axis). Results were determined from three 
independent experiments (N=3) using the SEM. 
 
3.4.8 Protein quantification of the HSC niche molecules and ligands by MC3T3-E1 
and primary osteoblast lineage cells using flow cytometry 
Flow cytometry was used to determine the number of MC3T3-E1 cells and primary 
OLCs, which were positive for the HSC niche molecules and their ligands. Figure 3.12a 
demonstrates an example of the flow cytometry plots produced for the staining of 
Jag-1 and the viability dye TO-PRO-3 using the MC3T3-E1 cells and primary OLCs. The 
mean percentage of cells, which were positive for each HSC niche molecule and 
ligand, are shown in Figure 3.12b. A summary of the percentages of cells which were 
positive for the HSC niche molecules and ligands is shown in Table 3.6. The MC3T3-
E1 cells and primary OLCs were positive for the ligands CXCL12 and Jag-1 and the HSC 
molecule Notch-1 and neither cell type was positive for Tie-2. A slightly higher 
number of primary OLCs were positive for CXCL12 compared to the MC3T3-E1 cells, 
whereas, a greater number of MC3T3-E1 cells were positive for Notch-1 and Jag-1 
a b 
c d 
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compared to the primary OLCs, where the difference was particularly obvious for Jag-
1, however, statistical analysis was unable to be conducted. 
 
Figure 3.12: The murine 
osteoblastic cells were positive 
for the complementary ligands 
CXCL12 and Jag-1 and HSC niche 
molecule Notch-1 using flow 
cytometry. The MC3T3-E1 cells 
and primary OLCs were 
incubated with directly 
conjugated primary antibodies 
for the ligands CXCL12 and Jag-1 
and HSC niche molecules Notch-
1 and Tie-2 or dose matched 
isotype control antibodies. This 
was followed by flow cytometry 
using a BD Calibur and Cell 
Quest software. a. An example 
of a representative scatter plot 
for the isotype and primary 
antibody for Jag-1 by the 
MC3T3-E1 cells (i-ii) and primary 
OLCs (iii-iv). Positive staining of 
Jag-1 and negative TO-PRO-3 is 
shown in the bottom right-hand 
side of the quadrant. b. 
Quantitative analysis for the 
percentage of viable cells, which 
were positive for CXCR4/CXCL12 
(i) and Notch-1/Jag-1 (ii) by the 
MC3T3-E1 and primary OLCs. 
Results were determined from 
three independent experiments 
(N=3) 
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Table 3.6: A summary of the quantitative analysis for the percentage of MC3T3-E1 cells and primary 
osteoblast lineage cells, which were positive for the HSC niche molecules and ligands using flow 
cytometry. 
Protein MC3T3-E1 Primary OLCs 
CXCL12 63.10 ± 3.10 75.53 ± 1.37 
Jag-1 54.70.± 0.95 12.63 ± 1.01 
Notch-1 82.48 ± 0.75 61.03 ± 6.64 
Tie-2 0.00 ± 0.00 0.00 ± 0.00 
Mean percentage of positive cells ± SEM. 
 
3.5 Discussion 
 
The aim of this chapter was to determine whether the HSC niche molecules CXCR4, 
Notch-1, Tie-2 and N-cad were expressed by the 5T33MMvt and 5TGM1-GFP cell 
lines, and to determine the expression of their complementary ligands CXCL12, Jag-
1, Ang-1 and N-cad by the MC3T3-E1 cells and murine primary OLCs in vitro. 
 
Firstly, murine BM cDNA was used in PCR experiments, and murine BM, splenocytes 
and blood cells were used for flow cytometry as positive controls to ensure that the 
PCR and flow cytometry reagents and protocols were working effectively. The 
expression of each HSC niche molecule and ligand by the murine BM was 
demonstrated in my studies, using each methodology. However, when comparing 
the BM PCR and flow cytometry data, the number of positive cells did not correlate 
with the gene expression. For example there was high expression of CXCL12 and 
Notch-1 using PCR, whereas the number of cells positive for CXCL12 and Notch-1 was 
below 12% and 3% respectively using flow cytometry. This difference may potentially 
be due to the preparation of the samples i.e. the RBCs were lysed in the flow 
cytometry samples whereas the entire BM population was used for RNA extraction, 
or it may also be due to inefficiency of the antibodies. It is also possible that high 
transcript levels of CXCL12 and Notch-1 are present in the BM samples but only in 
particular sub-populations of cells. Therefore, this may account for high levels of 
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expression in the PCR but low numbers of positive cells using flow cytometry, as flow 
cytometry did not account for the level of protein present, only the number of 
positive cells.  
 
A further explanation to account for differences in gene expression and presence of 
protein which has been highly explored in the literature, is that there is only a weak 
correlation between the levels of mRNA and protein within mammalian cells (209). 
Messenger RNA to protein studies were conducted using cells derived from a variety 
of different organisms including mouse, yeast and bacteria using specialised mRNA 
and protein quantification techniques. Results were analysed using both the 
Spearman rank coefficient and Pearson correlation coefficient statistical tests to 
compare mRNA and protein levels at one time by hundreds of genes and 
corresponding proteins. On average, a coefficient correlation value of 0.57 was 
established which illustrated a correlation of 57% between mRNA and protein levels 
in the different cell types (210). Therefore, mRNA and protein values were not 
directly correlated. Several factors have been implicated in this finding which 
included varying rates of mRNA synthesis and protein production, stability of the 
mRNA and protein, in addition to the state of mRNA synthesis (210). Previous studies 
found that mRNA was synthesised at a slower rate compared to proteins i.e. cells 
were found to produce two copies of mRNA per hour compared to a dozen copies of 
the corresponding protein (210). In one study, median translation rate was 
approximately 140 proteins per mRNA per hour however, this varied depending on 
the function of the proteins of interest; for example, proteins involved in translation 
regulation had much slower rates of translation (211). In addition, mRNA degrades 
quicker than proteins with a median half-life of 9 hours compared to proteins which 
are five times more stable with a median half-life of 46 hours (211). Housekeeping 
genes and small proteins were also found to be more stable (211), whereas genes 
and proteins for transcription factors and chromatic organisation were significantly 
less stable (211). In addition, the state of mRNA production when analysed 
influenced protein production. For example, if the cells were producing mRNA for a 
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particular protein at a steady state, the variability of protein production was high, 
whereas if the mRNA was synthesised at varying rates the corresponding protein out-
put correlated well (212). These concepts provide an insight as to why differences in 
mRNA and protein expression occur. However, the general concept implies that 
mRNA production may be slower and prone to degradation and therefore, this does 
not provide a theory as to why the CXCL12 and Notch-1 mRNA expression by the BM 
was higher compared to the level of protein. However, as stated above, the rates of 
mRNA synthesis and translation may be gene and protein specific and highly variable.  
 
Polymerase chain reaction, flow cytometry and IF were also used to determine the 
gene expression and presence of protein for the HSC molecules, ligands and CD138 
in the MCs. Taken together, using both gene and protein methodologies, the MCs 
expressed all HSC niche molecules as well as the ligands CXCL12, Ang-1 and Jag-1. 
However, similar to the BM analysis, there were some discrepancies between the 
gene expression and presence of protein in the MCs using both PCR and flow 
cytometry. There were no bands present for Tie-2, CXCL12, Ang-1 or Jag-1 by 
endpoint PCR in any of the MCs and only marginal expression of CXCL12, Tie-2 and 
Ang-1 (which varied depending on the cell type) and UD expression of Jag-1 in all 
MCs, by real-time PCR. Whereas, using flow cytometry, a high proportion of 5TGM1-
GFP cells (64%) and a lower number of 5T33-WT and 5T33-GFP cells (32% and 4%, 
respectively) were positive for CXCL12, Tie-2 was present at a low frequency only in 
the 5T33-WT and 5TGM1-GFP cells (4-5%), and Jag-1 was present only in the 5TGM1-
GFP cells (7%). The 5T33-GFP and 5TGM1-GFP cells were also positive for CXCL12 
using IF, where staining seemed to exist as discrete foci and there was no staining of 
Jag-1 or Tie-2 in the 5T33-GFP cells and 5TGM1-GFP cells. Again, the positive CXCL12, 
Jag-1 and Tie-2 staining in the flow cytometry and/or IF may be due to non-specific 
binding of the antibodies and WB could be used to determine the specificity. Low 
expression of CXCL12 and Tie-2, and UD expression of Jag-1 by the MCs using 
endpoint and real-time PCR could also be due to the inefficiency of the primers and 
probes used. However, the primers for endpoint PCR worked successfully using the 
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BM cDNA and the efficiency of the CXCL12 and Jag-1 probes were within the normal 
range as shown in Appendix 2, Section 2.5. The difference in gene expression and 
presence of protein may also be due to differences in mRNA and protein production 
rates as stated above, which may account for lower mRNA levels of CXCL12, Tie-2 
and Jag-1 compared to protein. In addition, sub-populations of cells could also be 
responsible. A small sub-population of MCs may express high levels of the molecules 
Tie-2 and Jag-1 however, because there are only low numbers of positive cells these 
are undetectable using real-time PCR.  
 
Another theory with regards to CXCL12 and the conflicting results between gene 
expression and presence of protein in the MCs, is that CXCL12 is internalised from 
the FBS in the media that the MCs are cultured in, resulting in false positives using 
flow cytometry and IF. In support of this, Hatse et al (213), reported that CXCL12 was 
internalised in bovine endothelial cells and in the T lymphoblastic cell line SupT1, 
visualised by flow cytometry using a fluorescent recombinant CXCL12 protein. 
However, further work is required to test this hypothesis in MCs. 
 
There were also some differences in the expression of some of the molecules and 
ligands between the MCs using real-time PCR, flow cytometry and IF. Differences 
between the cell types was particularly apparent with regards to N-cad using real-
time PCR, CXCL12, Notch-1 and Jag-1 using flow cytometry and CXCL12 using IF. The 
differences observed between the MCs maybe caused by several factors. Firstly, 
differences between the 5T33-WT and GFP cells may be due to the selection process 
after the GFP had been transduced into the 5T33MMvt cells (the process for this is 
unknown as the cells were transduced outside of the University) or their 
characteristics may have changed due to in vitro cell culture. The 5TGM1-GFP cell 
line, which was derived from the 5T33MMvt cells, demonstrates different 
characteristics in vivo, such as bone lesions; therefore, it may be unsurprising that 
the expression of some of the molecules differs in vitro. 
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Flow cytometry was also used to detect the number of N-cad positive 5T33-GFP and 
5TGM1-GFP cells. However, due to nonspecific binding of the primary antibody and 
unsuitable isotype control antibody, WB was used as an alternative. Western blotting 
was originally conducted using two different types of ECL. The ECL purchased from 
Thermo Scientific resulted in over-exposed bands despite less exposure time, 
whereas ECL purchased from Santa Cruz Biotechnology demonstrated more 
optimum band density despite a longer exposure time. Using both types of ECL, the 
5T33-GFP lysates did not produce a band for N-cad whereas the 5TGM1-GFP lysates 
produced a band of the correct size. Therefore, these data correlated with the real-
time PCR results where N-cad was not expressed in the 5T33-GFP cells but was 
detected in the 5TGM1-GFP cells. Western blotting is in some ways more 
advantageous than flow cytometry, because in addition to detecting the presence of 
protein is can also provide evidence for the specificity of the antibody. However, one 
of its limitations is that it is unable to provide a percentage of cells, which are positive 
for the protein of interest (POI). Therefore, from these studies it implies that N-cad 
is present in the 5TGM1-GFP cells but the percentage of positive cells is unknown. 
 
Taken together, the PCR, flow cytometry and IF data demonstrated that the HSC 
niche molecules were expressed by or present on the 5T33-WT, 5T33-GFP and 
5TGM1-GFP cells. These data are supported by previous studies, which have 
determined the expression of some of these molecules by MCs in vitro. CXCR4 
expression was previously determined by the 5T2MM and 5T33MMvt cells (170) and 
various human MCs (193-195) in vitro. Notch-1 was expressed by human MC lines 
and patient cells (198, 199, 214) and Tie-2 was expressed by the XG-1 cell line in vitro 
(201). N-cad was also expressed by several different human cell lines as well as 
patient cells (205-207). The MCs were also potentially positive for the ligands CXCL12, 
Jag-1 and Ang-1. CXCL12 expression was previously shown in MCs such as ARH-77, 
WL2, JIMI, LP-1, NCI-H929 and RPMI-8266 cells using real-time PCR and in human 
MM cells using IHC (215). However, as stated previously it is uncertain whether the 
MCs in these studies are producing CXCL12 themselves or whether they are 
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internalising it from the FBS present in the media. Jag-1 protein expression has 
previously been demonstrated in primary patient MC samples (198, 214) and Ang-1 
expression has also previously been shown in myeloma cell lines including RPMI-
8226, U266, OPM-2, XG-1, and XG-6 as well as patient samples (201). 
 
Endpoint and real-time PCR and flow cytometry demonstrated the expression of the 
ligands CXCL12, Jag-1, Ang-1 and N-cad and the receptor Notch-1 by both the MC3T3-
E1 and primary OLCs, whereas Tie-2 was only expressed by the primary OLCs. 
However, some of the findings between gene expression and presence of protein did 
not entirely correlate. The real-time PCR results implied greater expression of all 
ligands with the exception of N-cad by the primary OLCs compared to the MC3T3-E1 
cells (though these were not compared statistically). Whereas, using flow cytometry, 
the number of Notch-1 and Jag-1 positive cells were higher in the MC3T3-E1 cells 
compared to the primary OLCs, and Tie-2 staining was absent by flow cytometry in 
the primary OLCs, contradictory to the real-time PCR data. In addition, the difference 
in CXCL12 expression between the MC3T3-E1 cells and primary OLCs was obvious 
using real-time PCR however, by flow cytometry they differed only by 10 %. Again, 
inconsistencies between the gene expression and presence of protein may be due to 
differences in transcription and translation rates or the specificity of the PCR and flow 
cytometry reactions. The flow cytometry protocol may be particularly responsible for 
the contrasting results for Jag-1 and Tie-2. These are both membrane-bound 
proteins, and despite cautious efforts to retain its presence through careful 
dissociation of the cells from their flasks, the molecules may have been cleaved. This 
therefore may have resulted in the absence of Tie-2 and low Jag-1 positive cells in 
the primary OLCs using flow cytometry. In addition, flow cytometry only accounted 
for the number of cells, which were positive for each molecule, not the number of 
proteins present on a per cell basis therefore, this could result in differences between 
real-time PCR and flow cytometry.  
 
Chapter III: The in vitro expression of HSC niche molecules and their complimentary ligands by 
myeloma and osteoblastic cells Page 130 
 
The overall expression of the HSC niche molecules and ligands by osteoblastic cells 
are however, supported by the literature. Jag-1 expression has been detected in 
MC3T3-E1 cells (200, 216), BM stromal cells (199), C3H10T1/2 and C2C12 cell lines, 
murine primary osteoblastic cells (216) and osteoblasts in mice in vivo (82). Notch-1 
expression has previously been identified in MC3T3-E1 cells (200, 216), C3H10T1/2 
and C2C12 cell lines and murine primary osteoblastic cells (216). CXCL12 was 
expressed in MC3T3-E1 cells, human osteoblastic cells, stromal cells, MG63 cells 
(196) and by MSCs (217). Tie-2 is generally perceived as an endothelial marker 
however, Jeong et al (202) determined its expression in MC3T3-E1 cells, murine 
primary osteoblastic cells, C2C12 cells, C3H10T1/2 cells and ST-stromal cells. Ang-1 
expression has previously been identified in murine primary osteoblastic cells, ST-
stromal cells, C2C12 cells and C3H10T1/2 cells (202). N-cad expression has previously 
been identified in MC3T3-E1 cells, C3H10T1/2, ST-stromal cells, ATDC5 chondrogenic 
cells, NIH3T3 fibroblastic cells (218), KS483 osteoblastic cells (206), SAOS-2 cells (219) 
and by both oval and spindle shaped osteoblasts in vivo (83). 
 
In conclusion, these data support the hypothesis that MCs express and produce the 
same repertoire of molecules as HSCs, which include CXCR4, Notch-1, Tie-2 and N-
cad and that their complementary ligands; CXCL12, Jag-1, Ang-1 and N-cad are 
expressed by osteoblastic cells in vitro. However, their role within a MC niche is still 
unknown and therefore, further research is required to explore this.  
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4.1 Introduction 
 
As discussed previously, it has been suggested that MCs may home to a BM 
microenvironmental niche similar to that occupied by HSCs. To achieve this it was 
hypothesised that MCs express the same repertoire of HSC niche molecules, which 
anchor MCs to the niche and induce MC dormancy. 
 
Chapter III explored the expression and presence of the HSC niche molecules and 
complementary ligands in murine MCs (5T33-WT, 5T33-GFP and 5TGM1-GFP) and 
osteoblastic cells (MC3T3-E1 and primary OLCs) cultured in vitro. However, the 
expression of these molecules was not determined ex vivo or in vivo. It remains 
unknown whether the MCs express/utilise the same HSC niche molecules once 
injected into mice and also whether these molecules play a role in the homing, 
growth and subsequent survival of the MCs within the BM in vivo. 
 
Previous studies have determined the expression of some of the HSC niche molecules 
and their ligands in MCs isolated from BM or peripheral blood of mice or patients 
analysed ex vivo or in vivo using BM sections.  
 
Van de Broek et al (220) demonstrated that 59% of MM patients had CXCR4 positive 
BM MCs, when analysed ex vivo and this is supported by a separate study which 
found that 5/5 myeloma patient samples were positive for CXCR4 when isolated and 
analysed in a similar way (221). In addition, Alsayed et al (195) reported that both 
BM and peripheral blood MCs from MGUS and MM patients were positive for CXCR4 
using flow cytometry, analysed ex vivo.  
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CXCL12 expression was detected in human BM cells isolated from healthy donors and 
specifically in sorted mononuclear cell fractions, analysed ex vivo (193). CXCL12 
protein was also detected in human bone by immature osteoblastic cells lining the 
endosteum and stromal cells in the marrow space in vivo using IHC (111). In addition, 
the presence of CXCL12 was significantly higher in BM samples isolated from patients 
with MM compared to healthy controls and there were significantly higher levels of 
CXCL12 in the BM compared to samples from the peripheral blood (195). 
 
Previous studies have also demonstrated the expression of Notch-1 and Jag-1 by MCs 
and osteoblastic cells ex vivo and in vivo. Patient MCs were isolated from BM samples 
by CD38high/CD19low flow cytometry sorting and were cytospun on to slides followed 
by IHC staining for both Notch-1 and CD138. CD138 staining was observed on the 
membrane of the cells, whereas Notch-1 staining was cytoplasmic (198). The 
presence of Notch-1 protein in MCs was also visualised in vivo on BM trephines using 
IHC where 72 out of 78 (92.31%) MM patient samples were positive for Notch-1 
(214). Jag-1, the ligand for Notch-1 was expressed by human BM stromal cells 
isolated from healthy donors and analysed by WB (199). Jag-1 staining was also 
present on osteopontin (Opn) positive osteoblasts situated on trabecular bone 
surfaces on histological slides using IHC (82).  
 
As stated in Chapter III, there is little evidence in support of Tie-2 expression by MCs. 
However, Tie-2 expression was found in 4 out of 23 BM MC patient samples, 
determined by RT-PCR. In addition, 11 out of 22 samples also expressed Ang-1. 
Furthermore, stromal cells isolated from the BM of myeloma patients were positive 
for both Ang-1 and Tie-2 (201). In addition, the presence of Ang-1 protein was also 
detected by murine osteocalcin (Ocn) positive osteoblasts lining trabecular bone on 
histological slides in vivo (85). 
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N-cad expression has previously been observed in BM patient MCs as well as patient 
serum (205). N-cad was also implicated as a marker of prognosis, where patients with 
high circulating N-cad were found to have a poorer prognosis and a greater risk of 
death compared to those with low levels. In addition, N-cad protein was present in 
both spindle and oval-shaped osteoblasts in vivo (83) and by human primary OLCs 
isolated from trabecular bone chips using Northern blotting (152). 
 
Taken together, these studies provide evidence that the HSC niche molecules CXCR4, 
Notch-1, Tie-2 and N-cad are expressed by patient MCs isolated from the BM or 
circulation and analysed ex vivo, as well as being present on patient MCs analysed in 
vivo. In addition, their complementary ligands CXCL12, Jag-1, Ang-1 and N-cad are 
expressed by osteoblastic cells isolated from patient BM and analysed ex vivo as well 
as osteoblastic cells in vivo. 
 
While the above provides some evidence for the expression and activities of HSC 
niche molecules and ligands by both human and murine MCs, there is also little or no 
data, which systematically determines the expression or function of these molecules 
in the 5T33-GFP and 5TGM1-GFP models of myeloma either analysed ex vivo or in 
vivo.  
 
In this chapter, I have determined the presence of protein for CXCR4, Notch-1, Tie-2 
and N-cad in BM derived 5T33-GFP cells as well as BM and spleen derived 5TGM1-
GFP cells analysed ex vivo using flow cytometry. In addition, I have also mapped the 
growth of the 5TGM1-GFP cells and the presence of the HSC niche molecules and 
ligands over-time in vivo. 
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4.2 Hypothesis, aims and objectives 
 
4.2.1. Hypothesis and aims 
The aim of these studies was to test the hypothesis that “Myeloma cells express the 
same repertoire of molecules as HSCs when analysed ex vivo and in vivo.  
 
4.2.2 Objectives 
The hypothesis will be tested by the following objectives: 
1. To determine the presence of protein for the HSC niche molecules; CXCR4, 
Notch-1 and Tie-2, complementary ligands; CXCL12 and Jag-1, and CD138 in 
the BM derived 5T33-GFP cells as well as BM and spleen derived 5TGM1-GFP 
cell lines analysed ex vivo using flow cytometry. 
 
2. To determine the presence of CXCR4 and N-cad protein as well as CD138 by 
the 5TGM1-GFP cell lines grown in vivo over-time using IHC. 
 
4.3 Methods 
 
4.3.1 Murine models of multiple myeloma 
The 5T33-GFP and the 5TGM1-GFP murine models of MM were used to determine 
the presence of protein in BM and spleen derived HSC niche molecules and ligands. 
The individual characteristics of each murine myeloma model are described in 
Chapter I Section 1.5 and the experimental design for these studies are shown below 
in Figure 4.1. The study design for the 5T33-GFP model of MM is shown in Figure 
4.1a. Due to the variability of the tumour in this particular model, mice were 
sacrificed individually when they became ill and a control PBS treated mouse was 
sacrificed at the same time. The longitudinal study design for the 5TGM1-GFP model 
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of MM is shown in Figure 4.1b. At the final time point (23 days P-I) all mice were 
sacrificed at the same time rather than individually because the 5TGM1-GFP model 
was intrinsically less variable than the 5T33-GFP model. 
 
 
 
 
 
 
 
 
 
Figure 4.1: A schematic diagram of the 5T33-GFP and 5TGM1-GFP models of MM. a. One million 
5T33-GFP cells or PBS were injected IV via the tail vein into C57BL/KaLwRij mice and upon presentation 
of hind leg paralysis 4-6 weeks later, mice were sacrificed and samples were collected for ex vivo 
analysis of HSC niche molecule and ligand protein (N=8). b. Two million 5TGM1-GFP cells or PBS were 
injected into C57BL/KaLwRij mice and at 10, 14, 17 and 23 days P-I (when the first mouse presented 
with hind leg paralysis) the mice were sacrificed (N=4-6) and samples were collected for ex vivo analysis 
for the presence of HSC molecules and ligands. 
 
4.3.2 Protein analysis of bone marrow and spleen derived myeloma cells, analysed 
ex vivo 
4.3.2.1 Flow cytometry 
Murine BM was isolated from the 5T33-GFP, 5TGM1-GFP and PBS injected mice, as 
described previously in Chapter II Section 2.2.1.4. In addition, splenocytes were also 
isolated from the mice injected with the 5TGM1-GFP cells and complementary PBS 
controls, as mice in the 5TGM1-GFP model develop splenomegaly due to infiltration 
of tumour cells at this site of haematopoiesis. The spleen was also analysed to 
a 
b 
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determine any differences in the presence HSC niche molecules and ligands between 
BM and spleen derived cells. The presence of these molecules on either of the cell 
types may highlight which molecules may or may not be important for tumour 
growth specifically in the BM. These samples were isolated as previously described 
in Chapter II Section 2.2.1.4. 
Tumour burden was assessed using GFP expression as a marker for the percentage 
of MCs in each BM and spleen sample. The samples were also stained with the 
optimised quantity of antibody for the HSC niche molecules, ligands and CD138 as 
described in Chapter II Section 2.4.1.2. The number of GFP positive MCs, which were 
also positive for the HSC niche molecules and ligands, were measured using a FACS 
Calibur. Cell Quest software was used to analyse the data by gating against the 
negative isotype control antibodies, (which demonstrated less than 1% positive 
staining) to produce a percentage of cells, which were positive for each molecule. 
Each mouse was classed as a biological replicate to produce a mean percentage of 
cells, which were positive for each HSC niche molecule and ligand. 
 
4.3.3 Protein analysis of bone marrow derived myeloma cells, analysed in vivo  
4.3.3.1 IHC 
Immunohistochemistry was conducted to visualise positive staining of the HSC niche 
molecules in the BM cells and MCs in vivo. C57BL/KaLwRij mice were injected with 
either 2x106 5TGM1-GFP cells or PBS IV and at 0, 3, 7, 10, 14, 17 and 21 days P-I (N=3-
4 per group) mice were sacrificed as described previously. The hind limbs were 
dissected and then processed for histology, as described in Chapter II Section 2.4.3.2. 
Wax embedded sections from the 10-21 day time points were stained with anti-
CXCR4, anti-N-cad or anti-CD138 antibodies or complementary isotypes to each 
primary antibody. Images of the staining were taken using an Aperio Scan Scope slide 
scanner and visualised using Image Scope software. These time points were used, as 
clear MC colonies were visible by eye. 
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CD138 staining by IHC was also analysed by Dr Shelly Lawson (Department of 
Oncology, The University of Sheffield) using Osteomeasure Software. The number of 
single cells, colony number and area were calculated after 0, 3, 7, 10, 14, 17 and 21 
days P-I of 5TGM1-GFP cells (N=3-4 per group). 
 
4.3.4 Statistics 
Where relevant, non-parametric statistical tests were used. A Kruskal-Wallis test 
followed by Dunn’s post test (P<0.05) was used to determine any differences in 
tumour burden and HSC niche molecule, ligand and CD138 protein frequency in the 
BM and spleen over-time. A Mann-Whitney U test (P<0.05) was used to compare 
tumour burden in the BM of 5T33-GFP injected mice with 5TGM1-GFP injected mice 
at the end stage of disease. It was also used to compare the presence of HSC niche 
molecules, ligands and CD138 between the 5T33-GFP and 5TGM1-GFP cells at the 
end-stage of disease as well as between cells cultured in vitro. Where relevant, error 
bars were displayed on all graphs using the SEM, unless stated otherwise in the 
legend. 
 
4.4 Results 
 
4.4.1 Quantification of tumour burden at the end-stage of disease in the bone 
marrow of mice injected with 5T33-GFP and 5TGM1-GFP cells 
Flow cytometry was used to determine the number of 5T33-GFP and 5TGM1-GFP 
cells present in the BM of C57BL/KaLwRij mice based upon GFP expression. Figure 
4.2a shows an example of the flow cytometry profiles used to quantify the number 
of GFP positive MCs in both the 5T33-GFP and 5TGM1-GFP injected mice at the end-
stage of disease. The 5TGM1-GFP injected mice had significantly greater numbers of 
GFP positive tumour cells (53.71% ±4.70) (P<0.001) present in their BM compared to 
the 5T33-GFP injected mice (2.40% ±0.90). In addition, three of the 5T33-GFP injected 
mice included within the mean did not have obvious tumour burden from the flow 
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cytometry profiles with values less than 0.25% tumour burden. This contrasted with 
the mice injected with the 5TGM1-GFP cells, where all mice injected were positive 
for GFP positive tumour burden. 
 
Figure 4.2: Green fluorescent protein 
positive tumour burden was greater in 
mice injected with 5TGM1-GFP cells 
compared to 5T33-GFP cells at the 
end-stage of disease using flow 
cytometry. One million 5T33-GFP and 
2x106 5TGM1-GFP MCs were injected 
(IV) into 6-8 week old female 
C57BL/KaLwRij mice. Upon 
presentation of hind limb paralysis or 
general illness, the mice were sacrificed 
(4-6 weeks P-I for the 5T33-GFP 
injected mice and 23 days for the 
5TGM1-GFP injected mice) and the BM 
was isolated. Tumour burden was 
assessed by quantifying the number of 
GFP positive cells using a FACS Calibur 
and Cell Quest software. a. An example 
of a representative scatter plot for 
number of GFP positive cells in the BM 
samples of 5T33-GFP (i) and 5TGM1-
GFP (ii) injected mice. b. Quantitative 
analysis of the percentage of viable 
GFP positive cells in the 5T33-GFP and 
5TGM1-GFP injected mice. Data was 
analysed statistically using a Mann 
Whitney-U test (P<0.05). Results were 
 determined as a mean percentage of GFP positive cells in the BM of 5T33-GFP injected mice (N=8) and 
the 5TGM1-GFP injected mice (N=6). 
 
Flow cytometry was also used to determine the percentage of MCs present in the 
BM and spleen of mice injected with 5TGM1-GFP cells at 10, 14, 17 and 23 days P-I 
as shown in Figure 4.3. From the data, it was clear that there was a linear increase in 
GFP positive tumour burden in both the BM and spleen over-time. Statistically, there 
was significantly greater tumour burden at 23 days compared to 10 and 14 days in 
both the BM and spleen samples (P<0.05). In addition, there seemed to be higher 
tumour burden in the BM compared to the spleen, particularly at 14, 17 and 23 days 
P-I.  
b 
ai ii 
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Figure 4.3: Green fluorescent protein positive tumour burden in the bone marrow and spleen of mice 
injected with 5TGM1-GFP cells increased over-time and was greater in the bone marrow compared 
to the spleen using flow cytometry. Two million 5TGM1-GFP cells were injected (IV) into 6-8 week old 
female C57BL/KaLwRij mice. At 10, 14, 17 and 23 days P-I, the mice were sacrificed and the BM and 
spleen were isolated. Tumour burden was assessed by quantifying the number of viable GFP positive 
cells in the BM and spleen of 5TGM1-GFP injected mice using a FACS Calibur and Cell Quest software 
and displayed as a mean percentage of tumour burden. Data was analysed statistically using a Kruskal-
Wallis test followed by Dunn’s correct test to compare the tumour burden in the BM and spleen 
separately over-time (P<0.05). 
 
4.4.2 Protein quantification of the HSC niche molecules, ligands and CD138 by 5T33-
GFP and 5TGM1-GFP cells ex vivo using flow cytometry 
Flow cytometric analysis was used to determine the number of BM derived 5T33-GFP 
and 5TGM1-GFP MCs that were positive for the HSC niche molecules, ligands and 
CD138, analysed ex vivo. Table 4.1 shows a summary of the percentage of BM derived 
5T33-GFP and 5TGM1-GFP cells, which were positive for each HSC niche molecule, 
ligand and CD138, analysed ex vivo. Figure 4.4 shows the mean percentage of 5T33-
GFP and 5TGM1-GFP cells, which were positive for each HSC niche molecule, ligand 
and CD138 at the end stage of disease, analysed ex vivo using flow cytometry. A high 
percentage of BM derived 5T33-GFP and 5TGM1-GFP cells were positive for the HSC 
niche molecules CXCR4, Notch-1 but <2% were positive for Tie-2. The 5T33-GFP cells 
were also positive for ligand CXCL12, which was only expressed at a low frequency in 
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the 5TGM1-GFP cells. Both cell types were also marginally positive for the ligand Jag-
1 and highly positive for the plasma cell marker CD138. Statistically, a significantly 
greater number of 5T33-GFP cells were positive for HSC niche molecules CXCR4 and 
Notch-1 (P<0.05) and ligands CXCL12 (P<0.05) and Jag-1 (P<0.05) compared to the 
5TGM1-GFP cells. There was however, no statistical difference in the number of 
5T33-GFP and 5TGM1-GFP cells, which were positive for Tie-2 or CD138. 
 
Table 4.1: A summary of the quantitative analysis for the percentage of bone marrow derived 
myeloma cells, which were positive for the HSC niche molecules, ligands and CD138 using flow 
cytometry 
Protein 5T33-GFP 5TGM1-GFP 
CXCR4 99.53 ± 0.12 93.63 ± 2.05 
Notch-1 99.09 ± 0.27 86.83 ± 1.54 
Tie-2 1.91 ± 0.23 1.66 ± 0.62 
CXCL12 38.18 ± 3.03 1.01 ± 0.39 
Jag-1 8.55 ± 0.93 1.88 ± 0.37 
CD138 93.28 ± 1.78 93.19 ± 0.70 
Mean percentage of positive cells shown using the SEM. 
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Figure 4.4: 5T33-GFP and 5TGM1-GFP cells isolated from the bone marrow of mice were positive for 
the HSC niche molecules and ligands at varying frequencies at the end-stage of disease, analysed ex 
vivo using flow cytometry. One million 5T33-GFP and 2x106 5TGM1-GFP MCs were injected (IV) into 
6-8 week old female C57BL/KaLwRij mice. Upon presentation of hind limb paralysis or general illness, 
the mice were sacrificed (4-6 weeks P-I for the 5T33-GFP injected mice and 23 days for the 5TGM1-GFP 
injected mice) and the BM was isolated. Cells were incubated with directly conjugated primary 
antibodies for the HSC niche molecules CXCR4 (i), Notch-1 (iii) and Tie-2 (v), ligands CXCL12 (ii) and Jag-
1 (iv) and CD138 (vi) and dose matched isotype control antibodies. This was followed by flow cytometry 
using a FACS Calibur and Cell Quest software. Data was analysed statistically using a Mann-Whitney 
U test (P<0.05). Results were determined as a mean percentage of 5T33-GFP (N=8) and the 5TGM1-
GFP (N=6) which were positive for each molecule. 
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The number of BM derived 5T33-GFP and 5TGM1-GFP cells which were positive for 
each HSC niche molecule, ligand and CD138 at the end-stage of disease were 
compared to the number of cells which were positive for these molecules in vitro (the 
results for this were originally shown in Chapter III, Section 3.4.3). This is displayed in 
Figure 4.5 for the 5T33-GFP cells and Figure 4.6 for the 5TGM1-GFP cells. 
 
A significantly greater number of BM derived 5T33-GFP cells (“5T33-GFP ex vivo”) 
were positive for the HSC niche molecules CXCR4 (P<0.05), Notch-1 (P<0.05) and Tie-
2 (P<0.05) compared to the 5T33-GFP cells cultured in vitro (“5T33-GFP in vitro”). 
There was also a significantly greater number of “5T33-GFP ex vivo” cells which were 
positive for the ligands CXCL12 (P<0.05) and Jag-1 (P<0.05) compared to the “5T33 in 
vitro” cells.  
 
In contrast, significantly fewer BM derived 5TGM1-GFP cells (“5TGM1-GFP ex vivo”) 
were positive for the HSC niche molecules Notch-1 (P<0.05) and Tie-2 (P<0.05) 
compared to 5TGM1-GFP cells cultured in vitro (“5TGM1-GFP in vitro”). There was 
also a significantly lower number of “5TGM1-GFP ex vivo” cells which were positive 
for the ligands CXCL12 (P<0.05) and Jag-1 (P<0.05) compared to the “5TGM1-GFP 
cells in vitro” cells. In addition, there was a significant decrease in the number of 
“5TGM1-GFP ex vivo” cells which were positive for CD138 compared to the “5TGM1-
GFP in vitro” cells (P<0.05). 
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Figure 4.5: The presence of the HSC niche molecules and ligands was significantly higher in the bone 
marrow derived 5T33-GFP cells compared to in vitro 5T33-GFP cells by flow cytometry. 5T33-GFP 
cells were cultured in vitro (N=3), or in vivo, by injecting 6-8 week old female C57BL/KaLwRij mice with 
1x106 5T33-GFP (N=8) cells. At the end-stage of disease (when mice demonstrated hind-leg paralysis), 
the BM was subsequently isolated for flow cytometry. Both the 5T33-GFP cells analysed ex vivo and in 
vitro were incubated with directly conjugated primary antibodies for the HSC niche molecules; CXCR4 
(i), Notch-1 (iii) and Tie-2 (v), ligands; CXCL12 (ii) and Jag-1 (iv), and CD138 (vi) or dose matched isotype 
control antibodies. This was followed by flow cytometry using a FACS Calibur and Cell Quest software. 
Quantitative analysis for the percentage of viable 5T33-GFP cells analysed ex vivo and in vitro which 
were positive for each HSC niche molecule, ligand and CD138 was determined. Data was analysed 
statistically using a Mann-Whitney U test (P<0.05) to compare the percentage of 5T33-GFP cells which 
were positive for each HSC niche molecule, ligand and CD138. Results were determined as a mean 
percentage of 5T33-GFP cells, which were positive for each molecule. 
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Figure 4.6: The presence of the HSC niche molecules and ligands was significantly decreased in the 
BM derived 5TGM1-GFP cells compared to in vitro 5TGM1-GFP cells by flow cytometry.5TGM1-GFP 
cells were cultured in vitro (N=3), or in vivo, by injecting 6-8 week old female C57BL/KaLwRij mice with 
2x106 5TGM1-GFP (N=6) cells. At the end-stage of disease (when mice demonstrated hind-leg 
paralysis), the BM was subsequently isolated for flow cytometry. Both the 5TGM1-GFP cells analysed 
ex vivo and in vitro were incubated with directly conjugated primary antibodies for the HSC niche 
molecules; CXCR4 (i), Notch-1 (iii) and Tie-2 (v), ligands; CXCL12 (ii) and Jag-1 (iv), and CD138 (vi) or 
dose matched isotype control antibodies. This was followed by flow cytometry using a FACS Calibur 
and Cell Quest software. Quantitative analysis of the percentage of viable 5TGM1-GFP cells analysed 
ex vivo and in vitro which were positive for each HSC niche molecule, ligand and CD138 was 
determined. Data was analysed statistically using a Mann-Whitney U test (P<0.05) to compare the 
percentage of 5TGM1-GFP cells which were positive for each HSC niche molecule, ligand and CD138. 
Results were determined as a mean percentage of 5TGM1-GFP cells positive for each molecule. 
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4.4.3 Protein quantification of the HSC niche molecules and ligands by the bone 
marrow and spleen-derived 5TGM1-GFP cells over-time analysed ex vivo using flow 
cytometry.  
 
The presence of HSC molecules and ligands in the BM and spleen derived 5TGM1-
GFP cells was also quantified using flow cytometry over-time at 10, 14, 17 and 23 
days P-I of tumour cells, as shown in Figure 4.7. The HSC niche molecules CXCR4, 
Notch-1 and Tie-2, ligands CXCL12 and Jag-1, and plasma cell marker CD138 were 
present in both the BM and spleen derived 5TGM1-GFP cells at each time point.  
 
Flow cytometry showed that there were no clear patterns with regards to the 
frequency of HSC niche molecule and ligand positive cells over-time, with the 
exception of CXCL12. Using a Kruskal-Wallis test followed by Dunn’s post test there 
were significantly fewer BM derived 5TGM1-GFP cells, which were positive for 
CXCL12 after 23 days compared to 10 days and interestingly this reduced over the 
time course in a linear fashion. This pattern was however, only observed in the BM 
derived 5TGM1-GFP cells and not those isolated from the spleen. In addition, the 
frequency of Notch-1 positivity increased in the BM derived cells between 10 and 17 
days and CD138 was reduced from 14 days to 23 days. The spleen derived 5TGM1-
GFP cells also had significantly reduced numbers of cells, which were positive for 
CXCR4 between 10 and 17 days, and a significant increase in CD138 positive cells 
from 14 to 23 days.  
 
Differences in the number of BM and spleen derived MCs, which were positive for 
the HSC niche molecules and ligands, were unable to be analysed as no suitable non-
parametric two-way tests were available. However, from the data, there did seem to 
be fewer BM derived MCs which were positive for CXCL12 compared to those 
isolated from the spleen, particularly at 23 days P-I. Interestingly, the number of 
Notch-1 positive BM derived cells was lower at 10 days P-I compared to the spleen 
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derived cells and Tie-2 was absent in the spleen derived MCs at 10 days P-I, whereas 
a small proportion of BM derived cells were positive at this time point.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.7: Bone marrow and spleen derived 5TGM1-GFP cells were positive for the HSC niche 
molecules and ligands and the frequency of positive cells for some of the molecules changed over-
time. Two million 5TGM1-GFP MCs were injected (IV) into 6-8 week old female C57BL/KaLwRij mice. 
At 10, 14, 17 and 23 days P-I the mice were sacrificed and the BM and spleen were isolated (N=6). Cells 
were incubated with directly conjugated primary antibodies for the HSC niche molecules CXCR4 (i), 
Notch-1 (iii) and Tie-2 (v), ligands CXCL12 (ii) and Jag-1 (iv) and CD138 (vi) and dose matched isotype 
control antibodies. This was followed by flow cytometry using a FACS Calibur and Cell Quest software. 
Quantitative analysis for the percentage of viable BM and spleen derived 5TGM1-GFP cells, which were 
positive for each HSC niche molecule, ligand and CD138 was determined. Data was analysed 
statistically using a Kruskal-Wallis test followed by Dunn’s post test (P<0.05) to determine differences 
in the number of BM and spleen derived 5TGM1-GFP which were positive for each molecule separately 
over-time. Results were determined as a mean percentage of 5TGM1-GFP cells positive for each 
molecule. 
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4.4.4 Protein visualisation of the HSC niche molecules CXCR4 and N-cad, and CD138 
by the 5TGM1-GFP cells in histological bone sections, over-time using IHC 
 
Immunohistochemistry was used to visualise the presence of protein for CXCR4, N-
cad and CD138 in vivo over the disease course in histological bone sections taken 
from mice injected with 5TGM1-GFP cells or non-tumour bearing animals. Figure 4.8 
illustrates CD138 staining in histological bone sections taken from mice injected with 
5TGM1-GFP cells or PBS and stained by IHC at 10, 14, 17 and 21 days P-I. In the tibiae 
of PBS injected mice, only single cells were positive for CD138, unlike in the 5TGM1-
GFP injected mice where discrete colonies were observed. 5TGM1-GFP cells were 
morphologically different to the normal constituents of the BM as they 
demonstrated an enlarged nucleus and some cells were also multi-nuclear. Staining 
at 10 days P-I showed small CD138 positive colonies, which were mostly adjacent to 
sinusoid structures and as the disease progressed over-time the number of colonies 
increased. From 17 to 21 days P-I, the CD138 positive colonies had merged and 
therefore, colony number decreased despite colony area increasing. Quantification 
of the colony number over-time is shown in Figure 4.9 (analysed by Shelly Lawson, 
Department of Oncology, The University of Sheffield). These were taken from bone 
sections from the same study however, staining was conducted on the early time 
points (0, 3 and 7 days P-I) as well as the latter time points (10, 17 and 21) and 
analysed using Osteomeasure software. At the early time points of 0, 3 and 7 days, 
single cells were observed which were either normal murine plasma cells or MCs, 
however, the two are indistinguishable. From 7 days onwards, some colonies were 
observed though they were small and not always distinct. Following 7 days there was 
a linear increase in tumour burden as seen previously with the flow cytometry 
tumour burden data.  
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Figure 4.8: CD138 IHC staining increased over-time in the tibiae of 5TGM1-GFP injected mice. PBS (a) 
or 2x106 5TGM1-GFP cells (b-e) were injected into C57BL/KaLwRij mice and at 10 (b), 14 (c), 17 (d) and 
21 (e) days P-I, mice were sacrificed and tibiae were dissected. The Tibiae were fixed, decalcified, 
processed, embedded and cut into 3µm sections. Bone sections were stained by sandwich IHC using an 
anti-CD138 primary antibody or complementary isotype control antibody followed by biotinylated 
secondary antibody, streptavidin HRP and DAB substrate where positive staining is brown. Images of 
sections were taken using an Aperio Slide Scanner and subsequently visualised using Image Scope 
Software. At each time point, images were taken of primary antibody staining using a 2X magnification 
(i) followed by images using a 40X magnification of isotype (ii) and primary antibody (iii) staining of 
trabecular bone regions. Scale bars represent 900 µM (i) and 50 µM (ii and iii). 
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Figure 4.9: The number of CD138 colonies increased over-time before merging together. Bone 
sections of mouse tibiae, taken from mice injected with 5TGM1-GFP cells after 1, 3, 7, 14, 17 and 21 
days P-I, were stained for CD138 by IHC. The staining was analysed using Osteomeasure software to 
quantify the number of CD138 positive stained colonies per bone. (Sections were stained by Julia 
Hough, Department of Human Metabolism, The University of Sheffield and analysed by Shelly Lawson, 
Department of Oncology, The University of Sheffield). 
 
Figure 4.10 shows the positive staining of N-cad in histological bone sections of tibiae 
taken from mice injected with PBS or 5TGM1-GFP cells over-time. In the PBS control, 
positive staining for N-cad was visualised on what appeared to be osteoblastic cells 
lining both cortical and trabecular bone throughout the bone and staining was 
particularly intense in the growth plate region. In addition, the staining appeared to 
be primarily on the membrane of the cells.  
 
In the bones of mice that had been injected with 5TGM1-GFP cells, staining again was 
observed in osteoblastic cells in trabecular and cortical regions. In addition, all MC 
colonies, identified by morphology, were also positive for N-cad but staining was not 
as intense as the CD138 IHC staining. There was also a direct correlation of tumour 
burden with N-cad staining and as the tumour burden increased so did the number 
of N-cad stained cells and tumour area. The staining pattern of N-cad also differed 
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between the osteoblastic and MCs. The osteoblastic staining for N-cad was highly 
membranous, whereas the staining of N-cad in the MCs seemed to be cytoplasmic. 
In addition, the intensity of the staining seemed to increase until day 14 and following 
this, at 17 and 21 days P-I the intensity of staining decreased. 
 
Figure 4.11 illustrates IHC staining of CXCR4 in the BM of PBS or 5TGM1-GFP injected 
mice. Very little staining, if any, was present in the PBS injected mice, whereas in the 
5TGM1-GFP injected mice the staining was highly selective for the 5TGM1-GFP cells. 
In addition, all 5TGM1-GFP cells seemed to be positive for CXCR4 and staining 
correlated with an increase in tumour burden over-time. The staining pattern within 
the MCs was quite unusual and unexpected. The cells had both cytoplasmic staining 
and intense nuclear staining, which is not typical of G-protein coupled receptors 
(GPCRs). In addition, the staining intensity seemed to increase as the tumours 
increased in size over-time. 
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Figure 4.10: N-cad IHC staining increased over-time in the tibiae of 5TGM1-GFP injected mice. PBS 
(a) or 2x106 5TGM1-GFP cells (b-e) were injected into C57BL/KaLwRij mice and at 10 (b), 14 (c), 17 (d) 
and 21 (e) days P-I, mice were sacrificed and tibiae were dissected. The Tibiae were fixed, decalcified, 
processed, embedded and cut into 3µm sections. Bone sections were stained by sandwich IHC using an 
anti-N-cad primary antibody or complementary isotype control antibody followed by biotinylated 
secondary antibody, streptavidin HRP and DAB substrate where positive staining is brown. Images of 
sections were taken using an Aperio Slide Scanner and subsequently visualised using Image Scope 
Software. At each time point, images were taken of primary antibody staining using a 2X magnification 
(i) followed by images using a 40X magnification of isotype (ii) and primary antibody (iii) staining of 
trabecular bone regions. Scale bars represent 900 µM (i) and 50 µM (ii and iii). 
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Figure 4.11: CXCR4 IHC staining increased over-time in the tibiae of 5TGM1-GFP injected mice. PBS 
(a) or 2x106 5TGM1-GFP cells (b-e) were injected into C57BL/KaLwRij mice and at 10 (b), 14 (c), 17 (d) 
and 21 (e) days P-I, mice were sacrificed and tibiae were dissected. The Tibiae were fixed, decalcified, 
processed, embedded and cut into 3µm sections. Bone sections were stained by sandwich IHC using an 
anti-CXCR4 primary antibody or complementary isotype control antibody followed by biotinylated 
secondary antibody, streptavidin HRP and DAB substrate where positive staining is brown. Images of 
sections were taken using an Aperio Slide Scanner and subsequently visualised using Image Scope 
Software. At each time point, images were taken of primary antibody staining using a 2X magnification 
(i) followed by images using a 40X magnification of isotype (ii) and primary antibody (iii) staining of 
trabecular bone regions. Scale bars represent 900 µM (i) and 50 µM (ii and iii). 
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4.5 Discussion 
 
The aim of this chapter was to determine the number of 5T33-GFP and 5TGM1-GFP 
cells, isolated from the BM and/or spleen and analysed ex vivo, which were positive 
for the HSC niche molecules. An additional aim was to determine the presence of 
protein for HSC niche molecules by 5TGM1-GFP cells in histological bone sections at 
different stages of disease. 
 
Firstly, the tumour burden in the BM of mice injected with 5T33-GFP or 5TGM1-GFP 
cells was determined by GFP expression, using flow cytometry. Despite 5TGM1-GFP 
cells being a derivative of the 5T33MMvt cells (174) there were significant differences 
in tumour burden. The flow cytometry data demonstrated that the 5TGM1-GFP 
injected mice had significantly greater tumour burden in the BM compared to mice 
injected with 5T33-GFP cells. In addition, the take rate was 100% in the mice injected 
with 5TGM1-GFP cells whereas; the take rate was 63% for mice injected with 5T33-
GFP cells. This was slightly unusual; however, the preparation of the 5TGM1-GFP cells 
differs to that of the 5T33-GFP cells. As described by Dallas et. al (222) the 5TGM1-
GFP cells were “propagated by marrow transfer” in the C57BL/KaLwRij mice, by BM 
flushes followed by growth in vitro for 7 days and re-inoculation into mice, whereas 
the 5T33-GFP cells were continually cultured without in vivo passaging. Therefore, 
passaging through the animals may result in highly tumourgenic 5TGM1-GFP cells. It 
maybe that if the 5TGM1-GFP cells had been cultured extensively, as the 5T33-GFP 
cells had been, they would have lost certain characteristics required for the homing 
of cells to the BM and subsequent growth in vivo. Within our group, we have 
attempted to increase tumour take by in vivo passaging of the 5T33-GFP cells but 
with little success. However, continual in vivo passaging of the 5T33-GFP cells may be 
required to recapitulate the original tumourgenicity of these cells. 
 
Chapter IV: The ex vivo and in vivo expression of HSC niche molecules and their ligands by murine 
myeloma cells Page 155 
 
In the 5TGM1-GFP injected mice, tumour burden was observed in both the BM and 
spleen (sites of haematopoiesis in mice after birth), which is not typical of human 
myeloma disease. Tumour burden at both sites increased significantly over-time. The 
5TGM1-GFP cells grew in a linear fashion with an initial lag phase between 10 and 14 
days (the earliest time points where GFP positive cells were clearly visualised using 
flow cytometry) followed by an exponential growth phase from 14 days up until 23 
days. Interestingly, there was less tumour burden in the spleen at each time point 
compared to the BM (though this could not be statistically compared). These data 
therefore, suggested that the 5TGM1-GFP cells may either initially home to the BM 
and subsequently migrate to the spleen, or that the MCs arrive in the BM and spleen 
but grow at a slower rate in the spleen compared to the BM. Oyajobi et al (223) 
observed a high number of 5TGM1-GFP cells in the BM of live mice (Light Tools 
Imaging system) whereas, only a low number of 5TGM1-GFP cells were seen in the 
spleen of animals 4 weeks P-I. However, again, it is uncertain whether fewer cells 
home to the spleen initially or whether they proliferate at a slower rate compared to 
those in the BM. Additional studies are therefore, required to ascertain the number 
of cells initially homing to both the BM and spleen.  
 
The presence of HSC niche molecules; CXCR4, Notch-1 and Tie-2, their respective 
ligands; CXCL12 and Jag-1, and CD138 were shown in 5T33-GFP and 5TGM1-GFP cells 
isolated from the BM and analysed ex vivo. When the number of cells which were 
positive for the HSC niche molecules, ligands and CD138 were compared between 
the 5T33-GFP and 5TGM1-GFP cells isolated at the end stage of disease, several 
differences were identified. Significantly less BM derived 5TGM1-GFP cells were 
positive for CXCR4, Notch-1, CXCL12 and Jag-1 compared to the 5T33-GFP cells. 
Currently there is no data available that have compared the expression of these 
molecules between the two different MC lines. In my studies, differences between 
the cell lines at the time point when the 5TGM1-GFP treated animals were at end-
stage disease may be due to the differences in tumour infiltration in the BM. These 
molecules may be important in the early establishment of disease and therefore are 
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more highly expressed in the 5T33-GFP cells compared to the 5TGM1-GFP cells, 
which had fully infiltrated the BM at this time of analysis. In previous studies, CXCR4, 
Notch and Tie-2 signalling have been associated with several different mechanisms 
in healthy cells as well as cancer cells. Specifically, CXCR4 is important for chemotaxis 
via the activation of PI3-K (105) and MAPK/ERK (103) signalling following CXCL12 
stimulation of CXCR4. Notch-1 signalling also induces cell growth and enhances cell 
survival potentially via ERK and Akt signalling, following Notch-1 activation (224). 
Phosphatidylinositol 3-kinase and Akt signalling have also been associated with cell 
survival following activation of Tie-2 by Ang-1 (85). Chemotaxis, migration and 
proliferation are often mechanisms, which are important in the early time points of 
disease establishment therefore, it is likely that the molecules CXCR4, Tie-2, and 
Notch-1 which induce chemotaxis and/or proliferation are down-regulated in the 
5TGM1-GFP cells, which have successfully homed and established full disease in the 
BM compared to the 5T33-GFP cells.  
 
Previous studies have supported as well as disapproved the theory that early disease 
MCs have higher expression of the molecules CXCR4, Notch-1, Tie-2, CXCL12 and Jag-
1 compared to MCs in established disease. With regards to Notch-1, Skrtic et al (2010) 
found that MGUS patients, with less than 10% tumour infiltration, had MCs which 
were Notch-1 negative, compared with symptomatic myeloma patients, who had 
high Notch-1 expression (214). This is similar to prostate cancer where 41% of 
patients with high-grade disease and 61% of patients with prostate metastasis had 
Notch-1 positive prostate cancer cells, compared with 23% of patient with low-
graded prostate cancer (225). Taken together, this shows that Notch-1 seems to be 
present in latter stages of disease. The presence of Jag-1 on CD138 positive MCs has 
previously been demonstrated in primary patient samples (198) but previous studies 
have not identified its expression on murine 5T cells in vitro, ex vivo or in vivo. Jag-1 
expression seems to be associated with disease progression in myeloma. Samples 
from MGUS patients were negative for Jag-1 staining using IHC whereas, samples 
from symptomatic myeloma patients were positively stained for Jag-1 (214). This was 
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also demonstrated in prostate cancer, where localised primary tumours and 
metastatic samples had higher intensity of Jag-1 staining compared to benign 
samples. High levels of Jag-1 also correlated with reoccurrence of disease assessed 
by prostate-specific antigen free survival (226). Taken together, this disapproves my 
findings of higher expression in the early stages of myeloma disease. However, when 
comparing the presence of protein for the molecules in the 5TGM1-GFP time-course 
experiment rather than between the 5T33-GFP and 5TGM1-GFP cells at the end-
stage of disease the data, Notch-1 correlates with the experiments described above 
where Notch-1 expression was significantly lower at 10 days compared to 14 days.  
 
It is also difficult to rationalise why the number of cells positive for CXCL12 were 
lower in the 5TGM1-GFP cells compared to the 5T33-GFP cells and also why the 
number of CXCL12 positive cells decreased linearly over-time in the 5TGM1-GFP cells 
grown in the BM. As stated in Chapter III, whether CXCL12 is produced by the 
5T33MMvt and 5TGM1-GFP cells themselves or whether it is internalised from the 
local environment is uncertain. However, our hypothesis is that fewer 5TGM1-GFP 
cells were positive for CXCL12 towards the end-stage of disease because they no 
longer internalised CXCL12 from the BM environment. This may be because CXCL12 
levels were reduced in the BM, as fewer CXCL12 producing cells were present due to 
the physical expansion of MCs and reduction in CXCL12 positive osteoblastic cells. 
The 5T33-GFP cells isolated from the BM however, had a higher frequency of CXCL12 
positive cells than those cultured in vitro. This increase maybe due to induced 
production by the MCs themselves or because of the internalisation of CXCL12, which 
is still in abundance in the BM, due to low 5T33-GFP tumour burden. In support of 
CXCL12 internalisation, previous studies demonstrated that CXCL12 was internalised 
via CXCR4 in human and mouse ECs (93). In addition, previous studies showed 
internalisation of the receptor CXCR4 in MCs (195) and B lymphoblastic cells (227), 
which in turn may result in ligand internalisation, however these studies did not 
address that question. 
 
Chapter IV: The ex vivo and in vivo expression of HSC niche molecules and their ligands by murine 
myeloma cells Page 158 
 
The presence of protein for the HSC niche molecules, ligands and CD138 by the 5T33-
GFP and 5TGM1-GFP cells were compared between the BM derived MCs at the end-
stages of disease and the MCs cultured in vitro. In the 5T33-GFP cells, the HSC niche 
molecules; CXCR4, Notch-1 and Tie-2 and ligands; CXCL12 and Jag-1 were significantly 
up regulated in the BM derived cells compared to the 5T33-GFP cells cultured in vitro. 
Whereas, the HSC niche molecules; Notch-1 and Tie-2, ligands; CXCL12 and Jag-1, and 
CD138 were significantly down regulated in the BM derived 5TGM1-GFP cells 
compared to the 5TGM1-GFP cells cultured in vitro. The data were almost ‘mirror 
images’ of each other but again may reflect the difference in tumour growth rates in 
each cell line observed in my studies. As with the differences in protein frequency 
between the 5T33-GFP and 5TGM1-GFP, exactly why cells cultured in vitro have 
different numbers of positive cells to ex vivo cells is unknown. However, cell 
localisation in the BM to specific ligands or regulation by secreted factors would be 
likely to influence gene expression and protein production. Increases in the HSC 
molecules and ligands in the ex vivo 5T33-GFP cells but decreases in the 5TGM1-GFP 
cells again may be due to differences in the phase of cell growth. Whilst the 5T33-
GFP cells have not established full tumour infiltration, they produce proteins that 
promote their growth whereas, the 5TGM1-GFP cells, which have already reached 
full capacity in the BM, down-regulate molecules, which they no longer require, as 
discussed above. 
 
In addition, there were also several differences between the BM and spleen derived 
5TGM1-GFP cells. Notch-1 was present in a greater number of spleen derived 
5TGM1-GFP cells compared to the BM at 10 days P-I and also the number of cells 
positive for Tie-2 was greater in the BM compared to the spleen-derived cells at 10 
days. Differences in the frequency of these molecules between BM and spleen 
derived 5TGM1-GFP cells have not been reported in the literature. However, again 
the stage of tumour progression may be important with regards to presence of the 
HSC niche molecules and ligands and may account for differences for the presence 
of Notch-1. The numbers of cells, which were positive for Tie-2, compared to the BM 
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and spleen was extremely interesting. At day 10 P-I, the spleen derived 5TGM1-GFP 
cells were negative for Tie-2, and it was not until day 17 that they showed similar 
numbers of Tie-2 positive cells compared to the BM derived cells. Tie-2 expression 
by the 5TGM1-GFP cells remains ambiguous due the lack of gene expression using 
RT-PCR. However, it remains interesting that Tie-2 positive cells were observed in the 
BM derived cells but were absent initially in spleen derived cells, indicating that Tie-
2 may be a molecule required for initial tumour development specifically within the 
BM, opposed than the spleen.  
 
The presence of CXCR4, N-cad and CD138 protein was visualised by 5TGM1-GFP cells 
in vivo by IHC of BM sections taken from mice injected with 5TGM1-GFP and 
sacrificed at various time points. Using IHC and Osteomeasure analysis, CD138 
protein was mapped over-time in the 5TGM1-GFP infiltrated BM sections. The 
analysis showed that the tumour burden results correlated perfectly with the flow 
cytometry tumour burden data, whereby tumour increased exponentially over-time, 
therefore, highlighting the reliability of the staining. 
 
The distribution of N-cad was also mapped using IHC and the staining showed that 
all MC colonies were positive for N-cad in vivo at each time-point and the intensity 
of N-cad staining reached its peak at 14 days P-I of 5TGM1-GFP cells. The pattern of 
staining was also interesting. The osteoblastic cells in the bone had very distinct 
membranous staining around the cell whereas; the N-cad positive MCs displayed 
cytoplasmic staining. The staining patterns observed correlated partially with the 
literature where OPM-1 MCs positive for N-cad demonstrated cytoplasmic staining, 
however, they also demonstrated membranous staining (206). This also correlates 
with staining observed in patient prostate biopsies where again N-cad staining was 
observed in the cytoplasm but also on the membrane (228). However, Zhang et al 
(2003) also showed N-cad staining that “asymmetrically localised to the cell surface” 
of HSCs and N-cad positive spindle-shaped osteoblasts, rather than inside the cell.  
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CXCR4 appeared to be present throughout the development of disease however; the 
staining patterns were not as expected. From the IF experiments in the Chapter III, 
CXCR4 staining was displayed as discrete membranous staining around the cell 
however, in the IHC sections, CXCR4 was situated within the nucleus of the cells. 
Differences may be due to sample preparation, as the bones were fixed, processed 
and the bones were cut into wax sections. This process eliminates the requirement 
of permeablisation for antibody entry whereas, the cells for IF were not permeablised 
and the CXCR4 antibodies would therefore be unable to enter the cell. Previous 
studies also showed that CXCR4 nuclear localisation arises due to stimulation using 
CXCL12 in vitro, where treatment of MCs or lymphoblastic cells with recombinant 
CXCL12 resulted in internalisation of CXCR4 (195, 227). In addition, previous studies 
have demonstrated that nuclear staining of CXCR4 may be a marker for prognosis 
however; this remains to be a controversial concept. CXCR4 nuclear IHC staining has 
been reported in cancer cells in colo-rectal cancer (229), gall bladder cancer (230) 
and interestingly solely in prostate cells in the bone compared to the primary site and 
lymph nodes (104) and it is associated with poorer patient outcome. However, Eaton 
et al, (231) noted that nuclear CXCR4 staining was removed when prostate samples 
were blocked with normal horse serum (presumably the serum block for the 
secondary antibody) opposed to casein. The different serum block resulted in fewer 
cells, which were positive, and cells that were positive did not display nuclear staining 
but demonstrated “cytoplasmic, membranous or punctate positive staining”. 
Therefore, this study implies that IHC methodology may result in false positives for 
CXCR4 (231). In my studies, the specificity of the antibody needs to be further 
evaluated. The antibody used seemed highly specific for the MCs, which express 
CXCR4 however, whether it is binding to the correct epitope is unknown. Therefore, 
further experiments are required to confirm that the antibody is specific, possibly by 
WB. Also further in vitro experiments to explore the effect of CXCL12 stimulation 
upon the localisation of CXCR4 in the 5TGM1-GFP cells could be conducted to 
determine whether CXCL12 is responsible for CXCR4 internalisation in these cell 
types. 
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In conclusion, these data support the hypothesis that BM derived MCs are positive 
for the same repertoire of molecules as HSCs when analysed ex vivo and in vivo. 
However, their role in a MC niche is still unknown and further functional studies are 
required to explore this.  
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5.1 Introduction 
 
Osteoblasts are the cells within the bone responsible for production of osteoid, 
primarily composed of type 1 collagen which forms mineralised bone when calcified 
with hydroxyapatite, Ca10(PO4)6(OH)2 .They are also one of the important 
components in the BM microenvironment, which are potentially required to 
establish a niche for HSCs, inducing their quiescence. Increases in osteoblast 
numbers by constitutively activating the PTH/PTHrP receptor (PPR), using the Col1-
caPPR mouse model, also increased numbers of c-kit+, sca-1+, lin- (KSL) HSCs in vivo 
and BM cells from transgenic mice had higher engraftment into irradiated recipients 
compared to wild-type control BM cells (82). In addition, inactivation of BMP 
receptor 1 A (BMPR1A) in transgenic mice, resulted in an increase in BM osteoblastic 
cells and ectopic bone which correlated with an increase in HSCs (83). However, 
currently it is unknown whether all cells of the osteoblast cell lineage are involved in 
the osteoblastic niche or whether there is a particular sub-set of osteoblasts, which 
are particularly important. Zhang et al (83) noted that HSCs seemed to selectively 
adhere to a sub-population of N-cad positive, spindle-shaped cells on both trabecular 
and cortical bone, clarified to be early osteoblastic cells by Xie et al (84), supported 
by Clark et al (232) who defined spindle-shaped osteoblastic cells as immature 
osteoblastic cells.  
 
Osteoblasts originate from MSCs through a series of differentiation steps as shown 
in Figure 5.1, determined by Friedenstein et al (233).  
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Figure 5.1: Mesenchymal stem cell differentiation. Mesenchymal stem cells differentiate through a 
series of different lineages to produce myocytes, tendocytes, adipocytes, chondrocytes, stromal cells 
and osteoblastic cells. In particular, mesenchymal stem cells form preosteoblasts, followed by mature 
osteoid producing osteoblasts, which differentiate in to quiescent bone lining cells or osteocytes. 
Adapted from Harada and Rodan (234) and Caplan and Bruder  (235). 
 
Several transcription factors and cellular pathways have been associated with 
osteoblast differentiation. Transcription factors of particular importance are runt-
related transcription factor-2 (Runx-2) also known as CBF1α and osterix (Ostx).  
 
Transgenic mice with a deletion for the Runx-2 gene died shortly after birth and 
showed signs of dwarfism and an absence of bone formation. Very few osteoblasts 
were observed in the BM of embryo sections and those present had a flattened 
appearance with only marginal expression of the osteoblast marker osteopontin 
(Opn) and an absence of osteocalcin (Ocn) expression (a marker for late stage 
differentiation) by in situ hybridisation (78). This was confirmed also by Otto et al 
(236). Runx-2 also binds to the Ocn promoter, which stimulates late osteoblast 
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differentiation, and Runx-2 regulation also correlates with the expression of the bone 
differentiation markers; Opn, bone sialoprotein and TGF-β receptor I (237). 
 
Osterix is an important transcription factor for osteoblast differentiation. Over-
expression of Ostx in osteoblast cell lines C2C12 and C3H10T1/2 resulted in an 
increase in collagen type I α I (COL1A1) and Ocn expression. Whereas, when the Ostx 
gene was deleted in transgenic mice, the mice died postnatally and the embryos had 
a complete lack of mineralisation in the skeleton by alizarin red staining. In addition, 
Ostx null mice had reduced RNA expression of the early differentiation marker 
COL1A1, as well as undetectable bone sialoprotein, osteonectin (On), Opn and Ocn 
expression. Therefore, demonstrating that both early and late markers of osteoblast 
differentiation were absent within the Ostx null mice. (238).  
 
In addition, several pathways are important for osteoblast differentiation, which 
include the Wnt, TGFβ and BMP pathways.  
 
Osteogenic assays have been developed over approximately the last four decades. 
Three different primary sources have previously been used (239) including foetal 
calvarial cells by enzymatic digestion of calvarial bone (240), BM-derived stromal cells 
isolated from iliac crest aspirates or femoral heads during surgery (241, 242) and 
trabecular bone explants.  
Differentiation has also been mapped over-time and was defined within three stages, 
as shown in Figure 5.2 (183, 240), using rat calvarial cells.  
The main stages of differentiation are: 
1. Proliferation: Genes such as histone genes (H4) (markers of mitosis) are at 
maximal levels at 5 days of differentiation. Active proliferation results in high 
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expression of COL1A1, fibronectin and TGF-β at approximately 10-12 days of 
differentiation.  
2. Proliferation decline: Proliferation slows from approximately 10 days 
onwards and shortly afterwards collagen levels also decline at approximately 15-20 
days, after which it plateaus and remains at a basal level for the remainder of 
differentiation. Once collagen reaches basal levels, Alp levels reach their maximal at 
approximately 20 days.  
 
3. Mineralisation: Upon mineralisation, the Alp levels decline at approximately 
28 days but late markers such as Opn, bone sialoprotein and Ocn reach maximal 
levels. (183, 240). Detection of mineralisation is commonly assessed by alizarin red 
staining, which binds to calcium deposits, and Von Kossa staining, used to visualise 
phosphate (239). 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.2: Stages of osteoblast differentiation. Graph taken from Lian and Stein (183), mapping the 
stages of osteoblast differentiation using rat calvarial osteoblastic cells and Northern blotting. 
(Permission from The Iowa Orthopaedic Journal Editor, 27.11.13). 
 
 
To induce osteoblast differentiation, human and rodent MSCs are generally cultured 
with osteogenic media (OGM) containing 10 mM of β-glycerophosphate (BGP) and 
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50 µg/ ml of ascorbic acid (asc). Βeta-glycerophosphate is the source of phosphate to 
promote mineralisation whereas asc is responsible for collagen type I assembly (239). 
The addition of BGP in rat calvarial cultures resulted in the formation of mineral 
deposits compared to controls  cultured in the absence of BGP (243). Bellows et al 
(244) noted that mineralisation increased in a dose dependent manner as the 
amount of BGP added to the media was increased. 
 
Treatment of MC3T3-E1 cells with 50 µg/ml of asc alone resulted in an increase in 
bone sialoprotein, Ocn, PTH and PTHrP expression, which were not detected in cells 
cultured in the absence of asc (245). In addition, when BM MSCs were treated with 
OGM containing BGP, dexamethasone (dex) and increasing amounts of asc, it 
resulted in an increase in cell proliferation, particularly at 250 µM of asc, and it 
increased total phosphate and calcium staining particularly at 50 µM asc compared 
to controls (241). ST-2 cells cultured in asc alone had markedly increased Alp activity 
compared to those treated only with BGP, reaching maximal levels at 18 days. 
Ascorbic acid treatment using the ST-2 cells also resulted in increased Ocn mRNA 
expression at day 20 and calcium deposits which reached maximal levels at 75 µg/ 
ml after 24 days (246). 
 
Factors such as glucocorticoids including dex have also previously been used to 
enhance differentiation. Human MSCs treated with a combination of dex, asc and 
BGP were highly Alp positive at day 8 of culture and by day 12 a “bone-like material” 
had formed in the dish and mineralisation was evident (242). Alkaline phosphatase 
also increased in a dose dependent manner in MSCs, when cultured with BGP, asc 
and increasing doses of dex. The optimum concentration of dex was 10 mM for Alp 
and 1000 mM for mineralisation (242). In addition, when dex was administered 
alone, it resulted in an increase in Alp over-time in BM stromal cells compared to 
controls in standard media (247). Dexamethasone treatment also induced early 
expression of Runx-2, Ostx, Ocn and bone sialoprotein (248). Continuous combination 
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treatments of BGP, asc and dex using rat stromal cells isolated from the long bones 
also resulted in rapid proliferation in the first 24 hours, an increase in Alp production 
between 7-14 days for cells and Ocn expression between 14 and 21 days after 
treatment (249). 
 
As described above, extensive research has previously been conducted to define the 
stages of osteoblast differentiation using both human and rodent osteoblastic cells. 
It is therefore desirable in these experiments to validate an in vitro osteoblast 
differentiation model using mouse calvarial cells which will enable us to investigate 
the effects of OGM on murine primary OLCs over-time. Specific time points can then 
be used to determine the effect of differentiation upon the expression of the HSC 
niche molecules and ligands implicated within a HSC niche and to determine whether 
MCs selectively adhere to in vitro osteoblastic cells at a particular stage of 
differentiation.  
 
5.2 Hypothesis, aims and objectives 
 
5.2.1 Hypothesis and aims 
The aim of these studies was to test the following hypotheses: 
1. “Treatment of murine primary osteoblast lineage cells (OLCs) with osteogenic 
media (OGM) will result in osteoblast differentiation”. 
2. “Differentiating OLCs express HSC niche molecules and ligands in vitro”. 
3. “Myeloma cells adhere to OLCs at different stages of differentiation in vitro”. 
 
5.2.2 Objectives 
The hypothesis will be tested by the following objectives:  
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1. To determine whether treatment of murine primary OLCs with OGM results 
in osteoblast differentiation, tested by assessment of alkaline phosphatase 
(Alp) production, mineralisation and expression of differentiation bone 
markers by real-time PCR. 
2. To determine whether OLCs express the HSC niche molecules; CXCR4, Notch-
1, Tie-2 and N-cad and ligands; CXCL12, Jag-1, Ang-1 over the course of 
differentiation in vitro, using real-time PCR. 
3. To establish whether differentiating OLCs adhere to 5TGM1-GFP cells at 
specified stages of differentiation in vitro. 
 
5.3 Methods 
 
5.3.1 Assessment of primary osteoblast lineage cell differentiation 
5.3.1.1 Primary osteoblast lineage cell differentiation assay 
Murine primary OLCs were isolated and cultured as described in Chapter II Section 
2.1.2.7 and 2.2.1.2. Primary OLCs were initially seeded in quadruplicate at a density 
of 6000 cells/cm2  (N=4) and cultured for 3 days before culturing with OGM 
containing 10 mM of BGP and 50 µg/ ml of asc in MEMα-nuc (Day 0). The media was 
changed every 2-3 days over the course of 28 days. 
 
5.3.1.2 Alkaline phosphatase analysis 
Primary OLCs were seeded in quadruplicate into a 96 well plate using 150 µl standard 
or OGM. Cells were harvested on day 0, 3, 7, 10, 14, 21 and 28. At these time points, 
cells were lysed using 0.1% triton in PBS and Alp was detected using a PNPP reaction, 
assessed by spectroscopy using a SpectraMax 5Me plate reader over the course of 
90 min and analysed using SoftMax Pro 5.2 software as described in Chapter II, 
Section 2.5.1.2. This was followed by DNA concentration determination using the 
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Invitrogen PicoGreen® reagent followed by fluorescent spectroscopy using the 
SpectraMax 5Me plate reader and analysed using SoftMax Pro 5.2 software as 
described in Chapter II, Section 2.5.1.3. This was used to normalise Alp production, 
the calculations for which are shown in Appendix 2, Section 2.8, Table 2.6. Results 
were based upon four independent experiments (N=4). 
 
5.3.1.3 Mineralisation analysis 
Primary OLCs were seeded in quadruplicate into a 12 well plate in 1 ml OGM. 
Mineralisation was determined on day 7, 14, 21 and 28 by alizarin red staining as 
described in Chapter II, Section 2.5.2.1. Plates were scanned using an Epson 4990 
scanner and analysed using ImageJ software. Results were based upon four 
independent experiments (N=4). 
 
5.3.1.4 Gene expression analysis by real-time PCR 
Primary OLCs were seeded in quadruplicate into a T25 flask using 7 ml OGM. Primary 
OLCs were harvested at 7, 14, 21 and 28 days for gene expression analysis. 
Ribonucleic acid was extracted, cDNA was synthesised and real-time PCR was 
conducted (as described in Chapter II, Section 2.3.1.1, 2.3.2.1 and 2.3.5.2) to 
determine the expression of differentiation markers (COL1A1 and Runx-2) and the 
HSC niche molecules and ligands. Data was analysed using the comparative ΔΔCt 
method, by normalisation to β2M. Data was expressed as a fold change of gene 
expression using the week 1 data as the comparator. Results were based upon four 
independent experiments (N=4). 
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5.3.2 Assessment of 5TGM1-GFP adhesion to primary osteoblast lineage cells at 
different stages of differentiation 
5.3.2.1 Co-culture assessment 
Primary OLCs were differentiated for 3, 14 and 28 days in OGM, after which 5x104 
5TGM1-GFP cells were seeded onto the murine primary OLCs for 1 and 6 hours. The 
number of 5TGM1-GFP cells adhering to the primary OLCs was assessed by 
fluorescent microscopy using a Leica AF6000LX microscope, followed by 
quantification using Volocity software. Results were based upon four independent 
experiments (N=4). 
 
5.3.3 Statistics 
Where relevant, non-parametric statistical tests were used. A Friedman test followed 
by Dunn’s post test (P<0.05) was used to compare Alp production, DNA content, 
mineralisation, gene expression as well as 5TGM1-GFP cell adhesion to osteoblastic 
cells. In addition, a Wilcoxon Matched pairs signed rank test (P<0.05) was used to 
determine differences in the adhesion of 5TGM1-GFP cells to primary OLCs after 1 
and 6 hours. As a non-parametric paired two-way statistical test was unavailable, 
differences in the Alp production and DNA content between the primary OLCs 
cultured in standard and OGM media over-time was unable to be conducted. Where 
relevant, error bars were displayed on all graphs using the SEM, unless stated 
otherwise in the legend. 
 
5.4 Results 
5.4.1 Alkaline phosphatase production by primary osteoblast lineage cells cultured 
in standard or osteogenic media over-time 
Figure 5.3 demonstrates the differences in Alp production between primary OLCs 
cultured in standard media and OGM over-time. From the graph, it is clear that Alp 
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production increased in the primary OLCs cultured in standard media as well as OGM 
until 14 days, after which Alp production reduced. Using a Friedman test followed by 
Dunn’s post test, the changes in Alp production over-time were significant for both 
the sets of samples (P<0.05) however, the Dunn’s post test did not identify at which 
time points significant differences in Alp were apparent. It was also clear that Alp 
production was higher at each time-point in the OGM treated primary OLCs 
compared to the primary OLCs.  
 
 
 
 
 
 
 
 
 
Figure 5.3: Primary osteoblast lineage cells cultured in either standard or osteogenic media 
demonstrated an increase in alkaline phosphatase production over-time. Primary OLCs were cultured 
in standard MEMα-Nuc or OGM containing 10 mM BGP and 50 µg/ ml asc, beginning at day 0 as 
indicated by the arrow. At 0, 3, 7, 10, 14, 21 and 28 days, primary OLCs were lysed using 0.1% triton in 
PBS and the lysates were added to a solution containing 1 mg/ml PNPP and 0.2 M tris buffer. The 
presence of Alp was measured using a SpectraMax 5Me plate reader for 90 min and analysed using 
SoftMax Pro 5.2 software. Results were normalised against the DNA content providing a unit of Alp 
per µg of DNA (U of Alp/ µg DNA) (Y-axis) over-time (X-axis). Data was analysed statistically using a 
Friedman test followed by Dunn’s post test to determine any differences in Alp by the primary OLCs 
and primary OLCs cultured in OGM over-time (P<0.05). Results were determined from four independent 
experiments (N=4). 
 
5.4.2 DNA content of primary osteoblast lineage cells cultured in standard or 
osteogenic media over-time 
Figure 5.4 demonstrates the DNA content of the primary OLC samples cultured in 
standard media and OGM. From the graph, it is clear that as time progressed the 
OGM  
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amount of DNA in both the primary OLC samples and primary OLCs cultured in OGM 
samples increased. Therefore, as this was used as a surrogate for cell counts, we can 
surmise that the number of cells increased over-time. Statistically, this increase was 
significant between days 0 and 28 for both the primary OLCs and primary OLCs 
cultured in OGM (P<0.05). Interestingly from 7 days onwards the DNA content in the 
primary OLCs cultured in OGM was lower compared to the OLCs cultured in standard 
media, thus implying that proliferation in these cells may have decreased due to the 
addition of BG and Asc. This however, was not assessed statistically due to a lack of 
appropriate test. 
 
 
 
 
 
 
 
 
 
Figure 5.4: Primary osteoblast lineage cells cultured in osteogenic media demonstrated a reduction 
in proliferation over 28 days, assessed by DNA quantification. Primary OLCs were cultured in standard 
MEMα-Nuc or OGM MEMα-Nuc media containing 10 mM BGP and 50 µg/ ml asc, beginning at day 0 
as indicated by the arrow. After 0, 3, 7, 10, 14, 21 and 28 days, primary OLCs were lysed using 0.1% 
triton in PBS and the DNA content was measured using the PicoGreen® reagent. The DNA present was 
measured by fluorescence using a SpectraMax 5Me plate reader. Results were calculated by 
extrapolation from a standard curve of known amounts of DNA (ng). Data was analysed statistically 
using a Friedman test followed by Dunn’s post test (P<0.05) to determine differences in DNA content 
over-time. Results were determined from four independent experiments (N=4) 
 
OGM  
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5.4.3 Mineralisation of primary osteoblast lineage cells cultured in osteogenic 
media over-time 
Mineralisation was quantified in the primary OLCs cultured in OGM over-time, as 
shown in Figure 5.5. Figure 5.5a demonstrates representative images of 
mineralisation, where mineralisation was visualised as small red nodules stained 
positive with alizarin red. Figure 5.5b shows the percentage of mineralisation, 
demonstrating a significant increase in the percentage of mineralisation between 7 
and 21 days (P<0.01) of OGM. 
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Figure 5.5: Primary osteoblast lineage cells cultured in osteogenic media showed an increase in 
mineralisation until 21 days. Primary OLCs were cultured in OGM MEMα-Nuc media containing 10 
mM BGP and 50 µg/ ml asc. At 7, 14, 21 and 28 days of growth in OGM, primary OLCs were fixed in 
100% IMS over-night at 4°C followed by staining with 40 mM alizarin red for 90 min at room 
temperature and washed in 95% IMS and dried over-night. a. Representative images of mineralisation 
at 7 (i), 14 (ii), 21 (iii) and 28 (iv) days after growth in OGM, captured using an Epson 4990 scanner. b. 
The Percentage of osteoblast mineralisation was calculated using ImageJ software. Data was analysed 
statistically using a Friedman test followed by Dunn’s post test (P<0.05). Results were determined from 
four independent experiments (N=4). 
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5.4.4 Gene expression of osteoblast differentiation markers and HSC niche 
molecules and ligands by primary osteoblast lineage cells cultured in osteogenic 
media over-time 
Table 5.1 shows the Ct values generated using real-time PCR to determine the 
expression of the osteoblast differentiation markers COL1A1 and Runx-2, and HSC 
niche molecules and ligands by primary OLCs cultured in OGM.  
 
Table 5.1: A summary of the quantitative analysis for the absolute real-time PCR gene expression of 
the osteoblast differentiation markers, HSC niche molecules and ligands by primary osteoblast 
lineage cells cultured in osteogenic media over-time 
Gene 7 days 14 days 21 days 28 days 
COL1A1 18.11 ± 0.56 18.72 ± 0.50 18.84 ± 0.21 19.11 ± 0.16 
Runx-2 24.16 ± 0.26 24.08 ± 0.38 23.80 ± 0.52 23.90 ± 0.45 
CXCR4 33.25 ± 1.30 32.31 ± 0.17 31.10 ± 0.68 32.10 ± 0.56 
Notch-1 26.12 ± 0.42 26.31 ± 0.52 26.01 ± 0.55 26.15 ± 0.52 
Tie-2 28.53 ± 1.13 29.24 ± 1.43 28.59 ± 1.07 29.46 ± 1.25 
N-cad 25.26 ± 0.20 25.42 ± 0.47 24.83 ± 0.25 25.97 ± 0.61 
CXCL12 21.51 ± 1.08 22.55 ± 0.83 22.06 ± 0.98 21.52 ± 1.09 
Jag-1 25.02 ± 0.25 25.93 ± 0.54 25.35 ± 0.35 25.95 ± 0.42 
Ang-1 26.04 ± 0.42 26.74 ± 0.78 26.11 ± 0.47 25.95 ± 0.42 
Mean Ct values ± SEM 
 
Figure 5.6 demonstrates the results graphically using the fold change and percentage 
of gene expression above the columns using the comparative ΔΔCt method, using 
Day 7 as the comparator. CXCR4 was not shown graphically as the ΔΔCt method of 
analysis could not be used, as some of the Ct values were undetermined (UD). The 
differentiation markers COL1A1 and Runx-2 were both highly expressed by the 
primary OLCs at each time point and COL1A1 had the greatest expression. Over-time, 
COL1A1 expression declined, although this change did not reach significance, 
whereas, Runx-2 expression was stable across the time course. All of the HSC niche 
molecules were also expressed by the OLCs, though CXCR4 expression was 
inconsistent across the time course, as some samples were UD. Notch-1 and N-cad 
were highly expressed, whereas Tie-2 and CXCR4 were expressed at lower levels. The 
ligands CXCL12, Jag-1 and Ang-1 were also expressed by the primary OLCs at each 
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time point and CXCL12 was expressed at a higher level compared to both Jag-1 and 
Ang-1. Statistically, there were no significant differences in the expression of the HSC 
niche molecules or ligands over-time in the primary OLCs cultured with OGM. In 
addition, no apparent trends in the gene expression of the HSC niche molecules and 
ligands were observed over the time course with the exception of Jag-1 and N-cad, 
which decreased over-time.  
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Figure 5.6: There were no significant changes in the gene expression of bone and HSC niche markers 
over-time by primary osteoblast lineage cells cultured in osteogenic media over 28 days. Primary 
OLCs were cultured in OGM containing 10 mM BGP and 50 µg/ ml asc. At 7, 14, 21 and 28 days, RNA 
was extracted, cDNA was synthesised and real-time PCR reactions were run using approximately 40 ng 
(2 µl) of RT+ cDNA samples. An equal volume of RT- and H2O control samples were used to assess 
genomic and reagent contamination. Real-time PCR reactions were run using an Applied Biosystems’ 
7900HT Real-Time PCR machine and Applied Biosystems’ recommended settings. Data was analysed 
using the comparative ΔΔCt method and shown graphically using the fold change, and the percentage 
of gene expression is shown above the columns for collagen-1 α (a), Runx-2 (b) CXCR4 (c), CXCL12 (d), 
Notch-1 (e), Tie-2 (f), Ang-1 (g) and N-cad (h). Data was analysed statistically using a Friedman test 
followed by Dunn’s post test. Results were determined from four independent experiments (N=4). 
a b
. 
c d 
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Chapter V: Validating a model for primary osteoblast lineage cell differentiation in vitro, to 
determine the expression of HSC niche molecules and ligands, and to develop an osteoblastic and 
myeloma cell co-culture system Page 179 
  
5.4.5 Adhesion of 5TGM1-GFP cells to primary osteoblast lineage cells cultured in 
osteogenic media 
Figure 5.7a demonstrates representative images showing the adhesion of 5TGM1-
GFP cells to osteoblastic cells at the different time-points. Figure 5.7b shows the 
differences in the number of 5TGM1-GFP cells adhering to primary OLCs cultured in 
OGM for 7, 14 and 28 days after 1 and 6 hours. From the data, there seemed to be 
an increase in the number of 5TGM1-GFP cells adhering to the primary OLCs at 6 
hours compared to 1 hour at each of the differentiation time points however, using 
a Wilcoxon matched pairs signed rank test this difference did not reach significance. 
When the number of 5TGM1-GFP cells adhering to the primary OLCs cultured in OGM 
over-time were compared there was a decrease in the number of 5TGM1-GFP cells 
adhering to primary OLCs cultured in OGM for 28 days compared to 3 days however, 
this was only significant at the 6 hour time point (P<0.05).  
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Figure 5.7: A greater 
number of 5TGM1-GFP 
cells adhered to primary 
osteoblast lineage cells 
cultured in osteogenic 
media for 3 days compared 
to 28 days. Fifty-thousand 
5TGM1-GFP MCs were 
seeded on to primary OLCs 
cultured in OGM containing 
10 mM BGP and 50 µg/ ml 
asc) for 3, 14 and 28 days. 
Adhesion after 1 and 6 
hours was imaged using a 
Leica AF6000LX microscope 
at a 10X magnification 
using LAS LF software and 
analysed using Volocity 
software to determine the 
number of MCs adhering to 
primary OLCs per tile by GFP 
expression. a. 
Representative images of 
5TGM1-GFP cells adhering 
to primary OLCs cultured in 
OGM for 3, 14 and 28 days, 
and after 1 and 6 hours of 
adhesion. Scale bars 
represent 100 µM. b. The 
number of 5TGM1-GFP cells 
adhering to primary OLCs 
cultured in OGM for 3, 14 
and 28 days after 1 and 6 
hours. Data was analysed 
statistically using a 
Wilcoxon matched pairs 
signed rank test (P<0.05) to 
compare differences 
between the number of 
5TGM1-GFP cells adhering 
to primary OLCs after 1 and 
6 hours and Friedman test 
followed by Dunn’s post test 
(P<0.05) to compare 
differences in the 
 number of 5TGM1-GFP cells adhering to primary OLCs cultured in OGM for 3, 14 and 28 days. Results 
were determined from four independent experiments (N=4). 
 
 
a 
b 
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5.5 Discussion 
 
The aim of these experiments was to firstly, validate an in-house model to 
differentiate murine primary OLCs in vitro and secondly to use this system to 
determine whether changes in HSC niche molecules and ligand expression occurred 
at the different stages of differentiation and whether MCs adhered to a specific type 
of osteoblast in vitro, at a specific stage of differentiation. 
 
Firstly, Alp levels were established using the PNPP assay. Alkaline phosphatase is an 
enzyme, which is bound to the surface of osteoblasts by a phosphoinositol bond and 
is also found within the bone matrix. It is thought to act by removing inhibitors of 
hydrodroxyapatite crystal growth and also by increasing concentrations of 
phosphorus at the site of bone formation, to increase bone mineralisation (232). 
Therefore, Alp production increases before mineralisation occurs.  
 
In these experiments, murine primary OLCs were cultured with either standard 
MEMα-nuc or OGM. In both groups, there was an increase in Alp production until 
day 14 post treatment. However, this was to a lesser extent in the cells cultured in 
standard media compared to OGM. The increase in Alp over-time was also significant 
based on the Friedman statistical test however; a Dunn’s post test was unable to 
identify the specific time points, which were significantly different. This may be due 
to the high variability of the results in these experiments. The variability seemed to 
be a result of the first two and latter two experiments being conducted using two 
separate isolates of calvarial osteoblasts. Therefore, there seems to be high 
variability between different batches of isolated osteoblasts and for future studies, 
it would be desirable to use cells from the same batch. This variability may be 
unsurprising as previous experiments have experienced variability even within 
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osteoblastic cell lines where sub-clones of MC3T3-E1 cells expressed different 
amounts of Alp, Ocn and bone sialoprotein when differentiated (245).  
 
When comparing the pattern of Alp production over-time this varied slightly from 
results in the literature. Lian and Stein et al (240) and Lynch et al (250) reported 
maximal Alp production at 19-20 days of differentiation using rat calvarial 
osteoblasts, whereas, Alp peaked earlier at 14 days in these experiments. However, 
the results in this chapter seemed more so similar to differentiation experiments 
using rat stromal cells or MSCs, which demonstrated maximal Alp production 
between 14-21 days and 8-12 days respectively (242, 249).  
 
It is also difficult to determine whether previous experiments support the raw Alp 
values seen in these experiments, as early experiments mainly use Alp staining and 
studies that do use PNPP biochemical staining generally normalise to mg of protein 
rather than DNA, therefore, they are not directly comparable. However, a recent 
paper by Wang et al (187) demonstrated levels of 0.8 Units of Alp production per µg 
of DNA after 7 days of culture in standard media using C57BL/6 murine calvarial 
osteoblasts, which was slightly lower but similar to the values calculated in the 
studies in this Chapter.  
 
The presence of Alp and an increase in Alp over-time in osteoblastic cells cultured in 
standard media has also been described in previous experiments. Jaiswal et al (242) 
described how MSCs cultured in standard media, which didn’t contain BGP and asc, 
produced Alp, though not to the extent of media containing BGP and asc. In addition, 
the type of media used also affected basal levels of Alp, where MSCs cultured in 
DMEM had the lowest basal levels whereas, cells cultured in MEMα had the highest 
(242). 
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In the experiments in this chapter, the statistical difference in the Alp produced by 
the cells cultured in OGM and standard media over-time could not be performed due 
to a lack of non-parametric paired two-way test, however from the graphs it is clear 
that the OGM cultured cells do produce higher Alp. Therefore, it can be concluded 
that the OGM is causing an increase in Alp production, and potentially inducing 
osteoblast differentiation.  
 
Cell proliferation was also investigated in primary OLCs cultured with standard media 
and OGM. The concentration of DNA increased over-time significantly for both cell 
types from day 0 to day 28. However, again as a suitable test was unavailable to 
compare the two cell types it was difficult to confirm the differences in proliferation 
between cells culture in OGM compared to those cultured in standard media. 
However, by the patterns shown in the graphs it seemed that the OGM cultured cells 
had a lower DNA content than those cultured in standard media from 10 days 
onwards. Therefore, proliferation may be decreased in the OGM cultured cells. This 
is supported by studies conducted by Lian and Stein et al (240) who previously 
reported an initial increase in proliferation by histone determination in rat calvarial 
osteoblasts between days 5-10, which then reduced and plateaued for the remainder 
of the differentiation period examined, also reported by Choi et al (251) using 
MC3T3-E1 cells. However, experiments using human MSCs differentiated in OGM 
containing dex actually showed an increase in proliferation when measured by crystal 
violet staining of DNA (242). Therefore, the way in which proliferation is measured 
may provide a difference in determining whether proliferation remains active. Lynch 
et al (250) used fluorometric analysis of DNA from rat calvarial osteoblasts cultured 
in OGM and found an increase in DNA up to 21 days, supporting Jaiswal et al (242). 
Interestingly, in the same experiment, histone 4 was decreased from 5 days onwards, 
supporting Lian and Stein et al (240). In addition, the amount of FBS used in the 
culture may also affect proliferation rates. Previous papers have shown that some 
osteoblastic cells such as the cell line SAOS-2 are cultured in FBS at concentrations as 
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low as 0.5% (252), which slows proliferation and induces Alp production and 
mineralisation. 
 
Mineralisation is a later marker of osteoblast differentiation, associated with a down-
regulation of Alp and an up-regulation of Ocn, Opn and On (183, 240). Mineralisation 
in the experiments in this chapter occurred from the beginning of OGM treatment 
and peaked at 21 days. Therefore, mineralisation occurred earlier than previous 
reports, which showed mineralisation in rat calvarial osteoblastic cells and human 
osteoblastic cells at approximately 28 days onwards (183, 253). In addition, 
mineralisation usually begins when Alp decreases but mineralisation in these 
experiments continued to increase as Alp increased until 14 days. In support of my 
data, Nefussi et al (254) found that rat calvarial osteoblastic cells cultured in the 
presence of BGP demonstrated mineralisation within 14 days. One potential 
explanation for early mineralisation by the OLCs in these experiments is due to high 
basal levels of Alp present in the cells due to the type of media used and also, 
standard media contains phosphate which, combined with Alp, may stimulate 
immediate mineralisation (239).  
 
In addition, inconsistencies in the literature as well as between my data and previous 
studies may again be due to the variability between samples and the heterogeneous 
nature of the cells. In addition, other groups have found that BGP may not be the 
best source of phosphate for mineralisation and Gartland et al (252) found that 
inorganic phosphate was more suitable. In addition, it also difficult to conclude the 
effect of OGM on mineralisation as a standard media without BGP and asc control 
group was not used as a comparator in these experiments. The addition of this 
control would have provided evidence of basal levels of mineralisation in the 
presence of pre-existing phosphate in the media and therefore, the actual level of 
mineralisation due to OGM could have been assessed.  
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Real-time PCR was conducted to determine the gene expression of the 
differentiation markers COL1A1 and Runx-2 in primary OLCs cultured in OGM over-
time. There were no significant differences in COL1A1 and Runx-2 expression over-
time although; there was a slight decrease in COL1A1 expression. At each time point, 
COL1A1 expression was extremely high implying that the primary OLCs were 
secreting high amounts of collagen protein to begin with. Lian and Stein et al (183) 
previously described high COL1A1 expression in the early time points of 
differentiation, which drastically dropped after 12 days in rat calvarial osteoblasts. 
This was supported by Choi et al (251) using MC3T3-E1 cells whereby COL1A1 
expression was highest between 10-15 days and reduced significantly after 15 days. 
Therefore, these results coincide with the maximal expression of COL1A1 in the 
murine primary OLCs observed at 7 and 14 days. However, the drop after the 
maximal expression of COL1A1 was not significant but a longer period of 
differentiation may be required to detect a further reduction in the future.  
 
Runx-2 is an early marker of differentiation and its expression has been observed in 
a variety of primary OLCs at different stages as well as in MSCs. In the experiments in 
this chapter, Runx-2 was expressed by the primary OLCs at each time point but there 
was also no significant difference between Runx-2 expression over time. This is 
consistent with previous studies which found that the Runx-2 isoform II mRNA was 
constitutively expressed by the human stromal cell line hMS2-15 when treated with 
BGP, asc and dex over a 14 day period, whereas, the isoform I was not expressed at 
all (255). Another study determined the expression of Runx-2 in a variety of stromal 
and osteoblastic cells, which included “non-osteoblastic”; Cos-7, NIH3T3 and 
C3H10T1/2 cells, immature osteoblastic; ST-2 and MC3T3-E1 cells and mature 
osteoblastic; Ros 17/2.8, FRC, SaOS-2 and U20S cells. Each cell type expressed the 
RNA (assessed by Northern blot) for Runx-2 isoform I and both immature and mature 
osteoblastic cells expressed Runx-2 isoform II, whereas the RNA from the non-
osteoblastic cells for Runx-2 isoform II was negative. In contrast, using PCR the mRNA 
from the non-osteoblastic cells was positive for Runx-2 isoform II. The protein 
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expression was also different from the RNA and mRNA results where only the mature 
osteoblastic cells and the ROS 17/2.8 cells were positive for each isoform, whereas 
the immature osteoblastic cells were negative (256). This therefore, demonstrates 
the complexities of using Runx-2 as a marker for osteoblast differentiation and it is 
difficult to determine whether Runx-2 expression does differ over the course of 
differentiation due to the different isoforms and inconsistencies in RNA, mRNA and 
protein expression.  
 
To assess differences in the expression of HSC niche molecules and ligands by OGM 
treated primary OLCs, real-time PCR was used. Interestingly, the murine primary 
OLCs expressed CXCR4 at each time-point however; this was inconsistent as some 
values were UD between the different experiments. This was particularly interesting 
as previous experiments have focused upon the expression of its ligand CXCL12, 
shown to be expressed on endosteal osteoblasts, vessels and reticular cells in vivo 
(82, 196), and little emphasis has been placed on CXCR4 expression by osteoblasts. A 
study by Ponomaryov et al (111) demonstrated low expression of CXCR4 by MBA-15 
and BM stromal cells. In the studies in this chapter, there was no difference in the 
expression of CXCR4 over-time when treated with OGM, but this may be due to the 
heterogeneous nature of primary OLCs.  
 
CXCL12 was also shown to be expressed by murine primary OLCs at each time point 
of OGM treatment and was surprisingly high. Expression of CXCL12 by murine 
osteoblasts is consistent with previous experiments which demonstrated the 
expression of CXCL12 by the BM stroma and endosteal osteoblasts in vivo (82, 111). 
There were no significant differences in the expression of CXCL12 over-time implying 
that OGM treatment did not influence its expression. Interestingly, previous papers 
have categorised CXCL12 expressing osteoblasts as immature osteoblastic cells 
opposed to mature osteoblasts (111). This is supported by studies, which have 
compared the levels of CXCL12 between MG-63 and SAOS-2 cells. Previous studies 
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reported that SAOS-2 cells were more mature with high mineralisation compared to 
the MG63 cells which were described as immature and heterogeneous (196, 257). 
When the CXCL12 levels were compared, the more mature SaOS-2 cells had lower 
expression of CXCL12 compared to the immature MG-63 cells (111, 258). In addition, 
Jung et al (196) demonstrated that human osteoblastic cells, MG63 cells, BM stromal 
cells and MC3T3-E1 cells secreted SDF-1 in the early time points of differentiation 
(detected by enzyme-linked immunosorbent assay in conditioned media) and 
production of SDF-1 decreased over the time course, again highlighting that SDF-1 is 
produced in the early stages of osteoblastic differentiation. With regards to the 
experiments in this chapter, it may seem that the osteoblastic population used was 
still quite heterogeneous, particularly as CXCL12 expression decreased after 7 days 
and then reached maximal levels at 28 days. In addition, only mRNA was detected 
therefore, protein production may have provided different results.  
 
Notch-1 expression, was expressed by MC3T3-E1 osteoblastic cells (200), C3H10T1/2 
and C2C12 cell lines and murine undifferentiated primary OLCs (216), therefore, 
Notch-1 may be more prevalent in preosteoblastic cells rather than mature 
osteoblasts. Notch-1 expression in the experiments in this chapter was detected in 
osteoblasts at all time-points and no significant changes in Notch-1 expression over-
time were observed. Notch-1 expression did however, slightly decrease after 7 days 
but this was variable. If the experiment was conducted for a longer period, a further 
decrease may have been observed.  
 
Jag-1 was expressed at similar levels to Notch-1 at all time-points. Jag-1 expression 
has been determined in a variety of different osteoblastic cells including MC3T3-1 E1 
(200), BM stromal cells in vitro (199) and osteoblastic cells in vivo (82, 259). Jag-1 
expression levels by osteoblastic cells has not been associated with osteoblast 
differentiation states. Although, stromal cells and MC3T3-E1 cells are usually classed 
as immature osteoblasts or preosteoblasts, therefore, this correlates with the trend 
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observed whereby Jag-1 expression decreased from 7 days onwards in the 
experiments in this chapter.  
 
Tie-2 was expressed by the primary OLCs at each time-point. Its expression was 
particularly low and did not change over-time. Tie-2 is typically a marker of ECs and 
has not been a key focus in osteoblastic cells. However, low expression of Tie-2 was 
determined in MC3T3-E1 cells, murine primary OLCs, ST-stromal cells, C2C12 and 
C3H10T1/2 cells (202). Overall Tie-2 expression was higher in the C3H10T1/2 cells 
(202), which may imply that Tie-2 may be more prevalent in early mesenchymal 
progenitor cells, rather than immature or mature osteoblastic cells. However, this 
was contradicted in studies using primary osteoblastic cells and C2C12 cells, which 
seemed to demonstrate increased expression of Tie-2 following three days of culture 
in OGM, therefore, Tie-2 is present at higher levels in more differentiated cells in this 
instance (202). However, in the experiments in this chapter, no pattern of Tie-2 
expression was observed across the time course of differentiation, but again this 
could be due to the heterogeneity in the population. 
 
Ang-1 was expressed over-time at similar levels to Notch-1, Jag-1 and N-cad. Jeong 
et al (202) demonstrated an initial increase in Ang-1 expression within the first three 
days of primary murine osteoblastic cell differentiation compared to day 0 and this 
was then maintained at the same level for a further 25 days. In these experiments, 
differences in Ang-1 expression may not have been determined, as 7 days was the 
earliest time point used and any increase in Ang-1 expression may have already 
occurred. 
 
N-cad was expressed by the primary OLCs over-time. After 14 days of differentiation 
N-cad expression seemed to decrease however, this did not reach significance. N-cad 
was previously reported to be expressed by a variety of different MSC lineage cells 
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such as MC3T3-E1 cells, C3H10T1/2, ST-stromal cells, ATDC5 chondrogenic cells, 
NIH3T3 fibroblast cells (218) and KS483 osteoblastic cells (206). However, the effect 
of differentiation upon N-cad is currently unclear. Greenbaum et al (260) 
demonstrated expression of N-cad by primary murine osteoblastic cells which 
diminished following 15 days of differentiation whereas, Ferrari et al (219) 
demonstrated an increase in N-cad expression as SaOS-2 cells were differentiated 
over the course of 4 days. It is therefore, difficult to ascertain whether N-cad 
expression would increase upon differentiation stimuli. In the experiments in this 
chapter, no significant difference in N-cad expression was found over-time with OGM 
treatment. However, after 14 days there was a decrease in N-cad expression and 
again if the experiment was continued for a longer period, further declines may have 
been observed, correlating with the experiments conducted by Greenbaum et al 
(260). 
 
Again, as these experiments lacked the suitable control of OLCs cultured in standard 
medium as a comparator at each of the times points it is difficult to draw substantial 
conclusions. For example, Col1α and Runx-2 levels did not significantly change over-
time however; the levels of these may be significantly increased or decreased in OLCs 
cultured in OGM compared to OLCs cultured in control media, and similarly, the 
levels of HSC niche molecules and ligands may also be have significantly different 
between differentiating and non-differentiating OLCs. However, without the suitable 
non-OGM controls the actual effect of OGM and therefore differentiation upon bone 
marker or HSC niche molecule or ligand expression was unable to be suitably tested. 
 
The adhesion of MCs to osteoblastic cells after treatment with OGM was then 
determined. A higher number of 5TGM1-GFP cells adhered to the primary OLCs after 
6 hours compared to 1 hour although, this did not reach significance. In addition, 
significantly more MCs adhered to primary OLCs treated with OGM for 3 days 
compared to 28 days after 6 hours. This was quite interesting as it implies that MCs, 
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like HSCs, seem to preferentially adhere to osteoblastic cells in the early stages of 
differentiation, which is supported by Zhang et al (83) and Xie et al (84) when defining 
osteoblastic cells in the HSC niche. These results may also imply that the factors 
potentially responsible for this adhesion are not the HSC niche molecules or ligands 
described in this thesis, as no differences in their expression was seen over-time. 
However, as the day 3 time-point was not assessed by real-time PCR and as the 
standard media controls were not used, this cannot be completely concluded. 
 
There are several disadvantages related to subjectivity using this adhesion technique 
that need to be noted. Firstly, washing the cells can severely affect the results, as 
washing the cells with slightly different forces may either detach or retain adhesion. 
In addition, results may be subjective as only 5 out of a 25 tile area were imaged, 
which was particularly subjective as the majority of cells were found around the 
edges of the wells compared to the centre, despite this, the same areas were imaged 
in each well. Also at 28 days, the primary OLCs had begun to detach at the edges of 
the wells, resulting in less area for the cells to adhere to, which may have also 
influenced the results. Mineralisation may have also interfered with MC adhesion, 
which was greatest at 21 days and again this could have provided less area for the 
cells to adhere to. In addition, it may also have been desirable to examine the effect 
of using PBS compared to media. PBS was previously used when investigating the 
adhesion of HSCs and osteoblastic cells (261) for a short adhesion time of 15 min, 
although 6 hours may be too long a time for MCs to survive in PBS as they have a 
short life span when not in media. 
 
Survey of the literature did not provide a standardised time for the adhesion assays. 
Some experiments used 20 min (206), 2 hours, (262), 4 hours (263) or 6 hours (42). 
Therefore, an early (1 hour) and late (6 hours) time point was chosen. However, in 
retrospect, it may have been more desirable to look at the adhesion within the first 
15 min, which could capture early simple associations and possibly even later than 6 
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hours such as 12 or 24 hours, which could potentially detect more complex 
interactions involving gene expression in interacting cells. In addition, the number of 
cells plated onto osteoblasts varied. Some studies used 1x105 (206, 261) and 
5x106/ml (263) in a 96 well plate. However, in these experiments 5x104 cells were 
used, as the 96 well plates did not have the capacity for greater numbers than this. 
 
In conclusion, I have validated a model for the differentiation of murine primary OLCS 
in vitro. Some of the characteristics were similar to what has been previously 
reported using rat calvarial cells, BM stromal cells and osteoblastic cells however, 
there were also some inconsistencies particularly with respect to the mineralisation 
time points and peak expression of collagen. Treatment with OGM did not affect the 
expression of HSC molecules or ligands but despite this, MCs adhered highly to 
primary OLCS in the early time points of OGM treatment. Therefore, this may imply 
that other molecules besides the HSC niche molecules and ligands investigated here 
are important with regards to MC adhesion to osteoblasts, though as stated previous 
this isn’t conclusive due to a lack of standard media controls.  
 
Further research is now required to explore differences in the expression of other 
adhesion molecules using this system and also to further optimise the adhesion 
experiments. The assays used to determine the differentiation state of the BM 
cultures were population based and it would be have been helpful to assess 
differentiation in a per cell basis to determine the maturity of interacting cells. This 
was however beyond the scope of the present study, but should be considered in 
future studies. 
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6.1 Introduction 
 
In the studies described in Chapter III-V, I determined the expression of several HSC 
niche molecules by the 5T33MMvt and 5TGM1-GFP cells. These studies collectively 
showed that MCs produced the HSC niche molecules CXCR4, Notch-1, Tie-2 and N-
cad and the ligands CXCL12 and Jag-1. Expression of these molecules by MCs has 
previously been reported in the literature; however, the role of these molecules in a 
myeloma osteoblastic niche is yet to be determined.  
 
Previous preclinical studies have shown the importance of the CXCR4/CXCL12 axis for 
its role in the mobilisation of CXCR4 positive HSCs (94, 112) and various cancer cells 
including prostate (258, 264), breast (265, 266) and MCs (170, 194) towards a high 
concentration gradient of CXCL12 in vitro and in vivo. In MM, in vitro transwell 
experiments showed that 5T2MM and 5T33MM cells specifically migrated towards 
fibroblast conditioned media containing CXCL12 and recombinant CXCL12. This was 
significantly inhibited using the peptide antagonist 4F-benzoyl-TN14003 (170). These 
observations were also supported by studies using human MC lines and primary 
patient samples, where recombinant CXCL12 or conditioned media induced 
chemotaxis (193, 194, 221) which was blocked by an anti-CXCR4 inhibitory antibody 
or the CXCR4 antagonist AMD3100 (195). 
 
The interactions of Notch-1 and Jag-1 have also been investigated in MM. Activation 
of Notch-1 by Jag-1 and its effect upon cell proliferation is somewhat contradictory 
in the literature. Jundt et al (198) described a 2-fold increase in MC proliferation 
when stimulated with Jag-1, which was inhibited using the γ secretase inhibitor N-
[(3,5-Difluorophenyl)acetyl]-L-al-anyl-2-phenylglycine-1,1-dimethylethyl ester 
(DAPT). Whereas, Nefedova et al (199), described a reduction in proliferation and an 
increase in cells in the G0 phase of cycling when cells were co-cultured with Jag-1 
expressing stromal cells. In addition, the interaction of Jag-1 positive stromal cells 
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with MCs propagated chemoresistance when melphalan was administered (199).In a 
separate study, administration of a γ secretase inhibitor in combination with 
doxorubicin, also resulted in MC chemosensitisation and increased the percentage 
of apoptotic cells in vitro and in vivo (267).  
 
N-cad expression and function has been implicated in several cancers including 
breast, prostate and melanoma, particularly in relation to metastasis. Hazan et al 
(268) demonstrated that N-cad expression in MCF-7 breast cancer cells induced both 
migration and invasion in vitro and an increase in metastasis upon injection in vivo. 
This was also supported by Nieman et al (204), who demonstrated that N-cad positive 
breast cancer cell lines had higher invasion and motility. In prostate cancer, 93% of 
patients with established metastasis had tumours which were positive for N-cad, 
whereas only 56% of patients who had no known metastasis had N-cad positive 
tumours (228). In addition, when N-cad was knocked-down in melanoma cells, this 
resulted in a reduction in transwell migration in vitro (269). Furthermore, when N-
cad was blocked using an inhibitory antibody, this resulted in a reduction in 
melanoma cell adhesion to fibroblasts and endothelial cells, a reduction in migration 
towards fibroblasts in vitro and an increase in melanoma cell death (270).  
 
N-cad has also been implicated in MC adhesion to osteoblastic cells and in the early 
stages of MC homing and survival in the BM. NCIH929 MCs adhered to recombinant 
N-cad and N-cad expressing C3H10T1/2 osteoblastic cells in vitro and this interaction 
was subsequently blocked using an N-cad inhibitory antibody (206). The KD of N-cad 
in NCIH929 cells also resulted in a reduction of MC homing or survival in the BM and 
an increase in the number of cells in the circulation when injected into mice (206). In 
addition, Sadler et al (207) demonstrated that inhibition of MC adhesion to stromal 
cells in culture using an anti-N-cad antibody resulted in increased proliferation of 
MCs, therefore, N-cad signalling may be important for cell proliferation and control 
of cell cycle.  
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As stated previously, Tie-2 and Ang-1 have not been highly studied in MM. They have 
activities typically associated with blood vessel development. Tie-2 is highly 
expressed in blood vessels and is required for vessel stability and integrity, which is 
stimulated by Ang-1 and inhibited by Ang-2. However, vessel stability is an important 
mechanism for the establishment of solid tumours and Vacca et al (271) reported an 
increase in micro-vessel area in myeloma patients. Therefore, Tie-2/Ang-1 
interactions may be important in myeloma establishment in the BM.  
 
Successful interventions of all the molecule interactions discussed above in disease 
have now also been translated into clinical trials for various types of cancer, discussed 
in detail in the general discussion, Chapter VII. 
 
In this Chapter, I have used a shRNA gene KD strategy to supress the expression of 
genes for CXCR4 and N-cad in 5TGM1-GFP cells. I then conducted functional studies 
to determine the effect of the KD on the adhesion of the MCs to the differentiated 
primary OLCs (optimised in Chapter V) and also the effect upon tumour growth in 
vivo in a pilot study. These experiments were conducted to determine the role of 
these molecules in a MC niche and to identify whether these molecules are important 
targets for future intervention studies. The 5TGM1-GFP model was used, as it is 
intrinsically less variable in terms of tumour burden and tumour take compared to 
the 5T33-GFP model. The 5T33-WT model was also used in this chapter as a control 
to test the transduction of GFP using the lentiviral system. 
 
6.2 Hypothesis, aims and objectives 
 
6.2.1 Hypothesis and aims 
The aim of these studies was to test the hypothesis that “The knock-down (KD) of 
HSC niche molecules in MM cells, results in reduced myeloma cell (MC) adhesion to 
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primary osteoblast lineage cells (OLCs) in vitro and subsequent reduction in tumour 
burden in vivo”. 
 
6.2.2 Objectives 
The hypothesis will be tested by the following objectives:  
1. To KD HSC niche molecules in the 5TGM1-GFP cells using short hair-pin RNA 
(shRNA) and to transduce green fluorescent protein (GFP) into 5T33-WT cells. 
Gene KD will be validated using real-time PCR and Western blotting (WB), and 
GFP transduction will be confirmed using flow cytometry.  
2. To determine the effect of knocking down HSC niche molecules on MC adhesion 
to primary OLCs in vitro. 
3. To determine the effect of knocking down HSC niche molecules upon tumour 
burden in vivo. 
 
6.3 Methods 
 
6.3.1 Short hair-pin RNA knock-down strategy 
6.3.1.1 Puromycin killing curves 
5TGM1-GFP cells and 5T33-WT cells were seeded in triplicate at a density of 1x105 
cells into a 12 well plate in 2 ml complete RPMI media containing either 0 (an equal 
volume of PBS), 0.5, 1.0, 2.5, 5.0, 7.5 and 10 µg/ ml puromycin and after 2 and 4 days 
the cell viability was determined using TO-PRO-3 staining followed by flow cytometry 
using a FACS Calibur and Cell Quest software. The lowest dose required for 100% cell 
death over a 4-day period was then established by analysing the number of viable 
cells remaining at the different concentrations of puromycin at 2 and 4-day time 
points. Results were based on three independent experiments (N=3). This is 
described in more detail in Chapter II, Section 2.6.2.2. 
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6.3.1.2 Polybrene optimisation 
5TGM1-GFP and 5T33-WT cells were seeded in triplicate into a 48 well plate at a 
density of 5x104 in 500 µl complete RPMI media containing 0 (PBS of the same 
volume), 2.5, 5.0, 7.5 and 10.0 µg/ml polybrene and incubated for 24 hours. After 24 
hours, the number of cells in each well were counted using a haemocytometer to 
establish whether high concentrations of polybrene were toxic. Results were 
established from three independent experiments (N=3). This was described in more 
detail in Chapter II, Section 2.6.3.1. 
 
6.3.1.3 Lentiviral green fluorescent protein transduction 
The 5T33-WT cells were seeded at a density of 2x104 cells in 100 µl complete RPMI 
media containing 5.0 µg polybrene (determined from the optimisation experiments) 
in a 96 well plate and the lentiviral particles for GFP and scrambled controls at a 
multiplicity of infection (MOI) of 5 (CTRL 5), 15 (CTRL 15) and 25 (CTRL 25) were added 
and then incubated for 20 hours. Green fluorescent protein expression was 
determined in puromycin resistant colonies (treated with 7.5 µg puromycin) using 
flow cytometry. The stability of the GFP transduction was also established in cells in 
the absence of puromycin free media, four weeks after transduction. This was 
described in further detail in Chapter II, Section 2.6.4.1. 
 
6.3.1.4 Lentiviral short hair-pin RNA transduction for CXCR4 and N-cad 
The 5TGM1 cells were seeded at a density of 2x104 cells in 100 µl complete RPMI 
media containing 5.0 µg polybrene in a 96 well plate and the lentiviral particles 
containing shRNA for N-cad and CXCR4 at MOIs of 5 (KD 5), 15 (KD 15) and 25 (KD 25) 
or scrambled controls at the same MOIs were added and then incubated for 20 hours. 
Knock-down was detected in puromycin resistant colonies (treated with 5.0 µg/ ml 
puromycin) using real-time PCR and WB. The cells were then cultured in the absence 
of puromycin for four weeks to detect the stability of the KD, which was analysed 
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using real-time PCR and WB. This was described in further detail in Chapter II, Section 
2.6.4.1. 
 
6.3.2 Assessment of gene knock-down 
6.3.2.1 Real-time PCR 
For PCR analysis of the KD, 1x106 CXCR4 and N-cad KD 15 and 25 and CTRL 15 and 25 
treated cells were taken in triplicate for RNA extraction. RNA was extracted, cDNA 
was synthesised and real-time PCR was conducted as described in Chapter II, Sections 
2.3.1.1, 2.3.2.1 and 2.3.5.2. Real-time PCR was analysed using the comparative ΔΔCt 
method by normalising to the HK gene β2M and the percentage of KD was calculated 
as described in Chapter II, Section 2.6.4. Results were established from three 
independent experiments (N=3). 
 
6.3.2.2 Western blotting 
Western blotting was used to confirm the KD of protein in the 5TGM1-GFP cells. In 
each sample, 1x107 CTRL 15 and 25 and N-cad KD 15 and 25 cells were taken in 
triplicate and lysed using NP-40 buffer. The protein was quantified using a 
bicinchoninic acid (BCA) assay and run in a 7% resolving gel using 30% acrylamide by 
polyacrylamide gel electrophoresis (SDS-PAGE). The gel was transferred onto a 
nitrocellulose membrane and N-cad protein was determined using sandwich 
“immuno-blotting”. Results were visualised by chemoluminescence and quantified 
using ImageJ software to calculate band density. Knock-down was quantified by 
normalising to the HK protein β-actin and a percentage of protein KD was calculated. 
Results were established from three independent experiments (N=3). This is 
described in more details in Chapter II, Section 2.4.4. 
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6.3.3 Assessment of the in vitro effects of HSC niche molecule gene knock-down in 
transduced myeloma cells 
6.3.3.1 Growth curves 
To assess the effect of the HSC niche molecule KD upon cell proliferation in vitro, 
growth curve experiments were conducted, where 5x103 cells (5TGM1-GFP, CTRL 15 
and 25 and KD 15 and 25) were seeded into a 96 well plate in 200 µl complete RPMI 
media. Cell counts were recorded every 2 days for 12 days. Cell proliferation was 
presented in a graphical format to visualise each phase of growth and the doubling-
time in the exponential phase was calculated using the formula shown in Chapter II 
section 2.4.5.1. Results were established from three independent experiments (N=3).  
 
6.3.3.2 Adhesion experiments 
To assess the effect of the HSC niche molecule KD upon MC adhesion to primary 
OLCs, the same method was used as developed previously in Chapter V. In brief, 
5x104 cells (CTRL 15 and 25 and N-cad KD 15 and 25) were seeded in 200 µl complete 
RPMI media onto primary OLCs differentiated in 10 mM BGP and 50 µg/ml asc for 3, 
14 and 28 days in a 96 well plate. After 1 and 6 hours, plates were washed and the 
remaining cells that adhered to the primary OLCs were visualised using a Leica 
AF6000 fluorescent microscope and LAS LF software. This is described in more detail 
in Chapter II, Section 2.5.3.2. 
 
6.3.4 Assessment of the in vivo effects of HSC niche molecule gene knock-down in 
transduced myeloma cells 
A pilot in vivo experiment using the N-cad KD cells was conducted to firstly, identify 
any differences in tumour burden between the transduced cells and standard 
5TGM1-GFP cells (as it was suspected that prolonged in vitro culture may effect 
tumourgenicity) and secondly, to determine any differences in tumour burden 
between mice injected with CTRL 25 and N-cad KD 25 cells. Two million 5TGM1-GFP 
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cells (N=4), CTRL 25 (N=6) and KD 25 (N=6) cells were injected into 11 week old 
female C57BL/KaLwRij mice. When the first mouse became ill (at 25 days post 
injection), all mice were sacrificed and the hind limbs were dissected. The MM 
models are described in more detail in Chapter II, Section 2.2.2.1. 
 
6.3.4.1 Tumour burden analysis 
Both femurs from each mouse were flushed using PBS and analysed separately by 
flow cytometry to determine the percentage of GFP positive tumour cells in each 
femur as described in Chapter II, Sections 2.2.1.4 and 2.4.1.2. In addition, the left 
tibiae were fixed in 4% PFA, decalcified in PFA/EDTA and sections were cut and 
stained by CD138 IHC as described in Chapter II, Section 2.4.3.3. The stained slides 
were scanned using an Aperio Scan Scope slide scanner and tumour area and colony 
number were analysed manually using Image Scope software. 
 
6.3.4.2 Bone disease analysis 
The right tibia from each mouse was fixed in 10% formalin and scanned by µCT using 
a SkyScan 1172 at 50 Kv, 200 µA, an aluminium filter of 0.5 mm and pixel size of 4.3 
µm2. Images were reconstructed using N-Recon Software. Trabecular bone 0.2 mm 
below the growth plate was analysed using Ct-an and Batman software to provide 
data for bone parameters including BV/TV, tb.n and tb.th. This is described in greater 
detail in Chapter II, Section 2.7.1.2. Lesion number and area were also calculated 
using Ct-an software by utilising reconstructed µCT images of each tibiae. Following 
this, the images were resized; the cortical bone region of interest was selected for 
lesion analysis using ImageJ software. This is described in greater detail in Chapter II, 
Section 2.7.1.2. 
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6.3.5 Statistics 
Non-parametric statistical tests were used where relevant. A Friedman test followed 
by Dunn’s post test was used to determine differences in cell death between MCs 
treated with different concentrations of puromycin and polybrene and was also used 
to determine differences in GFP expression in MCs cultured in the absence of 
puromycin over-time. A Kruskal-Wallis test followed by a Dunn’s post test was used 
to determine differences in cell proliferation between CTRL and KD cells over-time. 
A Mann-Whitney U test was used to compare differences in CTRL and KD MC 
adhesion to primary OLCs cultured in OGM for 3, 14 and 28 days and a Friedman test 
was used to determine differences in MC adhesion to primary OLCS cultured in OGM 
for 3, 14 and 28 days. In addition, a Mann-Whitney U test was used to compare 
tumour burden and bone disease between CTRL 25 and N-cad KD injected mice in 
vivo. A Fisher’s exact test was also used to compare the tumour take. 
 
Where relevant, error bars were displayed on all graphs using the SEM unless stated 
otherwise in the legend. 
 
6.4 Results 
 
6.4.1 Killing curves to determine the optimum concentration of puromycin using 
flow cytometry 
Puromycin killing curves were conducted to determine the optimum concentration 
of puromycin to select for resistant colonies following lentiviral transduction for the 
KD of CXCR4 and N-cad by shRNA. Cell death was analysed by TO-PRO-3 staining using 
flow cytometry where non-viable cells were positive. 
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Figure 6.1 demonstrates the percentage of 5TGM1-GFP and 5T33-WT cell death after 
2 and 4 days using increasing doses of puromycin. As the concentration of puromycin 
increased, the percentage of TO-PRO-3 positive 5TGM1-GFP and 5T33-WT cells also 
increased. After 2 days, the number of TO-PRO-3 positive 5TGM1-GFP cells increased 
between 0.0-5.0 µg/ml puromycin after which cell death plateaued at the remaining 
concentrations. Cell death was significant at 5.0, 7.5 and 10.0 µg/ml puromycin 
compared to the control (P<0.05). After 4 days again there was an increase in TO-
PRO-3 positive cells, but the cell death plateaued earlier at 2.5 µg/ml, after which 
there was a 2% increase in cell death between 2.5 and 5.0 µg/ ml puromycin. The 
mean percentage of cell death of 97% then remained constant for the remainder of 
the concentrations. Statistically, cell death was significant at 5.0 µg/ ml puromycin 
compared to the control (P<0.05).  
 
After 2 days, the 5T33-WT cells demonstrated an increase in TO-PRO-3 positive cells 
from 0.0-5.0 µg/ml. This was then followed by a 5% increase between 5.0 µg/ml and 
7.5 µg/ml and a 2% increase between 7.5 µg/ml and 10.0 µg/ml. Statistically, there 
was a significant difference in the number of dead cells at 7.5 µg/ml (P<0.05) and 
10.0 µg/ml (P<0.01) compared to the control, and also between 0.5 µg/ml and 10.0 
µg/ml (P<0.05). After 4 days, the number of TO-PRO-3 positive cells increased 
between 0.0-5.0 µg/ml followed by a 2% increase between 5.0 µg/ml and 7.5 µg/ml 
and no increase between 7.5 µg/ ml and 10.0 µg/ml puromycin. Statistically, there 
was a significant difference in cell death between 7.5 µg/ml (P<0.01) and 10.0 µg/ml 
(P<0.05) puromycin compared to the controls. 
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Figure 6.1: Increasing doses of puromycin resulted in an increase in 5TGM1-GFP and 5T33-WT cell 
death. 5TGM1-GFP and 5T33-WT cells were seeded at 1x105 cells per 12 well plate in 2 ml of complete 
RPMI media and incubated over-night. The following day the cells were centrifuged at 300 x g for 5 
min and resuspended in 2 ml of complete RPMI media containing 0.0, 0.5, 1.0, 2.5, 5.0, 7.5 and 10.0 
µg/ml puromycin. After 2 and 4 days the number of dead cells were detected by TO-PRO-3 staining 
and flow cytometry using a FACS Calibur and Cell Quest software. a. 5TGM1-GFP cell death after 2 and 
4 days using increasing doses of puromycin. b. 5T33-WT cell death after 2 and 4 days using increasing 
doses of puromycin. Data was analysed statistically using a Friedman test followed by Dunns post test 
(P<0.05) to determine differences in TO-PRO-3 staining using the different doses of puromycin. Results 
were determined from four independent experiments (N=4).  
 
From the data, it was also clear that a higher number of cells were TO-PRO-3 positive 
after 4 days compared to 2 days using each concentration of puromycin and cell type. 
a 
b 
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In addition, the 5T33-WT cells seemed to be more resistant to the puromycin 
compared to 5TGM1-GFP cells as higher concentrations of puromycin were required 
to kill the same number of cells. However, due to a lack of non-parametric two-way 
paired test, neither of these findings were analysed statistically.  
 
From these experiments, I was able to determine the suitable dose of puromycin for 
use in future experiments, required to select for resistant colonies in the KD 
experiments. In future experiments, I used a dose of 5.0 µg/ml of puromycin to select 
resistant colonies using the 5TGM1-GFP cells and 7.5 µg/ml of puromycin to select 
for resistant 5T33-WT cells. Both of these concentrations produced significantly 
greater cell death compared to the controls. In addition, the manufacturer 
recommended using a concentration which kills 100% of cells within four days and 
using these concentrations in my experiments a plateau in cell death was 
demonstrated with no increase in cell death after use at these concentrations.  
 
6.4.2 The effect of polybrene upon cell viability after 24 hours of treatment 
The effect of polybrene upon cell viability was tested after 24 hours of treatment at 
several different dose from 0.0 (PBS vehicle control), 2.5, 5.0, 7.5 and 10.0 µg/ml 
polybrene, by cell counting using a haemocytometer. Cell counts were used opposed 
to TO-PRO-3 staining, as polybrene acts by increasing pore sizes and upon using TO-
PRO-3 and flow cytometry it resulted in false positives for dead cells.  
 
Figure 6.2 shows the effect of polybrene upon cell number. Statistically, polybrene 
had no significant effect upon cell viability using any concentrations between 0.0 and 
7.5 µg/ml in the 5TGM1-GFP cells, however, 10.0 µg/ml of polybrene resulted in a 
significant decrease in cell number (P<0.05) after 24 hours. Polybrene however, had 
no effect upon 5T33-WT cell number after 24 hours at any dose (0.0-10.0 µg/ml). As 
polybrene had no significant effect on proliferation at any of the doses using the 
5T33-WT cells and no affect upon proliferation up to 7.5 µg/ml using the 5TGM1-GFP 
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cells, the recommended dose by the manufacturer of 5.0 µg/ml was used for future 
experiments.  
 
 
 
 
 
 
 
 
 
 
Figure 6.2: Low doses of polybrene had no effect upon 5TGM1-GFP or 5T33-WT cell proliferation 
after 24 hours. 5TGM1-GFP and 5T33-WT cells were seeded at 5x104 cells per 48 well plate in 500 µl 
complete RPMI media containing 0.0 (PBS vehicle control), 2.5, 5.0, 7.5 and 10.0 µg/ml polybrene. 
After 24 hours the number of cells in each well, at each concentration (x-axis), were counted using a 
haemocytometer (y-axis). Data was analysed statistically using a Friedman test followed by Dunn’s 
post test (P<0.05) to determine differences in cell number following polybrene treatment. Results were 
determined from four independent experiments (N=4). 
 
6.4.3 Green fluorescent protein transduction in the 5T33-WT cells as a proof of 
principal 
A lentiviral GFP transduction system was used as a proof of principal to test whether 
lentiviral transduction using these particular reagents was possible in the MCs. The 
5T33-WT cells were chosen, as we did not possess the non-GFP transduced 5TGM1 
variety.  
 
Lentiviral particles containing the GFP sequence and puromycin resistance vector 
were transduced into the polybrene (5.0 µg/ml) treated 5T33-WT cells at MOIs of 5, 
15 and 25. This was followed by puromycin selection at 7.5 µg/ml, optimised as 
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shown in Chapter VI, Section 6.3.1, Figure 6.1. The cells treated with an MOI of 5 did 
not survive following puromycin selection whereas, those treated with an MOI of 15 
and 25 were viable, indicating that transduction of the puromycin resistance vector 
was successful at the higher MOIs in the 5T33-WT cells. 
 
Flow cytometry was used to detect the success of the GFP transduction in the 5T33-
WT cells following puromycin selection (0 days). To determine the stability of the GFP 
transduction, cells were cultured in puromycin free media for 7, 14, 21 and 28 days, 
followed by flow cytometry. As shown in Figure 6.3, the 5T33-WT cells, transduced 
using both MOIs, expressed GFP after puromycin selection and also in puromycin free 
media over-time. Statistically, there were no significant differences in the expression 
of GFP over-time using MOIs of 15 and 25.  
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Figure 6.3: Green fluorescent protein was susccessfully transduced into 5T33-WT cells using lentiviral 
particles and analysed by flow cytometry. 5T33-WT cells were seeded at 2x104 cells per 96 well plate 
in 100 µl complete RPMI media containing 5.0 µg/ml polybrene and 15 or 25 MOI of lentiviral GFP 
particles. After 20 hours the cells were washed twice in complete RPMI media and resuspended in 
complete RPMI media for 72 hours, after which they were treated with 7.5 µg/ml puromycin. Once 
selected colonies appeared, 1x106 cells were taken for flow cytometry (day 0) after which the cells were 
washed twice in RPMI media and cultured in complete media in the absence of puromycin for 7, 14, 21 
and 28 days and at each time point the number of cells positive for GFP per 1x106 sample was assessed 
(y-axis) using a FACS Calibur and Cell Quest software. (x-axis). Data was analysed using a Friedman 
test followed by Dunn’s post test (P<0.05) to compare differences in GFP expression by the MOI 15 and 
25 treated cells over-time. This experiment was conducted only once but set-up in triplicate. 
 
6.4.4 Real-time PCR to establish the success of knocking-down CXCR4 and N-cad 
using the lentiviral short hair-pin RNA transduction system 
The lentiviral shRNA system was used to KD the genes for CXCR4 and N-cad. Optimum 
conditions established using the 5T33-WT cells for GFP transduction were used. The 
5TGM1-GFP cells were treated with polybrene and the lentiviral particles at MOIs 15 
and 25. This was followed by puromycin selection at 5.0 µg/ml. 
 
The KD of CXCR4 and N-cad was determined using real-time PCR. Figure 6.4 
demonstrates the effect of lentiviral shRNA transduction upon gene expression of 
CXCR4 (Figure 6.4a) and N-cad (Figure 6.4b) at MOIs of 15 and 25 after puromycin 
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selection. When the KD of CXCR4 was assessed, there was only a 24% reduction in 
CXCR4 expression at an MOI of 15 and no difference using the MOI of 25 compared 
to the control. At this stage, and after a number of attempts, it was clear that the KD 
of CXCR4 in the 5TGM1-GFP cells was unsuccessful, as assessed by real-time PCR. 
Therefore, the CXCR4 shRNA transduced cells were not used in future experiments. 
In contrast to CXCR4, when the KD of N-cad was assessed, there was a reduction in 
N-cad gene expression of 70% using the MOI of 15 and 71% using the MOI of 25, 
compared to their corresponding controls. According to the manufacturer’s 
instructions, a successful KD is achieved if the KD is greater than 60%, therefore, KD 
of N-cad was successful at both MOIs and the N-cad shRNA transduced 5TGM1-GFP 
cells were used in future experiments.  
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Figure 6.4: N-cad was 
successfully knocked-down in 
the 5TGM1-GFP cells using 
short hair-pin RNA, analysed by 
real-time PCR. 5TGM1-GFP cells 
were seeded at 2x104 cells per 
96 well plate in 100 µl complete 
RPMI media containing 5.0 
µg/ml polybrene and 15 or 25 
MOI of CTRL, CXCR4 or N-cad 
lentiviral particles. After 20 
hours, the cells were washed 
twice in complete RPMI media 
and resuspended in complete 
RPMI media for 72 hours, after 
which they were treated with 5.0 
µg/ml puromycin. Once selected 
colonies appeared, 1x106 cells 
were taken for RNA extraction, 
cDNA synthesis and real-time 
PCR for N-cad and CXCR4. a. The 
KD of CXCR4 in the 5TGM1-GFP 
cells using CTRL or CXCR4 KD 
shRNA lentiviral particles at a 
MOI of 15 or 25. b. The KD of N-
cad in the 5TGM1-GFP cells 
using CTRL or N-cad shRNA 
lentiviral particles at a MOI of 15 
or 25. Data was analysed using 
the comparative ΔΔCt method 
relative to the HK gene β2M. 
Gene expression is shown using 
the fold change (y axis) and the 
percentage of gene expression is 
above the columns. Results were 
determined from three 
independent experiments (N=3) 
and presented using the SD. 
 
 
 
 
 
 
 
a 
b 
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6.4.5 Real-time PCR to establish the stability of N-cad knock-down in cells cultured 
in puromycin free media 
Experiments were conducted to assess the stability of the N-cad KD in cells no longer 
cultured under puromycin selection. The rationale for this was to ensure that cells 
remained knocked-down for N-cad in the absence of puromycin because once 
injected in vivo they would no longer be under selection conditions.  
 
Cells were cultured in vitro for 28 days without puromycin selection, followed by PCR 
analysis. This time-point was chosen due to the length of the 5TGM1-GFP in vivo 
model. Figure 6.5 demonstrates the effect of culturing the 5TGM1-GFP N-cad KD cells 
in the absence of puromycin after 28 days, upon N-cad gene KD. N-cad expression 
was reduced by 54% using a MOI of 15 and 75% using a MOI of 25. Therefore, after 
MC growth in complete media without puromycin, cells treated with a MOI of 15 
were no longer suitably knocked-down as the reduction was no longer greater than 
60% whereas, cells treated with an MOI of 25 remained successfully knocked-down 
with a reduction greater than 60%.  
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Figure 6.5: N-cad gene expression was stably knocked-down in the 5TGM1-GFP cells cultured in the 
absence of puromycin for 28 days, analysed by real-time PCR. 5TGM1-GFP CTRL 15 and 25 and KD 15 
and 25 cells were cultured in puromycin free complete RPMI media for 28 days after which 1x106 cells 
were taken for RNA extraction, cDNA synthesis and real-time PCR for N-cad. Data was analysed using 
the comparative ΔΔCt method relative to the HK gene β2M. Gene expression is shown using the fold 
change (y axis) and the percentage of gene expression is above the columns. Results were determined 
from three independent experiments (N=3) and presented using the SD. 
 
6.4.6 Western blotting to establish the success of knocking-down N-cad using the 
lentiviral short hair-pin RNA transduction system 
To further quantify the KD of N-cad in the 5TGM1-GFP KD cells, WB was used. Figure 
6.6 shows the effect of shRNA treatment in the 5TGM1-GFP cells upon N-cad protein 
production at MOIs of 15 and 25 compared to the corresponding controls. Western 
blotting clearly shows a decrease in protein for N-cad at an MOI of 15 and 25, based 
upon band density (Figure 6.6a). When band density was analysed (Figure 6.6b) the 
N-cad KD cells at a MOI of 15 demonstrated a KD in protein of 68% whereas, the KD 
25 cells demonstrated a KD of 65%. As with the real-time PCR data, N-cad KD was 
successful as KD was greater than 60%. 
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Figure 6.6: N-cad protein was 
successfully knocked-down in 
the 5TGM1-GFP cells using 
short- hair-pin RNA, analysed 
by Western blotting. N-cad 
was knocked-down in the 
5TGM1-GFP cells using N-cad 
shRNA at a MOI of 15 and 25 
followed by selection using 5.0 
µg/ml puromycin. Once 
selected colonies appeared, 
1x107 cells were lysed in NP-40 
buffer, 20 µg protein was 
loaded into a 7% acrylamide 
gel and run by SDS-PAGE. The 
gel was transferred onto a 
nitrocellulose membrane and 
immuno-blotted for N-cad and 
the HK β-actin. a. 
Representative image of a WB 
showing the protein for N-cad 
in the CTRL 15 and 25 lysates 
compared to KD 15 and 25. 
The size of the proteins are 
shown on the left. b. Western 
blotting analysis of N-cad 
protein density, calculated 
using ImageJ software. Data 
was analysed by normalising 
the protein band density of N-
cad to the HK β-actin (y-axis) 
followed by comparative WB 
analysis to produce a 
percentage of N-cad protein 
density in 5TGM1-GFP cells 
 using the different MOIs (above graphs). Results were determined from three independent 
experiments (N=3). 
 
 
6.4.7 Western blotting to establish the stability of N-cad knock-down in cells 
cultured in puromycin free media 
To determine the stability of N-cad protein KD in the 5TGM1-GFP cells, the cells were 
cultured for 28 days in the absence of puromycin, followed by WB analysis. Figure 
6.7a demonstrates the WB of the CTRL and KD 5TGM1-GFP cells at MOIs of 15 and 
25. Visually from the WB there was a reduction in N-cad protein in the cells at both 
the MOI of 15 and 25. Figure 6.7b demonstrates the quantification of N-cad protein 
KD in the 5TGM1-GFP cells at MOIs of 15 and 25. N-cad protein was reduced by 49% 
using the MOI of 15 and 60% using the MOI of 25. Therefore, as with the real-time 
a 
b 
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PCR analysis, the cells treated with a MOI of 15 and cultured in the absence of 
puromycin for 28 days, no longer have suitable protein KD for N-cad (reduction was 
less than 60%). Whereas, those treated with an MOI of 25 were still suitably knocked-
down, with 60% reduction in N-cad protein after 28 days.  
 
Figure 6.7: N-cad protein was 
stably knocked-down in the 
5TGM1-GFP cells cultured in 
the absence of puromycin, 
analysed by Western 
blotting. CTRL 15 and 25 and 
KD 15 and 25 cells were 
cultured in puromycin free 
complete RPMI media for 28 
days. Ten million cells were 
then lysed in NP-40 buffer, 20 
µg protein was loaded into a 
7% acrylamide gel and run by 
SDS-PAGE. The gel was 
transferred onto a 
nitrocellulose membrane and 
immuno-blotted for N-cad and 
the HK β-actin. a. A 
representative image of a WB 
showing the protein for N-cad 
in the CTRL 15 and 25 lysates 
compared to KD 15 and 25. 
The size of the proteins are 
shown on the left. b. Western 
blot analysis of N-cad protein 
band density, calculated using 
ImageJ software. Data was 
analysed by normalising the 
protein density of N-cad to the 
HK β-actin (y-axis) followed by 
comparative WB analysis to 
produce a percentage of N-
cad protein density in 5TGM1- 
GFP cells using the different MOIs (above graphs). Results were determined from three independent 
experiments (N=3). 
 
6.4.8 The effect of N-cad knock-down upon cell proliferation  
In vitro experiments were conducted to determine any differences in cell 
proliferation due to the KD of N-cad in the 5TGM1-GFP KD cells transduced using an 
MOI of 15 and 25. Figure 6.8a demonstrates the growth curves produced over a 12-
b 
a 
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day period using the un-transduced 5TGM1-GFP cells and CTRL and N-cad KD cells at 
MOIs of 15 and 25, displayed using the cell number recorded at each time point. The 
growth curves displayed different stages of proliferation, whereby there was an 
initial lag phase between days 0-4, a short exponential phase between 4-8 days, 
followed by a death phase from 8-12 days. A plateau phase was not observed within 
these cells types, potentially due to how quickly the cells proliferate, which may 
result in quicker depletions in media. The doubling time was then calculated from 
the cells numbers in the exponential phase, as shown in Figure 6.8b. Statistically, 
there were no significant differences in the doubling times between the standard 
5TGM1-GFP cells, transduced control cells and N-cad KD cells. 
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Figure 6.8: N-cad knock-down 
in the 5TGM1-GFP cells had 
no effect upon cell 
proliferation. 5TGM1-GFP, 
CTRL 15 and 25 and N-cad KD 
15 and 25 cells were seeded at 
5x103 cells into a 96 well plate 
in 200 µl complete RPMI 
media without puromycin for 
the standard 5TGM1-GFP cells 
and with 5.0 µg/ml of 
puromycin for the CTRL and 
KD cells. Cells were cultured 
over a 12 day period and 
counted every 2 days using a 
haemocytometer. a. Growth 
curves using cell number (y-
axis) of the 5TGM1-GFP, CTRL 
15 and 25 and N-cad KD 15 
and 25 at each time point (x-
axis). The different phases of 
growth are separated (black-
dashed lines) and labelled 
above that phase b. The 
doubling time in the 
exponential phase of growth, 
calculated using a standard 
formula. Data was analysed 
statistically using a Kruskal-
Wallis test followed by Dunn’s 
post test to compare the 
doubling times between the 
cell types. Results were 
determined from four 
independent experiments 
(N=4). 
 
6.4.9 The effect of N-cad knock-down upon adhesion to primary osteoblast lineage 
cells in vitro 
To test the effect of knocking-down N-cad in the 5TGM1-GFP cells upon adhesion to 
primary OLCs cells in vitro, using the same methodology developed in Chapter V,  
CTRL 15, CTRL 25, KD 15 and KD 25 cells were seeded onto primary OLCs which had 
been cultured in OGM for 3, 14 and 28 days.  
 
a 
b 
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The effect of knocking-down N-cad in the 5TGM1-GFP cells upon adhesion to primary 
OLCs in vitro was compared between the CTRL 15 and KD 15 cells and the CTRL 25 
and KD 25 cells after 1 hour and 6 hours, as shown in representative fluorescent 
images in Figure 6.9 and quantitative analysis in Figure 6.10. There were no 
significant differences between the adhesion of KD 15 cells to OLCs at all time-points 
compared to CTRL 15 cells. There was however, a consistent but not significant 
reduction in the adhesion of KD 25 cells to OLCs at all time-points compared to the 
CTRL 25 cells. In addition, there was also a trend for less adhesion of CTRL 25 cells to 
OLCs across the time course with <50% adhesion on day 28 compared to day 3 but 
again these did not reach significance.  
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Figure 6.9: Knock-down of N-cad in the 5TGM1-GFP cells had no significant effect upon myeloma cell 
adhesion to primary osteoblast lineage cells in vitro. CTRL 15 and 25 and KD 15 and 25 cells were 
seeded (5x104 cells per well) on to primary OLCs cultured in OGM containing 10 mM BGP and 50 µg/ml 
asc for 3, 14 and 28 days. Adhesion after 1 and 6 hours was imaged using a Leica AF6000LX microscope 
at a 10X magnification using LAS LF software. a. i-iv. Representative images of CTRL 15 and 25 and KD 
15 and 25 adhering to 3 day differentiated OCLs after 1 hour. v-viii. Representative images of CTRL 15 
and 25 and KD 15 and 25 adhering to 3 day differentiated OCLs after 6 hours. b. i-iv. Representative 
images of CTRL 15 and 25 and KD 15 and 25 adhering to 14 day differentiated OCLs after 1 hour. v-viii. 
Representative images of CTRL 15 and 25 and KD 15 and 25 adhering to 14 day differentiated OCLs 
after 6 hours. c. i-iv. Representative images of CTRL 15 and 25 and KD 15 and 25 adhering to 28 day 
differentiated OCLs after 1 hour. v-viii. Representative images of CTRL 15 and 25 and KD 15 and 25 
adhering to 28 day differentiated OCLs after 6 hours. Scale bars represent 100 µM 
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Figure 6.10: Knock-down of N-cad in the 5TGM1-GFP cells had no significant effect upon MC 
adhesion to primary osteoblast lineage cells in vitro. Fifty thousand CTRL 15 and 25 and KD 15 and 
25 cells were seeded on to primary OLCs cultured in OGM containing 10 mM BGP and 50 µg/ ml asc 
for 3, 14 and 28 days. Adhesion after 1 and 6 hours was imaged using a Leica AF6000LX microscope at 
a 10X magnification using LAS LF software and analysed using Volocity software to determine the 
number of MCs adhering to primary OLCs per tile. i-ii. A comparison between the number of CTRL 15 
and KD 15 cells adhering to primary OLCs cultured in OGM for 3, 14 and 28 days after 1 hour (i) and 6 
hours (ii). iii-iv. A comparison between the number of CTRL 25 and KD 25 cells adhering to primary 
OLCs cultured in OGM for 3, 14 and 28 days after 1 hour (iii) and 6 hours (iv). Data was analysed 
statistically using a Mann Whitney U test (P<0.05) to determine any differences in the number of CTRL 
and KD cells adhering to primary OLCs cultured in OGM for at 3, 14 and 28 days after 1 and 6 hours. A 
Friedman test followed by Dunn’s post test was used to determine any differences in MC adhesion to 
primary OLCs at 3, 14 and 28 days cultured in OGM (P<0.05). Results were determined from four 
independent experiments (N=4). 
 
6.4.10 Flow cytometry to determine the effect of knocking-down N-cad in the 
5TGM1-GFP cells upon myeloma cell growth in vivo 
An initial pilot study was conducted to firstly, determine whether the transduced 
CTRL 25 and KD 25 cells would home and grow in the BM of injected mice, as 
extensive time in culture could reduce tumourgenicity in these cells. Secondly, it was 
conducted to determine whether there was any difference in tumour load between 
the CTRL and KD groups.  
ii i 
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The standard 5TGM1-GFP cells, CTRL 25 or KD 25 cells were injected into 
C57BL/KaLwRij mice and all groups were sacrificed when one of the mice became ill, 
which was at 25 days P-I in the 5TGM1-GFP injected group. The left and right femora 
were dissected from each mouse and the BM was isolated to detect GFP positive 
tumour cells by flow cytometry. Figure 6.11 shows representative flow cytometry 
profiles of the BM from mice injected with standard 5TGM1-GFP cells, CTRL 25 and 
KD 25 cells. 
 
The GFP positive tumour cell number was assessed by flow cytometry, as shown in 
Figure 6.11b. The data demonstrated a higher number of GFP positive tumour cells 
in the BM of the 5TGM1-GFP injected animals (32.90% ± 3.7, data not shown) 
compared to the CTRL 25 injected animals (0.6% ± 0.59) and GFP positive KD 25 cells 
were not detected in the animals injected with KD 25 cells (0.01% ± 0.00) using flow 
cytometry. Interestingly, there was a significant reduction in KD 25 cells present in 
the BM of mice compared to CTRL 25 cell injected animals (P<0.05).  
 
Tumour take was assessed using a Fisher’s exact test, to compare the number of mice 
and number of bones (as two femurs were used) with positive tumour burden 
between the groups. Bones with more than 0.05% GFP positive cells were deemed 
positive for tumour burden. As shown in Figure 6.11c, each mouse in the 5TGM1-GFP 
group was positive for GFP (100%), in the CTRL 25 injected group 4 out of 6 mice had 
GFP positive tumour burden (67%) and no mice in the KD 25 demonstrated tumour 
burden greater than 0.05% (0%). When compared using the Fisher’s exact test there 
was a significant difference in the number of mice with tumour in the 5TGM1-GFP 
injected group compared to the KD 25 injected group (P<0.0048. However, there was 
no significant difference between the 5TGM1-GFP and CTRL 25 injected group 
(P<0.4667) or between the CTRL 25 and KD 25 groups (P<0.0606). 
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Figure 6.11: Mice injected with N-cad KD 25 cells had less tumour and reduced tumour take 
compared to mice injected with CTRL 25 cells, analysed by flow cytometry. 5TGM1-GFP (N=4), CTRL 
25 (N=6) and N-cad KD 25 (N=6) cells (2x106) were injected (IV) into 11 week old C57BL/KaLwRij mice. 
At 25 days P-I (when the first mouse developed hind limb paralysis) all mice were sacrificed. The left 
and right femora were dissected and the BM was isolated. Flow cytometry was used to quantify the 
number of GFP positive cells in the BM using a FACS Calibur and Cell quest software. a Representative 
flow cytometry plots demonstrating the GFP positive tumour in the 5TGM1-GFP (i), CTRL 25 (ii) and KD 
25 (iii) injected mice. b. The percentage of GFP positive tumour burden (in R1 of the FACS plot) in mice 
injected with 5TGM1-GFP, CTRL 25 and KD 25 cells. c. The percentage of tumour take per mouse, in 
mice injected with 5TGM1-GFP, CTRL 25 and N-cad KD 25 cells. d. The percentage of tumour take per 
femora, in mice injected with 5TGM1-GFP, CTRL 25 and N-cad KD 25 cells. Data was analysed using a 
Mann-Whitney U test to compare tumour burden between mice injected with CTRL 25 and N-cad KD 
25 cells. A Fisher’s exact test was used to compare the number of mice and femora with positive tumour 
burden between the 5TGM1-GFP, CTRL 25 and N-cad KD 25 injected mice. Each mouse was a biological 
replicate. 
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When the number of femora, which were positive for GFP was calculated, each 
femora in the 5TGM1-GFP injected mice group was positive for GFP positive (100%), 
6 out of 12 femora were positive for GFP in the CTRL 25 groups (50%) and again no 
bones were positive for GFP in the KD 25 group (0%), as demonstrated in Figure 
6.11d. Using the Fisher’s exact test there were significantly less femora which were 
positive in the CTRL 25 (P<0.0445) and KD 25 (P<0.0001) injected mice compared to 
the 5TGM1-GFP injected mice. There were also significantly less femora which were 
positive for GFP in the KD 25 injected group compared to the CTRL 25 injected group 
(P<0.0137). 
 
6.4.11 IHC to determine the effect of knocking-down N-cad in the 5TGM1-GFP cells 
upon myeloma cell growth in vivo 
Immunohistochemistry was also used to assess tumour burden. Figure 6.11a 
demonstrates representative images of histological sections of tibiae stained for 
CD138, taken from mice injected with CTRL 25 and N-cad KD 25 injected mice. 
Discrete tumour colonies were not observed in any of the KD 25 mice tibiae, though 
some CD138 staining was present in some of the bones as shown in Figure 6.12aiii-
iv. However, the staining present was not discrete membranous staining as observed 
in the CTRL 25 sections. In addition, all 5TGM1-GFP injected mice had fully infiltrated 
bones (data not shown), which correlated with the flow cytometry shown in Figure 
6.12. 
 
When tumour colony area and number was analysed using the Image Scope software 
there was interestingly, a significant decrease in tumour area in mice injected with 
N-cad KD cells compared to CTRL injected mice (P<0.0043) (Figure 6.12b). However, 
the 5TGM1-GFP injected mice had fully infiltrated bones with between 80.78-99.77% 
(colony area) (data not shown), compared to the low percentage in the CTRL 25 
injected mice. There was also a decrease in the number of colonies present in the BM 
of mice injected with CTRL 25 or KD 25 cells (Figure 6.12c) but this failed to reach 
significance. 
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When the number of mice which demonstrated positive tumour burden by CD138 
staining (positive tumour burden was classed as colony area greater than 0.2%) were 
compared between the groups using a Fisher’s exact test, significantly more mice 
(expressed as a percentage) in the CTRL 25 group had tumour compared to the KD 
25 group (P< 0.0152), shown in Figure 6.12d. 
 
 
 
 
 
 
  
 
 
 
 
  
 
Figure 6.12: Mice injected with N-cad KD 25 cells had significantly less tumour compared to mice 
injected with CTRL 25 cells, analysed by IHC. Two million CTRL 25 (N=6) and KD 25 (N=6) cells were 
injected (IV) into 11 week old C57BL/KaLwRij mice. At 25 days P-I (when the first mouse developed hind 
limb paralysis) all mice were sacrificed. The left tibia was dissected and processed for histology by 
fixation for 24 hours in 4% PFA, decalcification for 2 weeks in 0.5% PFA/0.5 M EDTA followed by 
dehydration and processing into wax. Sections were cut (3 µm) and stained by sandwich IHC for CD138. 
Sections were analysed using an Aperio Scan Scope slide scanner and Image Scope software to 
determine tumour colony area and number per mm2 of BM. a Representative images of CD138 stained 
sections of tibiae from mice injected with CTRL 25 cells (i-ii) and KD 25 cells (iii-iv). b. The percentage 
of total colony area in mice injected with CTRL 25 and KD 25 cells c. The number of tumour colonies 
present in mice injected with CTRL 25 and KD 25 cells. d. Tumour take in mice injected with CTRL 25 
and N-cad KD 25 cells. Data was analysed using a Mann-Whitney U test to compare colony area and 
number between the groups and a Fisher’s exact test was used to compare the number of mice with 
tumour between the CTRL 25 and KD 25 injected mice. Each mouse was a biological replicate. 
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6.4.12 Micro-computed tomography to determine the effect of knocking-down N-
cad in the 5TGM1-GFP cells upon bone parameters in vivo  
To assess any differences in bone parameters between the groups µCT was used. 
Figure 6.13 demonstrates the percentage of trabecular bone volume (BV/TV), 
trabecular number (tb.n) and trabecular thickness (tb.th) for the tibiae of mice 
injected with CTRL 25 and KD 25 cells. Statistically, there were no significant 
differences in percentage BV/TV, tb.n and tb.th between the CTRL 25 and KD 25 
injected mice. However, there did seem to be a slight trend whereby the N-cad KD 
25 cell injected mice had slightly higher values for the percentage BV/TV and tb.n, 
compared to the CTRL 25 injected mice.  
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Figure 6.13: There were no significant 
differences in bone parameters 
between mice injected with CTRL 25 
cells compared to mice injected with N-
cad KD 25 cells The right tibiae from 
mice injected with 2x106 CTRL 25 (N=6) 
and KD 25 (N=6) cells were dissected, 
fixed in 10% formalin and analysed by 
µCT analysis using a SkyScan 1172 at 50 
Kv, 200 µA, 0.5 mm aluminium filter and 
pixel size of 4.3 µm2. Images were 
reconstructed using N-Recon Software. 
Trabecular bone 0.2 mm below the 
growth plate was analysed using Ct-an 
and Batman software. a. Representative 
images of cross sectional tibiae taken 
from mice injected with CTRL 25 cells (i) 
and KD 25 cells (ii). b. Percentage BV/TV. 
c. Tb.th. d. Tb.n. Data was analysed 
using a Mann-Whitney U test (P<0.05) 
to compare bone parameters between 
the CTRL 25 and N-cad KD injected mice. 
Each mouse was a biological replicate. 
 
 
Lesion number and area were calculated using ImageJ software, as shown in Figure 
6.14. There was a trend towards a reduction in lesion number and area in mice 
b ai 
ii 
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injected with the KD 25 cells compared to the CTRL 25 cells however, this did not 
reach significance. 
 
 
 
 
 
 
 
 
Figure 6.14: There were no significant differences in lesion number or area between mice injected 
with CTRL 25 or N-cad KD 25 cells. The right  tibia from each mouse injected with 2x106 CTRL 25 (N=6) 
and KD 25 (N=6) cells was dissected, fixed in 10% formalin and analysed by µCT analysis using a 
SkyScan 1172 at 50 Kv, 200 µA, 0.5 mm aluminium filter and pixel size of 4.3 µm2. Images were 
reconstructed using N-Recon Software and ImageJ software was used to assess lesion number and 
area. a. Lesion number. b. Lesion area. Data was analysed using a Mann-Whitney U test to determine 
differences in lesion number and area between mice injected with CTRL 25 and N-cad KD 25 cells. Each 
mouse was a biological replicate. 
 
6.5 Discussion 
 
The aims of this chapter were to determine the role of HSC niche molecules in MC 
adhesion to osteoblastic cells in vitro as well as tumour growth in vivo. To achieve 
these aims, lentiviral particle shRNAs were used to KD HSC molecules in the 5TGM1-
GFP cells. Before transduction, optimisation of the technique was conducted to 
determine the optimum dose of puromycin and polybrene and also a suitable MOI 
of virus using GFP transduction.  
 
Firstly, puromycin concentrations were determined by conducting dose titration 
killing curves using TO-PRO-3 and flow cytometry. The final concentration of 
b a 
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puromycin used for the 5TGM1-GFP cells was 5.0 µg/ml and 7.5 µg/ml was used for 
the 5T33-WT cells. These concentrations produced significantly more cell death 
compared to the control and they were also the lowest doses required to kill the 
maximum amount of cells within four days, as suggested by the manufacturer. The 
potency of puromycin seemed to vary depending on the cell type, as shown by the 
higher dose required to kill the maximum amount of 5T33-WT cells. However, this 
higher dose was also used in previous studies where Glick et al (172) used puromycin 
at 7.0 µg/ml for the 5T33-WT cells. The difference between the sensitivity of MCs to 
puromycin has not previously been reported, but it was interesting that the 5TGM1-
GFP cells seemed to be more sensitive to puromycin compared to the 5T33-WT cells. 
 
Polybrene optimisation was then conducted by assessing differences in cell number 
following polybrene treatment after 24 hours. As there was no significant effect upon 
cell number following treatment, with the exception of 10.0 µg/ml using the 5TGM1-
GFP cells, 5.0 µg/ml was used as advised by the manufacturer. Further experiments 
could have been investigated to determine long-term effects of polybrene treatment 
although, the polybrene was only required to be incubated with the cells for 24 hours 
and the manufacturer reported no effects of toxicity at the 5.0 µg/ml dose. 
 
Following puromycin and polybrene optimisation, GFP transduction was conducted 
in the 5T33-WT cells as a proof of principal that the transduction technique would 
work in the MCs. Green fluorescent protein transduction was successful at MOIs of 
15 and 25 but not at a MOI of 5 due to a lack of resistance to the puromycin 
treatment. This implies that the lentiviral particles were either not successfully 
transduced or that the number of puromycin resistance gene sequences integrated 
into the host genome using a MOI of 5 was not sufficient to incur resistance to 
puromycin, resulting in cell death. Therefore, this suggests that at the higher doses 
of virus, an adequate amount of the puromycin resistance gene was integrated into 
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the genome to inhibit the effect of puromycin on protein synthesis, preventing cell 
death. 
 
These optimal conditions were used to KD N-cad and CXCR4 in the 5TGM1-GFP cells. 
N-cad was chosen due to its novelty in MM, as previous data is limited. CXCR4 was 
chosen as previous studies had largely focussed upon the role of CXCR4 in homing, 
but not in the context of a myeloma niche. Previous studies have also used 
compounds rather than KDs to block all CXCR4 positive cells, whereas, the KDs used 
here, were specific for the MCs. 
 
N-cad was successfully knocked-down at MOIs of 15 and 25 whereas, CXCR4 was 
slightly knocked-down at an MOI off 15 (24%) and there was no KD at all using a 
higher MOI of 25. From these experiments, it can be concluded that increasing the 
MOI did not increase CXCR4 KD. Therefore, increasing the numbers of sequence 
insertions into the host’s genome made no difference, implying that the shRNA 
sequences used were not effective at knocking down the gene. The lentiviral particles 
contained three different shRNA constructs, therefore, three different siRNAs would 
bind to three different sequences on the mRNA for CXCR4, increasing the probability 
that one sequence would result in the degradation of CXCR4 mRNA. However, in 
these experiments these sequences were not effective at knocking-down CXCR4. To 
improve this in the future, custom made shRNAs may be required with particular care 
to account for splice variants, which do occur within murine CXCR4. It may also help 
to use a different promoter such as the U6 rather than the H1, which was reported 
to be more effective (188). 
 
As the real-time PCR for N-cad was successful, further validation was conducted using 
WB, which confirmed the results found in the real-time PCR. Western blotting 
showed that there was a protein KD of 68% and 65% in the 5TGM1-GFP cells at MOIs 
of 15 and 25, respectively. However, when the cells were cultured in the absence of 
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puromycin this resulted in some loss of N-cad KD in the KD 15 cells using both real-
time PCR and WB whereas, using the KD 25 cells the gene and protein KD was stable. 
This implies that perhaps the amount of shRNA incorporated into the host DNA at 
the MOI of 15 was not sufficient to sustain the KD or that the original selection 
process was not selective enough, resulting in the expansion of cells without the 
shRNA, therefore, reducing the percentage of population KD.  
 
To confirm any effect upon proliferation in the N-cad KD cells, growth curves were 
conducted using the CTRL and N-cad KD cells. There were no significant differences 
in proliferation between the CTRL 15 and KD 15 and CTRL 25 and KD 25 cells with 
regards to doubling time. This is supported by Groen et al (206) who found that 
inhibition of N-cad using an antibody or by knocking-down N-cad in NCI-H929 MCs 
had no effect upon proliferation. Whereas, in prostate cancer, antibody inhibition of 
N-cad using 1H7 and 2A9 clones resulted in a significant reduction in PC3 and LNCAP-
C1 cell proliferation (203). However, these cells are highly adherent compared to the 
MCs, which may influence their requirement for N-cad signalling as a stimulant for 
proliferation. 
 
To test the effect of N-cad KD upon MC adhesion to osteoblastic cells, co-culture 
experiments were conducted using the conditions from Chapter V. Knock-down of N-
cad in the 5TGM1-GFP did not significantly impair their ability to adhere to primary 
OLCs cultured in OGM for 3, 14 and 28 days. There was however, a trend decrease in 
adhesion of KD 25 cells to primary OLCS at each of the time points compared to the 
CTRL 25 cells. Whereas, there was no obvious difference between the CTRL 15 and 
KD 15 cells. The difference between the MOI 15 and 25 cells may be due to the 
stability of the KD in the cells. As identified previously, N-cad KD using the MOI of 15 
was unstable compared to the MOI of 25 and therefore, the increase in N-cad protein 
could remove any inhibitory effect in the adhesion to the primary OLCs. As only a 
trend was observed towards a decrease in the adhesion of the KD 25 cells to the 
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primary OLCs this might imply that the N-cad is not the sole molecule responsible for 
MC adhesion to osteoblastic cells. Other molecules previously implicated in this 
interaction are; Notch-1 and Jag-1 (described for their role in osteoblast adhesion), 
intercellular adhesion molecule (ICAM) 1 (expressed by osteoblastic cells) (272) and 
LFA-4 (expressed by MCs) (273) and vascular cell adhesion molecule-1 (VCAM-1) 
(expressed by BM stromal cells) (274) and VLA-4 (expressed by MCs) (275). 
 
A lack of significance between N-cad KD and controls may also be due to the 
percentage of N-cad KD in the cells. N-cad has not been knocked-out but knocked-
down and using RT-PCR and WB it is uncertain whether 71% of cells are knocked-
down or whether protein within each individual cells is knocked-down by 71%. This 
therefore, means that N-cad is still present to a certain extent and therefore, even 
low levels may result in adhesion of MCs to the primary OLCs. However, to disprove 
this point, a previous paper has shown a significant reduction in the adhesion of N-
cad KD NCI-H929 MCs to C3H10T1/2 cells (206). Although, as the C3H10T1/2 cells are 
MSCs as opposed to preosteoblasts or mature osteoblasts, this could be a potential 
explanation as to why these results differ from my own. As stated previously in 
Chapter V this technique may also not provide reliable results due to elements within 
the technique, which may need further optimisation, such as the wash steps, cell 
numbers and types of media or FBS used. 
 
An initial pilot study was conducted, firstly, to test whether the CTRL 25 and KD 25 
cells, which had been cultured extensively in vitro, still homed and grew in the BM 
and secondly, to determine whether there was a difference in tumour burden 
between the mice injected with the KD 25 cells compared to those injected with the 
CTRL 25 cells. CTRL and KD 25 cells were used due to their high level of gene and 
protein KD and low gene and protein KD variability when in puromycin free 
conditions compared to the CTRL 15 and KD 15 cells. The flow cytometry data 
confirmed that the CTRL 25 and KD 25 cells cultured extensively in vitro did not either 
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home to the bone as effectively or grow as quickly in vivo compared to the normal 
5TGM1-GFP cells. This was shown by higher tumour take and tumour burden in the 
5TGM1-GFP injected mice compared to the CTRL 25 and N-cad KD 25 injected 
animals. As stated previously this was expected, as the 5TGM1-GFP cells require in 
vivo passaging to remain tumourgenic.  
 
The aspect of the data that was of most interest was the difference in tumour take 
and tumour burden between the CTRL 25 and KD 25 injected mice by flow cytometry 
and IHC. However, as stated previously, this was an initial pilot study and therefore, 
may need to be repeated to assess reproducibility. Based on the flow cytometry data 
there was a significant reduction in tumour burden in the mice injected with the KD 
25 cells compared to those injected with the CTRL 25 cells. When the number of mice 
with tumour were compared, 67% of the mice in the CTRL 25 group were positive 
compared to 0% of mice injected with KD 25 cells. Although, this difference was not 
significant as two mice in the CTRL group did not had have tumour. However, when 
the number of bones with tumour rather than per mouse were analysed, (as two 
femora per mouse were analysed), significantly fewer femora in the KD 25 injected 
group were positive for tumour compared to the CTRL 25 group. In addition, the IHC 
staining supported the flow cytometry results in the pilot study. Firstly, full 
infiltration of the BM was observed in all of the 5TGM1-GFP injected mice by CD138 
staining. In the CTRL 25 injected mice, distinct colonies were visualised whereas, in 
the KD 25 injected mice, only small less discrete colonies were observed. This slightly 
contradicts the flow cytometry data where no GFP positive tumour cells were present 
in the KD 25 injected mice. However, flow cytometry can be limiting, firstly due to 
the way the BM is flushed and secondly due to the sensitivity of detecting low 
numbers of GFP by the machinery and the software. Despite differences in 
techniques, both the flow cytometry and IHC results suggested that there was a 
significant reduction in tumour burden in the KD 25 injected mice compared to the 
CTRL 25 injected mice and there was also a trend towards fewer tumour colonies 
present in the KD 25 injected mice by IHC. These data may potentially suggest a role 
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for N-cad with regards to MC homing, MC survival in the BM following injection as 
well as MC proliferation, though the latter may be questionable as no proliferative 
effects were observed in the N-cad KD cells in vitro, though factors in vivo may affect 
this. 
 
Micro-CT was also conducted to examine the effect of N-cad KD upon bone disease, 
as the 5TGM1-GFP model results in lytic lesions in the mice. When comparing the 
CTRL 25 and KD 25 trabecular bone parameters, there were no significant differences 
between these groups. However, there was a slight trend towards an increase in the 
BV/TV, trabecular number, lesion number and lesion area in the KD 25 injected 
animals compared with the CTRL 25 group, which correlated with tumour burden. 
However, as little tumour burden was present in the mice it was unsurprising that no 
significant differences were found, as there may have not been sufficient tumour 
present to induce increases in osteoclastic bone resorption and decreases in 
osteoblastic bone formation. In addition, as a naïve mouse group was not used in this 
study there was also no comparator for normal bone parameters, therefore, whether 
either group of mice had evident bone disease was undetermined.  
 
The data in this chapter, particularly with regards to the pilot in vivo study, provides 
evidence in support of the hypothesis that N-cad is important for myeloma 
development. From these studies, the precise role of N-cad in myeloma development 
is unknown but these experiments may imply that N-cad is involved in MC homing, 
survival and/or proliferation; however, due to poor tumour burden and low N 
numbers these findings are not completely conclusive. Currently, very little evidence 
is available to determine the role of N-cad in MM and no studies have looked at the 
effect of knocking N-cad down in MM upon tumour burden at the end-stage of 
disease. Groen et al (206) has however, examined the effect of knocking-down N-cad 
in NCI-H929 cells upon the number of MCs in the BM after 3 days post-injection and 
found that fewer N-cad KD NCI-H929 cells were present in the bone and more of 
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these cells were in the circulation compared to control NCI-H929 cells. Therefore, N-
cad may be important for homing of MCs to the BM as well as attachment to a MC 
niche and MC survival. In addition, Sadler et al (207) found that inhibition of MC 
adhesion to stromal cells in vitro using an anti-N-cad antibody resulted in increased 
proliferation implying that MC attachment to stromal cells via N-cad is important for 
control of cell proliferation and cell cycle. However, this is contradictory to the 
experiments conducted in this chapter, which demonstrated reduced TB in mice 
injected with N-cad KD cells. However, as stated previously it is unknown as to 
whether the reduction in TB is due to reduced MC homing, survival or proliferation 
in the BM post-injection, and also as this is a KD not KO, cells arriving in the BM maybe 
N-cad positive and so no effect on proliferation would be observed. In addition, the 
experiment conducted by Sadler et al was conducted in vitro, and therefore, the 
behaviour of these cells in vivo may not be comparable. 
 
Previous studies also determined that N-cad was an important molecule with regards 
to cancer cell growth and metastasis as described in the introduction. Tanaka et al 
(203) demonstrated that inhibition of N-cad using two different monoclonal 
antibodies significantly inhibited PC3 and LAPC9-CR (prostate cell lines) invasion, 
proliferation and attachment to fibronectin in vitro and significantly reduced tumour 
volume of both PC3 and LAPC9-CR subcutaneous tumours as well as preventing 
metastasis to the lymph nodes in vivo. N-cad expression in breast cancer cell lines 
including MDA-MB-435, SUM-159 cells and MCF-7 cells was associated with higher 
motility and invasion in vitro (204, 268) and increased metastasis in vivo (268). N-cad 
expression has also been implicated in melanoma whereby inhibition of N-cad in 
melanoma cell lines using an inhibitory antibody reduced adhesion and migration to 
fibroblasts in vitro (270).  
 
In conclusion, I have been able to optimise a technique for the successful KD of one 
of the HSC niche molecules in the 5TGM1-GFP cells. However, the effect of the KD of 
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N-cad in the MCs with regards to adhesion to osteoblasts and its effect upon in vivo 
are still not completely conclusive. Therefore, further experiments are required to 
provide more conclusive evidence for the role for N-cad in an osteoblastic niche in 
bone using either the KD cells developed here or an N-cad inhibitor.  
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7.1 General discussion 
 
To date, MM is an incurable disease whereby only 5% of patients survive 5 years post-
diagnosis. It results in severe disorders such as renal failure, lytic bone disease and 
susceptibility to infection, which in turn cause morbidity. It has been speculated that 
high rates of patient relapse in MM patients are due to a chemoresistant population 
of myeloma cells, which are able to survive even after treatment, rendering current 
chemotherapeutic strategies ineffective at completely eradicating disease. 
Therefore, new treatment strategies are required in an attempt to provide curative 
treatments. In addition, preventative strategies are required to stop the progression 
of MGUS to symptomatic myeloma and asymptomatic to symptomatic myeloma, 
which have a 1% chance within one year post-diagnosis, and 10% chance within five 
years post-diagnosis, of progression respectively (276).  
 
Due to the potential survival of chemoresistant cells in patients after treatment, this 
led to the hypothesis that MM cells exist in a niche in the BM, which determines their 
proliferation, and promotes survival upon treatment with chemotherapeutic agents. 
This rationale was based upon previous studies, which identified a HSC niche in the 
BM. This HSC niche firstly; demonstrated the requirement of osteoblastic cells for 
HSC survival in the BM by a series of studies which reduced (71, 78, 79) or increased 
(81, 82) osteoblastic cell number using murine transgenic studies and hormone 
treatments. Secondly; HSCs seemed to localise and adhere specifically to osteoblastic 
cells (83) as well as endothelial cells (88, 89, 277) in vivo, which seemed a critical 
interaction for their survival. In addition, HSCs adhering to osteoblastic cells in the 
BM resided in a quiescent state but once activated began to proliferate (73, 142). 
 
To firstly provide evidence of MM cell localisation to osteoblastic cells in a similar 
way to HSCs, several in vivo studies were conducted by members of the myeloma 
research group at The University of Sheffield and The Garvan Institute, Sydney 
Australia (Paper in submission “A Novel Method for Longitudinal Tracking of Dormant 
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Cancer Cell Activation in the Skeleton as a Platform for Drug Discovery”). 
C57BL/KaLwRij mice were injected with 1,1′-dioctadecyl-3,3,3′,3′-
tetramethylindodicarbocyanine perchlorate (DiD) labelled 5TGM1-GFP cells and 
after 18 and 72 hours single labelled MCs were found in close proximity to bone. 
However, over a time course, the majority of cells moved away from the bone surface 
and began to proliferate whereas, only single un-dividing DiD labelled cells, which 
were potentially quiescent, were still adjacent to the bone surface. Therefore, these 
data may imply that the MCs that were in contact with bone were dormant, whereas 
those that were further away from the bone were actively dividing. However, 
without staining these cells with cell cycle dyes it is difficult to conclude whether 
these cells are actively dividing or quiescent. In support of this work, Chen et al (70) 
found that PKH26 labelled MCs were found in close proximity to osteoblastic cells in 
the bone and a higher frequency of PKH26 positive cells were present in osteoblastic 
niches compared to vascular and splenic niches in vivo. In addition, PKH26 positive 
cells were more resistant to chemotherapeutics in vitro compared to PKH26 negative 
MCs. Therefore, this supports the hypothesis that MCs reside in osteoblastic niches, 
which may result in MC chemoresistance, potentially mediated by cellular 
quiescence. 
 
Within my experiments in this thesis, I conducted in vitro experiments to determine 
whether the 5TGM1-GFP cells adhered to primary OLCs, as this again would provide 
evidence for the adhesion of MCs to osteoblastic cells (Chapter V). A large proportion 
of 5TGM1-GFP cells adhered to primary OLCs in vitro and the adhesion was highest 
when the OLCs had been differentiated for 3 days and 14 days compared to 28 days. 
This suggested that early primary OLCs may be more important for MM cell adhesion 
as described by Zhang et al (83) and Xie et al (84) in the HSC niche.  
 
To determine what molecule interactions may result in the adhesion of MM cells to 
osteoblastic cells, the expression of the HSC niche molecules and ligands was 
analysed using 5T33-WT, 5T33-GFP and 5TGM1-GFP cells. In addition, the expression 
of complementary ligands was explored using murine primary OLCs and MC3T3-E1 
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osteoblastic cells. It was hypothesised that the MM cells expressed the same 
repertoire of molecules as the HSCs and that their complementary ligands were 
expressed by osteoblastic cells. 
 
Within my studies, I determined the expression of the HSC niche molecules; CXCR4, 
Notch-1, Tie-2 and N-cad, and the complementary ligands; CXCL12 and Jag-1 by the 
MCs cultured in vitro (Chapter III), collectively using RT-PCR (endpoint and real-time), 
flow cytometry and IF. In addition, BM-derived ex vivo 5T33-GFP and 5TGM1-GFP 
cells also expressed the HSC niche molecules CXCR4, Notch-1, Tie-2 and 
complementary ligands CXCL12 and Jag-1 by flow cytometry, and BM sections 
infiltrated with 5TGM1-GFP cells also expressed CXCR4 and N-cad in vivo (Chapter 
IV). In addition, the expression of each of these molecules (excluding CXCR4) was 
reduced in the BM-derived 5TGM1-GFP at the end-stage of disease compared to the 
in vitro cells whereas, the protein frequency of all HSC niche molecules increased in 
the BM-derived 5T33-GFP cells compared to the 5T33-GFP cells cultured in vitro. 
Therefore, these data suggest that the expression of these molecules may be 
important in disease progression. 
 
The expression of these molecules by MCs is supported by a variety of studies. CXCR4 
was expressed by MC lines (170, 193-195) and primary patient MCs (195, 221) and 
its ligand CXCL12 was also expressed in human MC lines and patient samples (215). 
Notch-1 was expressed by several human MC lines (197) and patient MCs (198) and 
expression of Jag-1 was demonstrated in patient MC samples (198, 214). Tie-2 was 
also present in human MC lines and patient samples (201) as was Ang-1 (201). N-cad 
expression was also determined in patient MM cells (205) and the human MC lines 
(206, 207). 
 
I also analysed the expression of the complementary ligands CXCL12, Jag-1, Ang-1 
and N-cad, as well as the HSC niche molecules CXCR4, Notch-1 and Tie-2 using the 
MC3T3-E1 cells and primary OLCs (Chapter III). Each cell type expressed each 
complimentary ligand as well as the HSC niche molecule Notch-1 and the primary 
OLCs also expressed Tie-2. When the primary OLCs were cultured with OGM (Chapter 
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V), there were no significant differences in the expression of the HSC niche molecules 
or ligands, though there was a trend towards a decrease in Jag-1 and N-cad 
expression over-time. Therefore, differentiation of these cells did not significantly 
affect HSC niche and ligand expression, though as stated previously without the 
suitable controls this is difficult to conclude.  
 
The expression of each of the complementary ligands by osteoblastic cells was 
supported by previous studies. CXCL12 was expressed by human and murine 
osteoblast cell lines (111, 196); Jag-1 was expressed by human primary BM stromal 
cells (199) and the MC3T3-E1 osteoblastic cells (200); Ang-1 was expressed by murine 
primary osteoblasts (85); and N-cad was expressed by several stromal and osteoblast 
cell lines (206, 208, 219).  
 
Taken together, these studies supported the hypothesis that MCs express the same 
repertoire of niche molecules as HSCs and that their complementary ligands are 
expressed by osteoblastic cells. However, the function of each of these molecules in 
a MM cell niche was unknown. Therefore, to determine the role of these molecules 
I attempted to KD both CXCR4 and N-cad in the 5TGM1-GFP cells, with a successful 
KD of both gene and protein using N-cad shRNA (Chapter VI). As stated previously, 
these molecules were chosen, as little is known about the role of N-cad in MM, 
particularly as a candidate molecule in a MC niche. Whereas, CXCR4 has been highly 
studied with regards to mobilisation of MCs as well as other cell types, however, it 
has not been implicated specifically in an osteoblastic niche in MM. In addition, 
previous pre-clinical and clinical studies have focussed on inhibiting CXCR4/CXCL12 
signalling using antibodies and inhibitors such as AMD3100, which target all CXCR4 
positive cells, however, previous studies have not targeted CXCR4 specifically on the 
MCs, which the gene KD would achieve.  
 
I then determined the effect of knocking down N-cad in the 5TGM1-GFP upon 
adhesion to primary osteoblastic cells in vitro (Chapter VI). In these experiments a 
consistent trend towards a reduction in the adhesion of KD 25 cells to OLCs at all 
time-points compared to the CTRL 25 cells was observed, however this did not reach 
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significance. This trend is supported by other studies which showed that KD of N-cad 
significantly reduced MC adhesion to osteoblastic cells however,  this was using the 
human MC line NCI-H929 and C3H10T1/2 stromal cells (206). My results may imply 
that N-cad is not the only molecule responsible for MC adhesion to osteoblastic cells 
and as this is a KD of protein rather than KO, residual N-cad expression may still result 
in myeloma adhesion to osteoblastic cells.  
 
An initial in vivo pilot study was then conducted to test firstly, whether extensive 
growth of the CTRL 25 and KD 25 in vitro would affect their ability to home and grow 
in the BM and secondly to determine any differences in tumour burden in mice 
injected with CTRL and N-cad KD cells. I hypothesised that the cells that had been 
cultured extensively in vitro would not home and/or grow at the same rate as the 
standard 5TGM1-GFP cells. I also hypothesised that tumour burden would be 
reduced in the mice injected with the KD 25 cells compared to CTRL cells. In support 
of these hypotheses, mice that had been injected with either the CTRL 25 or KD 25 
cells, had significantly less tumour take (determined by flow cytometry and IHC) 
compared to the mice injected with the standard 5TGM1-GFP cells. Interestingly, to 
support the second part of the hypothesis, mice injected with the KD 25 cells had no 
GFP positive tumour determined by flow cytometry and a significant reduction in 
tumour area compared to mice injected with CTRL 25 cells. In addition, mice injected 
with the KD 25 cells also had a significantly lower take rate and fewer bones with 
tumour present compared to CTRL 25 injected mice using flow cytometry and IHC. 
This pilot study therefore, highlights the potential importance of N-cad for myeloma 
tumour development in the BM. However, as stated previously these results are not 
entirely conclusive due to poor tumour take and low N numbers. These results are 
however, supported by previous studies, which have explored the role of N-cad in 
other cancers such as breast, prostate and melanoma. In previous studies, N-cad 
expression was important for prostate and breast cancer cell invasion and metastasis 
(203, 204, 268), and interventions of N-cad inhibited tumour cell growth and 
metastasis in prostate and melanoma (203, 278). In addition, Groen et al (206), 
demonstrated that N-cad KD in the NCI-H929 MCs resulted in fewer cells homing to 
and/or surviving in the BM in vivo, and also found a higher number of these cells 
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present in the circulation. Therefore, N-cad may potentially be important for trans-
endomigration or adhesion to osteoblastic cells in the BM  and subsequent survival. 
 
As this was a pilot study, this experiment needs to be repeated to confirm the results. 
In addition, future studies need to focus on the localisation of MCs with the 
hypothesis that KD of N-cad will prevent MC attachment to an osteoblastic niche in 
the BM, which is required for MC development. In this pilot study, only the latter 
time points of active cell growth were determined rather than the initial homing and 
colonisation of cells to the bone. Therefore, future studies also need to concentrate 
on the early time points of disease to determine differences in the number of cells 
originally homing to the bone and also assessing their localisation to osteoblastic cells 
at that time.  
 
Other unanswered questions, which this study does not address is the potential for 
N-cad positive cells to promote chemoresistance in MCs. In addition, N-cad also 
seems to play an important role in epithelial-mesenchymal transition, where the 
switching between E-cadherin (E-cad) and N-cad determines the proliferative and 
metastatic state of the cells. In prostate cancer, high N-cad expression was associated 
with low E-cad expression in prostate cancer biopsies, which correlated with 
increasing severity of the prostate cancers (228, 279, 280) which were also associated 
with poorer patient outcome. In breast cancer, a reduction of E-cad staining in 
patient breast biopsies also correlated with increased severity of disease (281) and, 
several breast cancer cell lines which were positive for N-cad but had no evidence of 
E-cad expression were more invasive in vitro (204), suggesting again that cadherin 
switching may be important for tumour invasion and metastatic potential. Therefore, 
this suggests that the relationship between E-cad and N-cad may also be an 
important mechanism potentially in MM, where E-cad expression may precede N-
cad expression in quiescent tumour cells after which they may be activated resulting 
in cadherin switching from E-cad to N-cad triggering proliferation. Therefore, it would 
be of interest to determine whether a cadherin switch occurs throughout the 
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different stages of myeloma progression and whether it is the initial E-cad positive 
cells, which promote quiescence, followed by N-cad expression, which results in 
proliferation. In addition, future experiments could also focus on MC survival in vivo 
following chemotherapeutic treatment and identifying whether these cells are N-cad 
positive and also whether these cells reside in a quiescent state adjacent to 
osteoblastic cells, which facilitates resistance. This would then provide the rationale 
to inhibit the interaction between the MCs and osteoblastic cells using a potential N-
cad inhibitor, followed by chemotherapy. These are important questions to explore 
in the future to further characterise the role of N-cad in MM and a more detailed 
plan and further study modifications are discussed in Section 7.2, Future Work. 
 
The majority of functional studies conducted within this thesis focused upon the role 
of N-cad in MM rather than the other molecules and ligands. However, it is highly 
likely that N-cad is not the sole molecule, which will influence MC adhesion to 
osteoblastic cells as well as proliferation in vivo. Clinical trials have previously 
explored, or are currently being conducted, to determine the role of CXCR4/CXCL12, 
Notch-1/ Jag-1 and Tie-2/ Ang-1 in cancer. Inhibition of CXCR4/CXCL12 signalling has 
also been translated into several different clinical trials. For example, inhibition of 
CXCR4 using AMD3100 has been used to mobilise HSCs from the BM into the blood 
for HSC harvesting in healthy volunteers (282) and has now also been assessed in 
phrase three trials in combination with granulocyte colony-stimulating factor (GCSF) 
to mobilise HSCs from myeloma patients before receiving chemotherapy (283). 
Furthermore, an anti-CXCR4 antibody, known as BMS-936564, inhibited CXCL12 
induced migration of B lymphoblast Burkitt lymphoma and T lymphoblast leukaemia 
cells in vitro and resulted in a decrease in the volume of subcutaneous tumours using 
a myeloma xenograft model (284). The inhibitory peptide, 4F-benzoyl-TN14003, also 
known as BKT140, originally used by Menu et al (170) in pre-clinical studies to treat 
MM, also inhibited the growth of human non-small cell lung carcinoma cells in vitro 
and enhanced chemosensitisation (285) in vivo and reduced the size of subcutaneous 
tumours in myeloma xenograft models (286). 
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Several clinical trials are currently underway, using γ secretase inhibitors such as PF-
03084014 and R04929097, to inhibit Notch-1 signalling. PF-03084014, is currently in 
phase I trials for use in patients with grade III breast cancer and T-cell leukaemic 
patients. Previous studies have shown a reduction in Notch-1 intracellular signalling 
which resulted in inhibition of cell growth and an increase in apoptosis in vitro as well 
as a reduction in tumour volume in vivo, using T-cell leukaemic cells (287, 288), as 
well as in breast cancer cells (289). In addition, the γ secretase inhibitor RO4929097, 
is also currently in phase I clinical trials for use in lymphomas as well as a variety of 
metastatic solid tumours. In previous studies, this γ secretase inhibitor also inhibited 
tumour growth in human non-small cell lung carcinoma cell xenograft models and in 
some cases of solid tumours in humans (290, 291). The effects of these γ secretase 
inhibitors are yet to be explored in myeloma but may be of interest in the future. 
 
Arcari et al (292) developed a series of Tie-2 inhibitors some of which reduced 
tumour volume in a rat glioblastoma model. Trebananib, a peptide Tie-2 inhibitor has 
also been tested in phase I clinical trials. However, use of this peptide did not 
considerably reduce progression free survival or overall survival in colorectal cancer 
patients (293). Whereas, the Tie-2 inhibitor, CEP-11981, also in clinical trials, reduced 
tumour volume and increased survival of animals in both glioblastoma and 
melanoma models in vivo (294). The mechanism of tumour reduction in these studies 
was not determined but a decrease in angiogenesis was speculated. Therefore, Tie-
2 inhibition could be a future treatment strategy in myeloma, as inhibition may result 
in a reduction in angiogenesis, which is increased in myeloma patients (271) and this 
may result in a reduction in tumour load. 
 
From the data collected in these studies there are several limitations, which need to 
be considered. Firstly, all of the experiments were conducted using murine MCs as 
opposed to human cells. The 5TGM1-GFP model has several advantages including 
excellent tumour take rate and growth in the BM of C57BL/KalwRij mice as well as 
producing osteolytic disease. This model is also fairly representative of patient 
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myeloma, particularly concerning tumour infiltration and bone disease, though it is 
more aggressive than MM disease occurring in patients. Another approach to 
investigate MM in pre-clinical studies is to use xenograft models of MM where, 
human cell lines and primary MM samples are injected into SCID mice (157-162, 165, 
295). I could therefore, in future experiments use human cell lines and patients 
samples to assess the expression of the HSC niche molecules and ligands and to 
explore the importance of N-cad in vivo in xenograft models of MM. However, these 
models also have limitations in that immune-compromised mice are used as opposed 
to mice with an intact immune system and again isn’t completely representative of 
human disease.  
 
In addition, as mentioned previously, the use of KD cells as opposed to clinically 
relevant inhibitors are another limitation. Knock-down of genes to determine the 
role of the corresponding protein is a good proof of principal experiment. However, 
from these experiments it seemed to produce quite high variability in both the in 
vitro KD experiments and in the in vivo experiment. This was possibly due to the 
percentage of KD, which was not 100% as well as extensive cell growth in vitro and 
antibiotic selection. Knock-down experiments also inevitably will require 
interventions using compounds or antibodies. Therefore, for future experiments it 
may also be desirable to use peptides as well as functional inhibitory antibodies. 
Currently, an N-cad inhibitory peptide, known as adherin-1 (ADH-1), is in clinical trials 
for use in treating patients with solid tumours. Adherin-1 is a cyclic peptide with a 
specific “HAV” amino acid sequence which inhibits N-cad and its function was 
originally determined within retinal explants, resulting in a reduction in neurite 
outgrowth and a reduction in adhesion of LN-229 cells (a glioblastoma cell line) to 
recombinant N-cad in vitro (296). The use of this peptide was particularly beneficial 
in rats treated with melanoma DM366 cells by subcutaneous injection, followed by 
ADH-1 and melphalan treatment. Rats with melanoma, when treated with ADH-1 and 
melphalan in combination, had significantly lower tumour volume compared to those 
treated with ADH-1 and melphalan alone (278). Again this compound may be a 
suitable therapeutic in MM. 
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In conclusion, these experiments provide evidence in support of the overall 
hypothesis, that “myeloma cells exist within an osteoblastic niche similar to that 
occupied by HSCs”. Within these experiments, MCs expressed the same repertoire of 
molecules expressed by HSCs, and their complementary ligands were expressed by 
osteoblastic cells at varying stages of differentiation. In addition, the KD of one of 
these key molecules, N-cad, reduced (though not significantly) the adhesion of MCs 
to osteoblastic cells in vitro and potentially reduced tumour growth in vivo. This 
reduction may be due to fewer cells originally homing to the BM or inhibition in the 
adhesion of MCs to osteoblastic cells, which may be an essential interaction for MC 
survival in the BM. However, further experiments are required to confirm the role of 
N-cad in myeloma development and to determine the precise role of osteoblastic 
cells in this interaction. These studies do however; provide the rationale to continue 
to target the niche with the theory that detaching cells from the niche will result in 
chemosensitisation, which can be targeted by conventional chemotherapies. 
However, it is currently unknown if this would in fact increase tumour growth (as 
seen by Sadler et al (207) in vitro), and so one would have to proceed with caution 
by extensively testing such treatment strategies in preclinical models. In addition, it 
is also unlikely that one molecule alone will facilitate MC attachment to a niche in 
the BM and in future experiments using a combination of molecule interventions will 
be required. Therefore, future experiments aim to establish treatment strategies, 
which could more effectively kill MCs and prevent chemo-evasion. 
 
7.2 Future studies 
 
To assess the effect of knocking-down N-cad in the 5TGM1-GFP cells on homing, 
localisation and growth over-time in vivo 
To further assess the effect of knocking-down N-cad in the 5TGM1-GFP cells upon 
tumour growth in vivo, certain aspects of the pilot study need to be repeated and 
additional aspects need to be investigated. Firstly, it would be desirable to determine 
whether different numbers of 5TGM1-GFP cells home to the BM. This could be done 
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by labelling the 5TGM1-GFP cells with the membrane dye DiD prior to injection. 
Three days after injection, labelled 5TGM1-GFP cells in the BM or circulation could 
be quantified by flow cytometry and their location could be determined using multi-
photon microscopy. Secondly, analysis at the end stage of disease would be 
repeated. However, rather than sacrificing the mice at 3 weeks P-I the experiment 
would continue until the first mouse in either the CTRL 25 or KD 25 group became ill, 
as the standard 5TGM1-GFP group would no longer be required. Tumour burden 
would be quantified using IHC and flow cytometry and as the length of the study 
would be extended this would allow larger tumours to form in the CTRL 25 group, 
which may reduce variability in the tumour burden analysis. Another endpoint would 
be to analyse the number of single DID labelled cells present in the bones of mice at 
the end stage of disease and to determine the proliferative state of these cells to 
establish whether they are quiescent. To reduce variability, mouse numbers in the 
groups would be increased. This would be based on power calculations using 
standard deviations from the pilot study. A PBS control group would also be used to 
provide background CD138 positive plasma cell analysis to quantify CD138 staining 
at the early time points of disease by IHC as well as providing basal trabecular bone 
parameter values to determine any differences between the PBS control group and 
the CTRL 25 and KD 25 injected mice. 
 
Determining the effects of a clinically relevant inhibitor of N-cad upon myeloma 
cell homing, colonisation and subsequent growth in the bone marrow 
The N-cad KD experimental design could also be used to determine the effects of a 
clinically relevant inhibitor of N-cad upon MC homing, colonisation and subsequent 
growth in the BM. Initially, optimisation experiments to determine a suitable dose of 
an inhibitor, such as ADH-1 or inhibitory antibodies, would be required to assess 
toxicity and whether the compounds have any effect on tumour burden at the end 
stage of disease. If differences were seen, it would then be desirable to analyse the 
early stages of disease, using DID labelled MCs to establish whether treatment of 
mice with an N-cad inhibitor prevented MC homing to the BM and also to determine 
the localisation of the MCs in the BM in vivo. A potential limitation to this study would 
be that the detachment of MCs from the niche might induce proliferation of these 
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“dormant” cells increasing tumour burden as well as the potential to increase 
metastasis. 
 
 
Quantifying and profiling the myeloma cells present in the bone marrow following 
chemotherapy 
To assess whether N-cad or the other HSC niche molecules are important with 
regards to MC chemoresistance, further in vitro and in vivo studies are required. 
Firstly in vitro chemo-titration studies could be conducted to examine the effect of 
different doses upon MC death, using modern chemotherapies such as lenalidomide 
or pomalidomide. This would be followed by treatment of cells with optimised doses 
of chemotherapies followed by genetic profiling of cells before and after therapy to 
determine any key molecules, which may enable chemoresistance.  
 
This would then be translated into in vivo experiments, to establish the genetic 
profile of the cells surviving after chemotherapeutic treatment in vivo (identified by 
DID labelling), which would include analysing the expression of the HSC niche 
molecules. In addition, molecules involved in cell signalling pathways could also be 
assessed in the chemoresistant cells to determine whether any of these pathways 
are activated following chemotherapeutic intervention. 
 
  
Determining the effect of N-cad intervention in combination with 
chemotherapeutic treatment 
Following on from both the separate N-cad intervention studies and chemo-titration 
experiments, both of these could be combined to form a new treatment strategy. 
Mice could be injected with 5TGM1-GFP cells and upon colonisation at approximately 
10 days P-I; they could then be treated with the N-cad inhibitor (inhibitory peptide 
or antibody), which may potentially dislodge the attachment of MCs from BM niches, 
rendering them more chemosensitive. This could then be followed by 
chemotherapeutic intervention using modern agents such as lenalidomide or 
pomalidomide as well as potentially in combination with proteasome inhibitors such 
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as bortezomib or carfilzomib. Following the combination treatment, the mice could 
be maintained in a survival study to determine whether mice, which received the 
combination treatment, survive longer or do not relapse compared to mice receiving 
chemotherapy alone. At the end of these studies the long bones could then be 
analysed for DID labelled cell number analysis as well as CD138 IHC to determine 
whether any MCs had remained in the BM following chemotherapy or N-cad 
intervention treatments. As already discussed, this strategy could be quite unsafe 
due to detachment of cells from the niche, which may result in cell proliferation and 
an increase in metastasis. However, if the chemotherapeutic strategy is at the correct 
dose these cells should be targeted.  
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Appendices 
Appendix 1: Equipment, materials and reagents  
1.1 Tissue culture 
Table 1.1: Equipment, materials and reagents required for tissue culture 
Item Supplier 
Disposable tips (10, 200 & 1000 µl) Star labs 
Eppendorph tubes (0.5 ml & 1 ml) Sarstedt 
Flasks (T25, T75 & T175) Nalgene Nunc Ltd 
Falcon tubes (50 ml) BD Pharmingen 
Universal tubes (20 ml) Costar 
15 ml tubes BD Pharmingen 
Bijoux tubes Costar 
Petri dishes (60 and 100 mm) Nunc 
Multi-well plates (6, 12, 24, 48, 96) Nalgene Nunc Ltd. 
Cryovials (1.5 ml) Nalgene Nunc Ltd 
Cell scrapers Corning 
Syringes BD Pharmingen 
MEMα medium (GlutaMAX and phenol red) Gibco 
MEMα-Nuc medium (GlutaMAX, 
deoxyribonucleosides, ribonucleosides and 
phenol red) 
Gibco 
RPMI 1640 medium (GlutaMAX and Phenol 
red) 
Gibco 
FBS Gibco 
NEAA (100X) Gibco 
NaP (100mM of sodium pyruvate) Gibco 
PS (10,000 units of penicillin and 10,000 
µg/ml of streptomycin) 
Gibco 
FZ (250 µg of Amphotericin B and 205 µg of 
sodium deoxycholate/ml) 
Gibco 
PBS Gibco 
Trypsin/ EDTA (2.5 g trypsin, 0.38 g EDTA 
and 4Na per litre of Hank’s balanced salt 
solution per litre) 
Gibco 
Trypan blue Sigma Aldrich 
DMSO Sigma Aldrich 
70 IMS Fisher Scientific 
Haemocytometer Neubauer 
Cover-slips Fisher Scientific 
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1.2 Animal cell isolation 
Table 1.2: Equipment, materials and reagents required for animal cell isolation 
Item Supplier 
HBSS (calcium and magnesium) Gibco 
Collagenase Type II Gibco 
EDTA Fluk analytical 
Insulin Myjector needles (27 
Gauge) 
Terumo 
Vacutainers BD Pharmingen 
RBC lysis (10X) and wash buffer 
(10X) 
R & D Systems 
DMEM media containing  Gibco 
Pentabarbitone (concentration) J M Loveridge Ltd 
 
1.3 RNA extraction 
Table 1.3: Materials and reagents required for RNA extraction 
Item Supplier 
Ultra spec (A 14 M guanidine 
salt/urea RNA isolation system) 
BioTecx 
Molecular grade chloroform Sigma Aldrich 
Molecular grade 2-propanol Sigma Aldrich 
Molecular grade ethanol Sigma Aldrich 
DEPC water Ambion 
RNase Zap Ambion 
 
1.4 Reverse transcription 
Table 1.4: Equipment, materials and reagents required for reverse transcription 
Item Supplier 
0.5 ml RNase and DNase free tubes Alpha laboratories 
PTC 200 thermal cycler MJ Research 
UV hood Jencons 
Nuclease free water Ambion 
Random primers (500 ng/ µl) Promega 
RNasin (40 U/µl) 
Promega 
SuperScript III first-strand synthesis system, 
Reverse transcriptase (200 U µl) Life Technologies 
DTT (100 mM) 
Life Technologies 
First strand buffer (5X solution containing 250 
mM Tris-HCl (pH 8.3), 375 mM potassium 
chloride (KCl), 15 mM MgCl2) 
Life Technologies 
dNTPs (100 mM), 
Bioline 
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1.5 Endpoint PCR 
Table 1.5: Materials and reagents required for endpoint PCR 
Item Supplier 
RT-PCR H2O Ambion 
MgCl2 (50 mM) Bioline 
Ammonium reaction buffer 
(10X) 
Bioline 
Taq polymerase (5 U/µl) Bioline 
Murine PCR primers (5 µM) 
Thermo Scientific and Life 
Technologies 
 
1.6 Gel electrophoresis 
Table 1.6 Equipment, materials and reagents required for gel electrophoresis 
Item Supplier 
Electrophoresis tank Biorad 
PowerPac Biorad 
Gel combs Biorad 
Gel casting mould Biorad 
Trizma base Sigma Aldrich 
Hyperladder IV 100-1000 BP Bioline 
Loading buffer (5X) Bioline 
Ultra-pure agarose Sigma Aldrich 
Glacial acetic acid Fisher Scientific 
Ethidium bromide (10 mg/ml) Life Technologies 
 
1.7 Real-time PCR 
Table 1.7: Equipment, materials and reagents required for real-time PCR  
Item Supplier 
384 well plates Greiner Bio-one Ltd 
Micro-seal adhesive covers Bio-Rad 
7900 Ht real-time PCR machine Life Technologies 
Endogenous control assays and 
experimental probes (20X) 
Life Technologies 
Real-time PCR Master Mix: (2x 
containing AmpliTaq GoldDNA 
Polymerase, Uracil DNA 
Glycosylase, dNTPs 
deoxyuridine triphosphate 
(dUTP) 
Life Technologies 
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1.8 Flow cytometry 
Table 1.8: Equipment, materials and reagents required for flow cytometry 
Item Supplier 
FACS Calibur machine BD Pharmingen 
96 V bottom well plate Sterilin 
Flow cytometry tubes Elkay Laboratory Products 
Cell strainers BD Pharmingen 
Goat serum Vector Laboratories 
BSA Sigma Aldrich 
Cell dissociation solution Sigma Aldrich 
Fixation buffer (4% PFA) BD Pharmingen 
Permeablisation buffer 
(Saponin) (10X) 
BD Pharmingen 
Fluorescent antibodies Various suppliers-see Table 2.23 
PI (1 mg/ml) Life Technologies 
TO-PRO-3 (1 mM) Life Technologies 
 
1.9 Immunofluorescence 
Table 1.9: Equipment, materials and reagents required for immunofluorescence 
Item Supplier 
Hydrophobic barrier pen Vector Laboratories 
Super-frost slides VWR International 
Cover-slips (22 x 22 mm) Menzel glaser 
Cytospin equipment and 
machine 
Shandon 
Hot plate Thermo Scientific 
Leica AF6000 microscope Leica Microsystems 
PBS tablets Oxoid 
Paraformaldehyde Fisher Scientific 
NaOH Fisher Scientific 
Prolong gold anti-fade aqueous 
mounting media with 4’,-6-
diamidino-2-phenylindole 
(DAPI) 
Life Technologies 
Tween Fisher Scientific 
Nail varnish Boots Pharmacy 
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1.10 IHC 
Table 1.10: Equipment, materials and reagents required for IHC 
Item Supplier 
Processing cassettes Leica Microsystems 
Processing carousal Leica 
TP2010 
Leica Microsystems 
Blocking System II embedder Raymond Lamb 
Leica RM 2265 microtome Leica Microsystems 
Hot plate Raymond Lamb 
Water baths Raymond Lamb 
Oven Scientific Laboratory Supplies 
Processing wax  
Xylene Fisher Scientific 
Alcohols Fisher Scientific 
EDTA Fisher Scientific 
Trypsin antigen retrieval kit A.Menarini Diagnostics 
H2O2 VWR 
Streptavidin horse radish 
peroxidase 
Dakocytomation 
DPX mountant VWR international 
Primary antibodies- see table 
2.12 
Various suppliers- see table 
2.12 
Goat anti-rat biotinylated 
secondary antibody 
Santa Cruz Biotechnology 
Goat anti-rabbit biotinylated 
secondary antibody 
Vector Laboratories 
DAB peroxidase substrate kit Vector Laboratories 
Gill’s haematoxylin Fisher Scientific 
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1.11 Western blotting 
Table 1.11: Equipment, materials and reagents required for Western blotting 
Item Supplier 
Mini protean WB equipment: gel casting 
stands, casting frames, electrophoresis tank 
and electrode assembly, transfer cassettes, 
transfer electrodes 
Bio-Rad 
1.5 mm separator and cover plate Bio-Rad 
1.5 mm combs (15 wells) Bio-Rad 
Filter paper Whatman 
Teflon pads Bio-Rad 
Tris HCl Sigma Aldrich 
BCA Sigma Aldrich 
NaCl Sigma Aldrich 
Glycine Fisher Scientific 
NP-40 substitute Fuka Biochemika 
TEMED Sigma Aldrich 
Laemmli sample buffer (4X) Biorad 
PIC Calbiochem 
Acrylamide National Diagnostics 
APS Bioproducts ltd 
β-mercaptoethanol Sigma Aldrich 
SDS Sigma Aldrich 
Milk powder Cooperative supermarket 
Goat anti-rabbit horse radish peroxidase 
antibody 
Dako cytomation 
Anti-biotin antibody HRP Cell signalling 
Rabbit anti β-actin antibody Abcam 
Pre-stained all Blue protein ladder Bio-rad 
Biotinylated molecular weight standards Cell signalling 
Nitrocellulose membranes Amersham 
Methanol Fisher Scientific 
Luminol reagent (ECL) Santa Cruz Biotechnology 
Luminol reagent (ECL) Thermo Scientific 
Hyper film Amersham 
Developing solutions AGFA 
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1.12 Primary osteoblast lineage cell differentiation 
Table 1.12: Equipment, materials and reagents required for primary osteoblast lineage cell 
differentiation 
Item Supplier 
Spectra Max M5e plate reader Molecular devices 
BGP Sigma Aldrich 
Asc Sigma Aldrich 
PNPP tablets, containing PNPP (20 mg/ml) 
and tris buffer tablets (4 M) 
Sigma Aldrich 
Alizarin red Sigma Aldrich 
Quant-it Pico green reagent: containing 
the dsDNA picogreen component, 
tris/EDTA buffer (20X) containing 200 
mM Tris-HCl, 20 mM EDTA pH 7.5 and 
the lambda DNA standards (100 µg/ml) 
 
Life Technologies 
 
1.13 Gene knock-down using short hair-pin RNA 
Table 1.13: Materials and reagents required for short hair-pin RNA knock-down 
Item Supplier 
Puromycin (25 mg/ml) Santa Cruz Biotechnology 
Polybrene (10 mg/ml) Santa Cruz Biotechnology 
CXCR4 and N-cad shRNA 
lentiviral particles  
Santa Cruz Biotechnology 
GFP lentiviral particles Santa Cruz Biotechnology 
Scrambled control lentiviral 
particles 
Santa Cruz Biotechnology 
 
1.14 Micro-computed tomography 
Table 1.14: Equipment, materials and reagents required for micro-computed tomography 
Item Supplier 
SkyScan 1172 µCT machine SkyScan 
Sodium dihydrogen 
orthophosphate dihydrate 
VWR international 
Disodium hydrogen 
orthophosphate dihydrate 
VWR international 
Concentrated formaldehyde 
(i.e. 37-41%) 
VWR international 
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Appendix 2: Additional information for methodologies 
2.1 RNA quantification and contamination analysis 
 
 
 
 
 
 
 
 
 
Figure 2.1: An example of a RNA spectrophotometry curve to detect contaminants. Ribonucleic acid 
was extracted and analysed using a NanoDrop 2000 and NanoDrop 2000 software. A graph was 
generated which summarised the quality of the RNA and generated contamination ratios (260:280, 
260:230). 
 
2.2 RNA fragment length analysis 
Figure 2.2: An example of 
RNA fragment length 
analysis. Ribonucleic acid 
integrity was measured 
using an Agilent 
Bioanalyser 2100 and 
analysed using 2100 Expert 
Software. The RNA integrity 
was scored and used if the 
RNA integrity was between 
8 and 10.  
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2.3 Endpoint PCR primer information 
Table 2.1: Primer annealing temperatures, cycle number and product size for endpoint PCR  
Gene 
Primer annealing 
temperature (°C) 
Cycle number Product size (BP) 
GAPDH 53 25 354 
CXCR4 48 35 711 
CXCL12 48 35 205 
Notch-1 48 35 348 
Jag-1 48 35 370 
Tie-2 48 35 648 
Ang-1 48 35 401 
N-cad 55 35 560 
CD138 48 35 559 
 
2.4 Endpoint PCR primer sequence information 
Table 2.2: Endpoint PCR primer sequences, gene accession numbers and primer melting 
temperatures  
Primer Primer annealing Sequence 
Accession 
number 
(NM) 
Tm 
(°C) 
Sense GAPDH 5’-TTGTCAGCAATGCATCCTGC-3’ 008084 53 
Anti-sense GAPDH 5’-GCTTCACCACCTTCTTGATG-3’ 008084 53 
Sense CXCR4 5-’ATGGAACCGATCAGTGTGAG-3’ 009911 49 
Anti-sense CXCR4 5-‘CTTGGAGTGTGACAGCTTAG-3’ 009911 45 
Sense CXCL12 5’-TCAGTGACGGTAAACCAGTC-3’ 021704 47 
Anti-sense CXCL12 5’-GCTTTCTCCAGGTACTCTTG-3’ 021704 46 
Sense Notch-1 5’-TAATGAGTGCAGCCAGAACC-3’ 008714 50 
Anti-sense Notch-1 5’-TCCTCTGTACAGTACTGACC-3’ 008714 41 
Sense Jag-1 5’-AGATCCTGTCCATGCAGAAC-3’ 013822 49 
Anti-sense Jag-1 5’-ATCATGCCTGAGTGAGAAGC-3’ 013822 49 
Sense Tie-2 5’-GTTCGAGGACAGGCTATAAG-3’ 013690 46 
Anti-sense Tie-2 5’-CTCTTCATTGGTACAGTGGC-3’ 013690 47 
Sense Ang-1 5’-CATTCTTCCAGAACACGACG-3’ 009640 51 
Anti-sense Ang-1 5’-GGAGAAGTTGCTTCTCTAGC-3’ 009640 45 
Sense N-cad 5’-CAGGTAGCTGTAAACCTGAG-3’ 007664 55 
Anti-sense N-cad 5’-CCATTCAGGGCATTTGGATC-3’ 007664 55 
Sense CD138 5’-TGTTCCTCCTGAAGATCAGG-3’ 011519 49 
Anti-sense CD138 5’-TGATTGGCAGTTCCATCCTC-3’ 011519 52 
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2.5 Probes used for real-time PCR 
Table 2.3: Probes used for real-time PCR  
Gene Reference number 
β2M Mm00437762_m1 
HPRT Mm00446968_m1 
TFRC Mm00441941_m1 
Col1A1 Mm00801666_g1 
Runx-2 Mm00501584_m1 
CXCR4 Mm01292123_m1 
CXCL12 Mm00445552_m1 
Notch-1 Mm00435249_m1 
Jag-1 Mm00496902_m1 
Tie-2 Mm00443243_m1 
Ang-1 Mm00456503_m1 
N-cad Mm01162497_m1 
CD138 Mm00448918_m1 
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2.6 Real-time PCR probe efficiencies 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.3: Primer efficiencies for fluorescent probes used for real-time PCR: Primer efficiencies were 
determined by adding a serial dilution of normal murine BM cDNA to the fluorescent probes for β2M 
(a), HPRT (b), TFRC (c) (HK genes), CXCR4 (d), CXCL12 (e), Notch-1 (f), Jag-1 (g), Tie-2 (h), Ang-1 (i), N-
cad (j) and CD138 (k), using real-time PCR. The Ct values (y-axis) were plotted against the dilution of 
cDNA (x-axis) and the slope and R2 values were calculated using linear regression. 
 
 
 
a b c 
e f 
g h i 
j k 
d 
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Table 2.6: The percentage of fluorescent probe efficiency  
 
 
 
 
 
 
 
The percentage of fluorescent probe efficiency was calculated using the equation:                              
Efficiency = 10(-1/slope) -1 * 100, using the slope from the graphs calculated in Appendix Figure 2.3. 
Probes within a range of 90-110% were used in real-time PCR. 
 
2.7 Optimisation experiments to determine the optimum amount of protein 
required to visualise N-cad using Western blotting 
 
Figure 2.4: Western blotting to optimise the amount 
of protein used to detect N-cad in 5TGM1-GFP cells. 
Increasing amounts of 5TGM1-GFP protein (5, 10, 20, 
40 and 60 µg) were loaded and run by SDS-PAGE and 
blotted using an anti-N-cad primary antibody followed 
by anti-rabbit HRP conjugated secondary Blots were 
visualised using ECL purchased from Santa Cruz. 
 
 
 
 
 
 
 
 
 
Gene Primer efficiency (%) 
β2M 93.12 
HPRT 107.55 
TFRC 72.66 
CXCR4 100.16 
CXCL12 90.57 
Notch-1 94.50 
Jag-1 93.09 
Tie-2 99.18 
Ang-1 98.84 
N-cad 98.89 
CD138 90.66 
Appendices Page 260 
 
2.8 Alkaline phosphatase analysis 
Table 2.6: An example of alkaline phosphatase calculations used to determine differences in primary 
osteoblast lineage cell differentiation 
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